

COVID-19 Immunogenicity Analysis Report
mock Study

USG COVID-19 Response Biostatistics Team

March 31, 2021

Contents

1	Tabular Description of Immunogenicity Data	15
2	Graphical Description of Immunogenicity Data	413
2.1	Pairs plots of antibody markers for overall per-protocol cohort	413
2.2	RCDF plots of antibody markers for overall per-protocol cohort	430
2.3	Scatter plots of antibody markers versus age for overall per-protocol cohort	442
2.4	Box plots of antibody markers for overall per-protocol cohort	446
2.5	Spaghetti plots of antibody markers over time for the overall per-protocol cohort	462
2.6	RCDF plots of antibody markers by demographics for per-protocol cohort	464
2.7	Boxplots of antibody markers by demographics for per-protocol cohort	536

List of Tables

1.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	15
1.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	17
1.3	Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by All participants	18
1.4	Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age	20
1.5	Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Risk for Severe Covid-19	24
1.6	Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age, Risk for Severe Covid-19	28
1.7	Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Sex	37
1.8	Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age, sex	41
1.9	Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Hispanic or Latino ethnicity	49
1.10	Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Race	56
1.11	Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Underrepresented minority status	74
1.12	Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age, Underrepresented minority status	79
1.13	Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants	90
1.14	Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age	91
1.15	Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19	93
1.16	Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19	95

1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex	98
1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex	100
1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity	103
1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race	106
1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status	112
1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status	114
1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants	118
1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age	122
1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19	130
1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19	138
1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex	154
1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex	162
1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity	178
1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race	190
1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status	222
1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status	230
1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants	246
1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age	249
1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19	255
1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19	261
1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex	275
1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex	281

1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity	294
1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race	305
1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . .	335
1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status	342
1.43 Table 7. The ratios of GMTs/GMCs between groups	360
1.44 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the vaccine arm and the placebo arm by All participants	407
1.45 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)	409
1.46 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)	410
1.47 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)	411
1.48 Table 12. Antibody levels in the per-protocol cohort (placebo recipients)	412

List of Figures

2.1	Pair plots of D29 Ab markers: baseline negative vaccine arm	414
2.2	Pair plots of D57 Ab markers: baseline negative vaccine arm	415
2.3	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	416
2.4	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	417
2.5	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . .	418
2.6	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . .	419
2.7	Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm	420
2.8	Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm	421
2.9	Pair plots of D29 Ab markers: baseline negative vaccine arm	422
2.10	Pair plots of D57 Ab markers: baseline negative vaccine arm	423
2.11	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	424
2.12	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	425
2.13	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . .	426
2.14	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . .	427
2.15	Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm	428
2.16	Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm	429
2.17	RCDF plots for D29 Ab markers: by baseline status x randomization arm	430
2.18	RCDF plots for D57 Ab markers: by baseline status x randomization arm	431
2.19	RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm .	432
2.20	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm .	433
2.21	RCDF plots for D29 Ab markers: by baseline status for the vaccine arm	434
2.22	RCDF plots for D57 Ab markers: by baseline status for the vaccine arm	435
2.23	RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm .	436
2.24	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm .	437
2.25	RCDF plots for D29 Ab markers: baseline negative vaccine arm	438
2.26	RCDF plots for D57 Ab markers: baseline negative vaccine arm	439
2.27	RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	440
2.28	RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	441

2.29 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm	442
2.30 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm	443
2.31 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm	444
2.32 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm	445
2.33 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms	446
2.34 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms	447
2.35 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	448
2.36 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	449
2.37 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms	450
2.38 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms	451
2.39 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	452
2.40 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	453
2.41 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm	454
2.42 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm	455
2.43 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	456
2.44 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	457
2.45 Boxplots of D29 Ab markers: baseline positive + negative placebo arm	458
2.46 Boxplots of D57 Ab markers: baseline positive + negative placebo arm	459
2.47 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	460
2.48 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	461
2.49 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm	462
2.50 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm	463
2.51 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.	464
2.52 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.	465
2.53 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	466
2.54 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	467
2.55 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.	468
2.56 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.	469
2.57 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	470
2.58 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	471
2.59 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.	472
2.60 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.	473
2.61 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	474
2.62 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	475

2.63 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.	476
2.64 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.	477
2.65 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	478
2.66 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	479
2.67 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	480
2.68 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	481
2.69 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	482
2.70 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.	483
2.71 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.	484
2.72 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.	485
2.73 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. .	486
2.74 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. .	487
2.75 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.	488
2.76 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.	489
2.77 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. . .	490
2.78 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. . .	491
2.79 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	492
2.80 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	493
2.81 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	494
2.82 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	495
2.83 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	496
2.84 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	497
2.85 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	498
2.86 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	499
2.87 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.	500
2.88 RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.	501
2.89 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	502

2.90 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	503
2.91 RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.	504
2.92 RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.	505
2.93 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	506
2.94 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	507
2.95 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.	508
2.96 RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.	509
2.97 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	510
2.98 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	511
2.99 RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.	512
2.100RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.	513
2.101RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	514
2.102RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	515
2.103RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	516
2.104RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	517
2.105RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	518
2.106RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	519
2.107RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.	520
2.108RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.	521
2.109RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.	522
2.110RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.	523
2.111RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.	524
2.112RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.	525
2.113RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	526
2.114RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	527
2.115RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	528
2.116RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	529
2.117RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	530

2.118RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	531
2.119RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	532
2.120RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	533
2.121RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	534
2.122RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	535
2.123Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.	536
2.124Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.	537
2.125Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	538
2.126Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	539
2.127Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. . .	540
2.128Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. . .	541
2.129Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . .	542
2.130Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . .	543
2.131Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	544
2.132Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	545
2.133Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	546
2.134Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	547
2.135Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. .	549
2.136Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. .	550
2.137Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	551
2.138Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	552
2.139Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	553
2.140Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	554
2.141Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	555
2.142Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	556

2.143Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	557
2.144Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	558
2.145Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	559
2.146Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	560
2.147Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	561
2.148Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	562
2.149Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	563
2.150Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	564
2.151Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	565
2.152Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	566

MOT

Chapter 1

Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 914)	Placebo (N = 163)	Total (N = 1077)
Age			
Age < 65	432 (47.3%)	80 (49.1%)	512 (47.5%)
Age ≥ 65	482 (52.7%)	83 (50.9%)	565 (52.5%)
Mean (Range)	58.6 (18.0, 85.0)	59.0 (18.0, 85.0)	58.7 (18.0, 85.0)
BMI			
Mean ± SD	30.1 ± 7.0	29.6 ± 7.2	30.0 ± 7.0
Sex			
Female	519 (56.8%)	87 (53.4%)	606 (56.3%)
Male	395 (43.2%)	76 (46.6%)	471 (43.7%)
Race			
White Non-Hispanic	362 (43.8%)	67 (44.7%)	429 (43.9%)
Black or African American	195 (23.6%)	39 (26.0%)	234 (24.0%)
Asian	67 (8.1%)	12 (8.0%)	79 (8.1%)
American Indian or Alaska Native	13 (1.6%)	5 (3.3%)	18 (1.8%)
Native Hawaiian or Other Pacific Islander	17 (2.1%)	1 (0.7%)	18 (1.8%)
Multiracial	52 (6.3%)	8 (5.3%)	60 (6.1%)
Other	34 (4.1%)	4 (2.7%)	38 (3.9%)
Not reported and unknown	87 (10.5%)	14 (9.3%)	101 (10.3%)
Communities of Color	420 (53.7%)	73 (52.1%)	493 (53.5%)
Hispanic or Latino ethnicity			
Hispanic or Latino	136 (14.9%)	20 (12.3%)	156 (14.5%)
Not Hispanic or Latino	690 (75.5%)	130 (79.8%)	820 (76.1%)
Not reported and unknown	88 (9.6%)	13 (8.0%)	101 (9.4%)
Risk for Severe Covid-19			
At-risk	469 (51.3%)	84 (51.5%)	553 (51.3%)
Not at-risk	445 (48.7%)	79 (48.5%)	524 (48.7%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	214 (23.4%)	40 (24.5%)	254 (23.6%)

(continued)

Characteristics	Vaccine (N = 914)	Placebo (N = 163)	Total (N = 1077)
Age < 65 Not at-risk	218 (23.9%)	40 (24.5%)	258 (24.0%)
Age \geq 65	482 (52.7%)	83 (50.9%)	565 (52.5%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm \times Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) \times Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age \geq 65) \times Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 274)	Placebo (N = 270)	Total (N = 544)
Age			
Age < 65	146 (53.3%)	147 (54.4%)	293 (53.9%)
Age ≥ 65	128 (46.7%)	123 (45.6%)	251 (46.1%)
Mean (Range)	56.0 (18.0, 85.0)	55.8 (18.0, 85.0)	55.9 (18.0, 85.0)
BMI			
Mean ± SD	30.7 ± 6.8	30.1 ± 7.2	30.4 ± 7.0
Sex			
Female	153 (55.8%)	155 (57.4%)	308 (56.6%)
Male	121 (44.2%)	115 (42.6%)	236 (43.4%)
Race			
White Non-Hispanic	125 (49.8%)	121 (49.0%)	246 (49.4%)
Black or African American	52 (20.7%)	60 (24.3%)	112 (22.5%)
Asian	24 (9.6%)	13 (5.3%)	37 (7.4%)
American Indian or Alaska Native	6 (2.4%)	4 (1.6%)	10 (2.0%)
Native Hawaiian or Other Pacific Islander	5 (2.0%)	1 (0.4%)	6 (1.2%)
Multiracial	12 (4.8%)	19 (7.7%)	31 (6.2%)
Other	7 (2.8%)	5 (2.0%)	12 (2.4%)
Not reported and unknown	20 (8.0%)	24 (9.7%)	44 (8.8%)
Communities of Color	120 (49.0%)	111 (47.8%)	231 (48.4%)
Hispanic or Latino ethnicity			
Hispanic or Latino	35 (12.8%)	38 (14.1%)	73 (13.4%)
Not Hispanic or Latino	217 (79.2%)	214 (79.3%)	431 (79.2%)
Not reported and unknown	22 (8.0%)	18 (6.7%)	40 (7.4%)
Risk for Severe Covid-19			
At-risk	125 (45.6%)	123 (45.6%)	248 (45.6%)
Not at-risk	149 (54.4%)	147 (54.4%)	296 (54.4%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	73 (26.6%)	75 (27.8%)	148 (27.2%)
Age < 65 Not at-risk	73 (26.6%)	72 (26.7%)	145 (26.7%)
Age ≥ 65	128 (46.7%)	123 (45.6%)	251 (46.1%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
All participants								
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	914	13295/13295 = 100.0% (100.0%, 100.0%)	13268.1/13295 = 99.8% (98.6%, 100.0%)	13268.1/13295 = 99.8% (98.6%, 100.0%)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	163	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	163	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	163	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)	1354.5/1357 = 99.8% (98.7%, 100.0%)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	914	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)	13295/13295 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	163	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	163	76.3/13359 = 0.6% (0.1%, 4.0%)	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	163	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)	1357/1357 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration. Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Age								
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	432	10518/10518 = 100.0% (100.0%, 100.0%)	10491.1/10518 = 99.7% (98.2%, 100.0%)	10491.1/10518 = 99.7% (98.2%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	80	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	147	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)	1095.5/1098 = 99.8% (98.4%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	147	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	147	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	432	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)	10518/10518 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	80	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	80	76.3/10234 = 0.7% (0.1%, 5.3%)	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	147	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	147	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	147	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)	1098/1098 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	482	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	83	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	83	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	83	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	482	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)	2777/2777 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	83	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	83	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	83	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)	0/3125 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	469	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	84	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	84	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	84	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)	328.8/331.2 = 99.3% (94.8%, 99.9%)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	469	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)	3736.6/3736.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	84	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	84	76.3/4096.4 = 1.9% (0.2%, 12.6%)	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	84	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)	331.2/331.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	445	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9531.4/9558.4 = 99.7% (98.0%, 100.0%)	9531.4/9558.4 = 99.7% (98.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	147	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	147	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	147	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)	9558.4/9558.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	147	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	147	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	147	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)	1025.8/1025.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	214	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	223.5/226 = 98.9% (92.3%, 99.9%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	214	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)	2279/2279 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	76.3/2454 = 3.1% (0.4%, 20.6%)	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	8239/8239 = 100.0% (100.0%, 100.0%)	8212.1/8239 = 99.7% (97.7%, 100.0%)	8212.1/8239 = 99.7% (97.7%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	72	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	72	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)	8239/8239 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	72	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	72	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	72	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)	872/872 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	255	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	255	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)	1457.6/1457.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Sex								
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	395	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)	526.8/529.2 = 99.5% (96.7%, 99.9%)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	395	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)	5298.6/5298.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	76.3/4771.7 = 1.6% (0.2%, 11.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)	529.2/529.2 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	519	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7969.4/7996.4 = 99.7% (97.6%, 100.0%)	7969.4/7996.4 = 99.7% (97.6%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	87	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	87	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	87	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	155	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	155	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	155	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	519	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)	7996.4/7996.4 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	87	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	87	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	87	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)	0/8587.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	155	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	155	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	155	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)	827.8/827.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	269	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6497.4/6524.4 = 99.6% (97.1%, 99.9%)	6497.4/6524.4 = 99.6% (97.1%, 99.9%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	83	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	83	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	83	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	269	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)	6524.4/6524.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	83	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	83	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	83	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)	673.1/673.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	163	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	28	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	28	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	28	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)	422.4/424.9 = 99.4% (95.8%, 99.9%)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	163	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)	3993.6/3993.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	28	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	28	76.3/3045.2 = 2.5% (0.3%, 17.6%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	28	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)	424.9/424.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	232	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	48	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	48	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	48	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	232	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)	1305/1305 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	48	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	48	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	48	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	250	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	250	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)	1472/1472 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)	0/1398.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times LLOD$	% Greater than $4 \times LLOD$
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	136	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	136	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)	1363.4/1363.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	690	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10454.2/10481.2 = 99.7% (98.2%, 100.0%)	10454.2/10481.2 = 99.7% (98.2%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	130	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	130	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	130	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	214	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1119.3/1121.8 = 99.8% (98.4%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	214	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	214	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	690	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)	10481.2/10481.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	130	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	130	76.3/10828.8 = 0.7% (0.1%, 4.9%)	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	130	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	214	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	214	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	214	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)	1121.8/1121.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	18	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	18	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	18	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	18	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	18	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	18	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)	101.5/101.5 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.



Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	76.3/6586.8 = 1.2% (0.2%, 8.1%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	195	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	1985.2/2012.2 = 98.7% (90.9%, 99.8%)	1985.2/2012.2 = 98.7% (90.9%, 99.8%)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)	262.6/265.1 = 99.1% (93.4%, 99.9%)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	195	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)	2012.2/2012.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)	265.1/265.1 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	67	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	13	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	13	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	13	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	67	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)	673.6/673.6 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	13	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	13	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	13	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)	48.4/48.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	52	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	52	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)	498.5/498.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	14	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	14	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	14	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	24	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	24	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	24	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	14	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	14	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	14	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	24	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	24	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)	165.4/165.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	420	4289/4289 = 100.0% (100.0%, 100.0%)	4262.1/4289 = 99.4% (95.6%, 99.9%)	4262.1/4289 = 99.4% (95.6%, 99.9%)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0%	4289/4289 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	73	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	73	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	73	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	111	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)	436.5/439 = 99.4% (96.0%, 99.9%)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	111	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	111	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	420	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)	4289/4289 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	73	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	73	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	73	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	111	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	111	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	111	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)	439/439 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)	6597/6597 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	76.3/6586.8 = 1.2% (0.2%, 8.1%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)	666.4/666.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times \text{LLOD}$	% Greater than $4 \times \text{LLOD}$
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	192	3386/3386 = 100.0% (100.0%, 100.0%)	3359.1/3386 = 99.2% (94.5%, 99.9%)	3359.1/3386 = 99.2% (94.5%, 99.9%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)	358.5/361 = 99.3% (95.1%, 99.9%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	192	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)	3386/3386 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)	361/361 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	175	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	175	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)	5217.3/5217.3 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	76.3/4988.2 = 1.5% (0.2%, 11.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)	517.6/517.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	228	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	228	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)	903/903 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	187	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0%	1379.7/1379.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0%	1379.7/1379.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0%	1379.7/1379.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	187	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0% (100.0%, 100.0%)	1379.7/1379.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
All participants								
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	914	11733.1/13295 = 88.3% (84.7%, 91.0%)	11787.2/13295 = 88.7% (85.2%, 91.4%)	10870.9/13295 = 81.8% (77.9%, 85.1%)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	274	1383.1/1432 = 96.6% (91.6%, 98.7%)	1383.1/1432 = 96.6% (91.6%, 98.7%)	1287.8/1432 = 89.9% (83.3%, 94.1%)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	163	149.5/13359 = 1.1% (0.3%, 3.8%)	149.5/13359 = 1.1% (0.3%, 3.8%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	270	1139.8/1357 = 84.0% (76.8%, 89.3%)	1143.2/1357 = 84.2% (77.0%, 89.5%)	906/1357 = 66.8% (58.6%, 74.0%)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	914	13159.4/13295 = 99.0% (98.0%, 99.5%)	13159.4/13295 = 99.0% (98.0%, 99.5%)	12955/13295 = 97.4% (95.6%, 98.5%)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	274	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	163	131.9/13359 = 1.0% (0.3%, 3.0%)	131.9/13359 = 1.0% (0.3%, 3.0%)	0/13359 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	270	1301.8/1357 = 95.9% (90.6%, 98.3%)	1301.8/1357 = 95.9% (90.6%, 98.3%)	1253.1/1357 = 92.3% (86.0%, 95.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age								
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	432	9050.2/10518 = 86.0% (81.6%, 89.5%)	9096.9/10518 = 86.5% (82.1%, 89.9%)	8317.2/10518 = 79.1% (74.2%, 83.2%)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	146	1103/1145 = 96.3% (89.7%, 98.7%)	1103/1145 = 96.3% (89.7%, 98.7%)	1010.3/1145 = 88.2% (80.0%, 93.4%)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	80	76.3/10234 = 0.7% (0.1%, 5.3%)	76.3/10234 = 0.7% (0.1%, 5.3%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	147	896.3/1098 = 81.6% (72.7%, 88.1%)	899.7/1098 = 81.9% (73.1%, 88.4%)	682.7/1098 = 62.2% (52.3%, 71.1%)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	432	10405/10518 = 98.9% (97.6%, 99.5%)	10405/10518 = 98.9% (97.6%, 99.5%)	10226.7/10518 = 97.2% (94.8%, 98.5%)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	146	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)	1145/1145 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	80	43.1/10234 = 0.4% (0.1%, 3.0%)	43.1/10234 = 0.4% (0.1%, 3.0%)	0/10234 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	147	1042.8/1098 = 95.0% (88.4%, 97.9%)	1042.8/1098 = 95.0% (88.4%, 97.9%)	995.7/1098 = 90.7% (82.9%, 95.1%)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	482	2682.9/2777 = 96.6% (94.4%, 98.0%)	2690.3/2777 = 96.9% (94.8%, 98.2%)	2553.6/2777 = 92.0% (89.1%, 94.1%)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	128	280.1/287 = 97.6% (92.6%, 99.3%)	280.1/287 = 97.6% (92.6%, 99.3%)	277.5/287 = 96.7% (91.3%, 98.8%)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	83	73.2/3125 = 2.3% (0.5%, 9.5%)	73.2/3125 = 2.3% (0.5%, 9.5%)	0/3125 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	243.5/259 = 94.0% (87.7%, 97.2%)	243.5/259 = 94.0% (87.7%, 97.2%)	223.3/259 = 86.2% (78.6%, 91.4%)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	482	2754.3/2777 = 99.2% (97.7%, 99.7%)	2754.3/2777 = 99.2% (97.7%, 99.7%)	2728.2/2777 = 98.2% (96.4%, 99.1%)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	128	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)	287/287 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	83	88.8/3125 = 2.8% (0.7%, 10.9%)	88.8/3125 = 2.8% (0.7%, 10.9%)	0/3125 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	259/259 = 100.0% (100.0%, 100.0%)	259/259 = 100.0% (100.0%, 100.0%)	257.4/259 = 99.4% (95.7%, 99.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	469	3353.3/3736.6 = 89.7% (86.3%, 92.4%)	3360.6/3736.6 = 89.9% (86.6%, 92.5%)	3035.3/3736.6 = 81.2% (77.1%, 84.8%)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	355.1/368.8 = 96.3% (90.0%, 98.7%)	355.1/368.8 = 96.3% (90.0%, 98.7%)	332.9/368.8 = 90.3% (82.5%, 94.8%)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	84	149.5/4096.4 = 3.6% (1.0%, 12.0%)	149.5/4096.4 = 3.6% (1.0%, 12.0%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	284.5/331.2 = 85.9% (78.4%, 91.1%)	287.9/331.2 = 86.9% (79.6%, 91.9%)	248.5/331.2 = 75.0% (66.5%, 82.0%)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	469	3654.9/3736.6 = 97.8% (95.6%, 98.9%)	3654.9/3736.6 = 97.8% (95.6%, 98.9%)	3597.8/3736.6 = 96.3% (93.7%, 97.8%)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)	368.8/368.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	84	43.1/4096.4 = 1.1% (0.1%, 7.4%)	43.1/4096.4 = 1.1% (0.1%, 7.4%)	0/4096.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	322.9/331.2 = 97.5% (92.2%, 99.2%)	322.9/331.2 = 97.5% (92.2%, 99.2%)	317/331.2 = 95.7% (89.9%, 98.2%)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	445	8379.9/9558.4 = 87.7% (82.8%, 91.3%)	8426.5/9558.4 = 88.2% (83.4%, 91.7%)	7835.6/9558.4 = 82.0% (76.7%, 86.3%)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	149	1028/1063.2 = 96.7% (89.2%, 99.0%)	1028/1063.2 = 96.7% (89.2%, 99.0%)	954.9/1063.2 = 89.8% (80.7%, 94.9%)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	147	855.3/1025.8 = 83.4% (73.8%, 89.9%)	855.3/1025.8 = 83.4% (73.8%, 89.9%)	657.5/1025.8 = 64.1% (53.6%, 73.4%)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	445	9504.5/9558.4 = 99.4% (97.8%, 99.9%)	9504.5/9558.4 = 99.4% (97.8%, 99.9%)	9357.2/9558.4 = 97.9% (95.0%, 99.1%)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	149	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)	1063.2/1063.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	88.8/9262.6 = 1.0% (0.2%, 3.7%)	88.8/9262.6 = 1.0% (0.2%, 3.7%)	0/9262.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	147	978.9/1025.8 = 95.4% (88.1%, 98.3%)	978.9/1025.8 = 95.4% (88.1%, 98.3%)	936.2/1025.8 = 91.3% (82.8%, 95.8%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	214	1967.1/2279 = 86.3% (81.1%, 90.3%)	1967.1/2279 = 86.3% (81.1%, 90.3%)	1729.6/2279 = 75.9% (69.6%, 81.2%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	236.9/248 = 95.5% (86.2%, 98.7%)	236.9/248 = 95.5% (86.2%, 98.7%)	214.7/248 = 86.6% (75.4%, 93.1%)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	76.3/2454 = 3.1% (0.4%, 20.6%)	76.3/2454 = 3.1% (0.4%, 20.6%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	186.7/226 = 82.6% (72.4%, 89.6%)	190.1/226 = 84.1% (74.3%, 90.7%)	160.7/226 = 71.1% (59.9%, 80.2%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	214	2219.9/2279 = 97.4% (93.8%, 98.9%)	2219.9/2279 = 97.4% (93.8%, 98.9%)	2181.6/2279 = 95.7% (91.6%, 97.9%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	43.1/2454 = 1.8% (0.2%, 12.3%)	43.1/2454 = 1.8% (0.2%, 12.3%)	0/2454 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	217.6/226 = 96.3% (88.7%, 98.9%)	217.6/226 = 96.3% (88.7%, 98.9%)	211.8/226 = 93.7% (85.3%, 97.4%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	7083.2/8239 = 86.0% (80.3%, 90.2%)	7129.8/8239 = 86.5% (81.0%, 90.7%)	6587.7/8239 = 80.0% (73.8%, 85.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	866.1/897 = 96.6% (86.9%, 99.2%)	866.1/897 = 96.6% (86.9%, 99.2%)	795.6/897 = 88.7% (77.8%, 94.6%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	72	709.6/872 = 81.4% (70.1%, 89.1%)	709.6/872 = 81.4% (70.1%, 89.1%)	522.1/872 = 59.9% (47.7%, 70.9%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	8185.1/8239 = 99.3% (97.4%, 99.8%)	8185.1/8239 = 99.3% (97.4%, 99.8%)	8045.2/8239 = 97.6% (94.3%, 99.1%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)	897/897 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)	0/7780 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	72	825.1/872 = 94.6% (86.0%, 98.1%)	825.1/872 = 94.6% (86.0%, 98.1%)	783.9/872 = 89.9% (79.8%, 95.2%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	255	1386.2/1457.6 = 95.1% (91.4%, 97.3%)	1393.5/1457.6 = 95.6% (92.0%, 97.6%)	1305.7/1457.6 = 89.6% (85.0%, 92.9%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	118.2/120.8 = 97.8% (85.4%, 99.7%)	118.2/120.8 = 97.8% (85.4%, 99.7%)	118.2/120.8 = 97.8% (85.4%, 99.7%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	44	73.2/1642.4 = 4.5% (1.0%, 17.7%)	73.2/1642.4 = 4.5% (1.0%, 17.7%)	0/1642.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48	97.8/105.2 = 92.9% (79.7%, 97.8%)	97.8/105.2 = 92.9% (79.7%, 97.8%)	87.9/105.2 = 83.5% (69.0%, 92.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	255	1434.9/1457.6 = 98.4% (95.7%, 99.4%)	1434.9/1457.6 = 98.4% (95.7%, 99.4%)	1416.2/1457.6 = 97.2% (94.0%, 98.7%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)	120.8/120.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	44	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)	0/1642.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	48	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)	105.2/105.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	227	1296.7/1319.4 = 98.3% (95.3%, 99.4%)	1296.7/1319.4 = 98.3% (95.3%, 99.4%)	1247.9/1319.4 = 94.6% (90.5%, 97.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	161.9/166.2 = 97.4% (89.6%, 99.4%)	161.9/166.2 = 97.4% (89.6%, 99.4%)	159.3/166.2 = 95.8% (87.3%, 98.7%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	145.7/153.8 = 94.7% (86.2%, 98.1%)	145.7/153.8 = 94.7% (86.2%, 98.1%)	135.4/153.8 = 88.1% (78.7%, 93.6%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	227	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1319.4/1319.4 = 100.0% (100.0%, 100.0%)	1312/1319.4 = 99.4% (96.1%, 99.9%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)	166.2/166.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	88.8/1482.6 = 6.0% (1.4%, 22.0%)	88.8/1482.6 = 6.0% (1.4%, 22.0%)	0/1482.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	153.8/153.8 = 100.0% (100.0%, 100.0%)	153.8/153.8 = 100.0% (100.0%, 100.0%)	152.2/153.8 = 99.0% (92.9%, 99.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Sex								
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	395	4737.9/5298.6 = 89.4% (83.8%, 93.2%)	4745.3/5298.6 = 89.6% (83.9%, 93.4%)	4439.5/5298.6 = 83.8% (77.6%, 88.5%)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	557.7/564.7 = 98.8% (94.9%, 99.7%)	557.7/564.7 = 98.8% (94.9%, 99.7%)	522.3/564.7 = 92.5% (83.1%, 96.9%)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	105.1/4771.7 = 2.2% (0.5%, 9.9%)	105.1/4771.7 = 2.2% (0.5%, 9.9%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	433.2/529.2 = 81.9% (69.1%, 90.1%)	433.2/529.2 = 81.9% (69.1%, 90.1%)	328.3/529.2 = 62.0% (49.2%, 73.4%)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	395	5254.4/5298.6 = 99.2% (97.9%, 99.7%)	5254.4/5298.6 = 99.2% (97.9%, 99.7%)	5101.6/5298.6 = 96.3% (91.7%, 98.4%)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)	564.7/564.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	44.4/4771.7 = 0.9% (0.1%, 6.6%)	44.4/4771.7 = 0.9% (0.1%, 6.6%)	0/4771.7 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	517/529.2 = 97.7% (88.9%, 99.6%)	517/529.2 = 97.7% (88.9%, 99.6%)	483.7/529.2 = 91.4% (79.2%, 96.7%)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	519	6995.2/7996.4 = 87.5% (82.6%, 91.1%)	7041.9/7996.4 = 88.1% (83.3%, 91.6%)	6431.3/7996.4 = 80.4% (75.1%, 84.8%)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	153	825.4/867.3 = 95.2% (86.7%, 98.3%)	825.4/867.3 = 95.2% (86.7%, 98.3%)	765.4/867.3 = 88.3% (78.1%, 94.1%)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	87	44.4/8587.3 = 0.5% (0.1%, 3.7%)	44.4/8587.3 = 0.5% (0.1%, 3.7%)	0/8587.3 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	155	706.6/827.8 = 85.4% (75.6%, 91.7%)	710/827.8 = 85.8% (76.0%, 92.0%)	577.7/827.8 = 69.8% (58.8%, 78.9%)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	519	7905/7996.4 = 98.9% (97.2%, 99.5%)	7905/7996.4 = 98.9% (97.2%, 99.5%)	7853.4/7996.4 = 98.2% (96.6%, 99.1%)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	153	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)	867.3/867.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	87	87.5/8587.3 = 1.0% (0.2%, 4.1%)	87.5/8587.3 = 1.0% (0.2%, 4.1%)	0/8587.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	155	784.7/827.8 = 94.8% (86.4%, 98.1%)	784.7/827.8 = 94.8% (86.4%, 98.1%)	769.4/827.8 = 93.0% (84.0%, 97.1%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	269	5560.6/6524.4 = 85.2% (79.3%, 89.7%)	5607.3/6524.4 = 85.9% (80.1%, 90.3%)	5076.7/6524.4 = 77.8% (71.3%, 83.2%)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	79	664.2/701.8 = 94.6% (83.7%, 98.4%)	664.2/701.8 = 94.6% (83.7%, 98.4%)	606.9/701.8 = 86.5% (73.8%, 93.5%)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	52	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	83	561/673.1 = 83.3% (71.3%, 91.0%)	564.4/673.1 = 83.8% (71.8%, 91.4%)	437.7/673.1 = 65.0% (51.8%, 76.3%)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	269	6437/6524.4 = 98.7% (96.5%, 99.5%)	6437/6524.4 = 98.7% (96.5%, 99.5%)	6411.4/6524.4 = 98.3% (96.2%, 99.2%)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	79	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	52	43.1/7188.8 = 0.6% (0.1%, 4.4%)	43.1/7188.8 = 0.6% (0.1%, 4.4%)	0/7188.8 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	83	630.1/673.1 = 93.6% (83.3%, 97.7%)	630.1/673.1 = 93.6% (83.3%, 97.7%)	616.4/673.1 = 91.6% (80.5%, 96.6%)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	163	3489.6/3993.6 = 87.4% (79.9%, 92.3%)	3489.6/3993.6 = 87.4% (79.9%, 92.3%)	3240.5/3993.6 = 81.1% (73.0%, 87.2%)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	67	438.8/443.2 = 99.0% (93.0%, 99.9%)	438.8/443.2 = 99.0% (93.0%, 99.9%)	403.4/443.2 = 91.0% (79.0%, 96.5%)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	28	76.3/3045.2 = 2.5% (0.3%, 17.6%)	76.3/3045.2 = 2.5% (0.3%, 17.6%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	335.3/424.9 = 78.9% (63.2%, 89.1%)	335.3/424.9 = 78.9% (63.2%, 89.1%)	245/424.9 = 57.7% (42.2%, 71.8%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	163	3968.1/3993.6 = 99.4% (97.5%, 99.8%)	3968.1/3993.6 = 99.4% (97.5%, 99.8%)	3815.3/3993.6 = 95.5% (89.2%, 98.2%)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	67	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)	443.2/443.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	28	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)	0/3045.2 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	412.7/424.9 = 97.1% (86.1%, 99.5%)	412.7/424.9 = 97.1% (86.1%, 99.5%)	379.3/424.9 = 89.3% (74.3%, 96.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	232	1248.3/1305 = 95.7% (91.9%, 97.7%)	1255.7/1305 = 96.2% (92.6%, 98.1%)	1199/1305 = 91.9% (87.3%, 94.9%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	118.9/121.5 = 97.9% (85.5%, 99.7%)	118.9/121.5 = 97.9% (85.5%, 99.7%)	118.9/121.5 = 97.9% (85.5%, 99.7%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	48	28.8/1726.6 = 1.7% (0.2%, 11.6%)	28.8/1726.6 = 1.7% (0.2%, 11.6%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51	97.9/104.4 = 93.8% (81.3%, 98.1%)	97.9/104.4 = 93.8% (81.3%, 98.1%)	83.3/104.4 = 79.8% (65.3%, 89.2%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	232	1286.3/1305 = 98.6% (95.4%, 99.6%)	1286.3/1305 = 98.6% (95.4%, 99.6%)	1286.3/1305 = 98.6% (95.4%, 99.6%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)	121.5/121.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	48	44.4/1726.6 = 2.6% (0.3%, 17.2%)	44.4/1726.6 = 2.6% (0.3%, 17.2%)	0/1726.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	51	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)	104.4/104.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	250	1434.6/1472 = 97.5% (94.3%, 98.9%)	1434.6/1472 = 97.5% (94.3%, 98.9%)	1354.6/1472 = 92.0% (87.8%, 94.9%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	74	161.2/165.5 = 97.4% (89.5%, 99.4%)	161.2/165.5 = 97.4% (89.5%, 99.4%)	158.6/165.5 = 95.8% (87.3%, 98.7%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	44.4/1398.4 = 3.2% (0.4%, 21.1%)	44.4/1398.4 = 3.2% (0.4%, 21.1%)	0/1398.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	72	145.6/154.6 = 94.2% (84.9%, 97.9%)	145.6/154.6 = 94.2% (84.9%, 97.9%)	140/154.6 = 90.6% (80.8%, 95.6%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	250	1468/1472 = 99.7% (98.1%, 100.0%)	1468/1472 = 99.7% (98.1%, 100.0%)	1441.9/1472 = 98.0% (95.0%, 99.2%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	74	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)	165.5/165.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	44.4/1398.4 = 3.2% (0.4%, 21.1%)	44.4/1398.4 = 3.2% (0.4%, 21.1%)	0/1398.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	72	154.6/154.6 = 100.0% (100.0%, 100.0%)	154.6/154.6 = 100.0% (100.0%, 100.0%)	153.1/154.6 = 99.0% (92.9%, 99.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	136	1226.3/1363.4 = 89.9% (81.7%, 94.7%)	1226.3/1363.4 = 89.9% (81.7%, 94.7%)	1109.8/1363.4 = 81.4% (71.0%, 88.7%)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	35	144/145.7 = 98.8% (91.4%, 99.9%)	144/145.7 = 98.8% (91.4%, 99.9%)	141.7/145.7 = 97.2% (88.7%, 99.4%)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	20	28.8/1237.6 = 2.3% (0.3%, 17.1%)	28.8/1237.6 = 2.3% (0.3%, 17.1%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	38	125.7/133.7 = 94.0% (84.6%, 97.8%)	125.7/133.7 = 94.0% (84.6%, 97.8%)	90/133.7 = 67.3% (42.1%, 85.3%)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	136	1328.6/1363.4 = 97.4% (88.5%, 99.5%)	1328.6/1363.4 = 97.4% (88.5%, 99.5%)	1328.6/1363.4 = 97.4% (88.5%, 99.5%)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	35	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)	145.7/145.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	20	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)	0/1237.6 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	38	133.7/133.7 = 100.0% (100.0%, 100.0%)	133.7/133.7 = 100.0% (100.0%, 100.0%)	129.7/133.7 = 97.0% (87.6%, 99.3%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	690	9218.1/10481.2 = 87.9% (83.8%, 91.2%)	9272.1/10481.2 = 88.5% (84.4%, 91.6%)	8529.4/10481.2 = 81.4% (76.8%, 85.2%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	217	1119.5/1162.3 = 96.3% (90.0%, 98.7%)	1119.5/1162.3 = 96.3% (90.0%, 98.7%)	1030.9/1162.3 = 88.7% (80.6%, 93.7%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	130	120.7/10828.8 = 1.1% (0.3%, 4.6%)	120.7/10828.8 = 1.1% (0.3%, 4.6%)	0/10828.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	214	941.9/1121.8 = 84.0% (75.7%, 89.8%)	945.4/1121.8 = 84.3% (76.0%, 90.1%)	743.9/1121.8 = 66.3% (57.1%, 74.4%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	690	10380.4/10481.2 = 99.0% (97.9%, 99.6%)	10380.4/10481.2 = 99.0% (97.9%, 99.6%)	10269.3/10481.2 = 98.0% (96.3%, 98.9%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	217	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)	1162.3/1162.3 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	130	87.5/10828.8 = 0.8% (0.2%, 3.2%)	87.5/10828.8 = 0.8% (0.2%, 3.2%)	0/10828.8 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	214	1076.3/1121.8 = 95.9% (89.7%, 98.5%)	1076.3/1121.8 = 95.9% (89.7%, 98.5%)	1048.8/1121.8 = 93.5% (86.3%, 97.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	88	1288.7/1450.4 = 88.9% (74.6%, 95.6%)	1288.7/1450.4 = 88.9% (74.6%, 95.6%)	1231.7/1450.4 = 84.9% (71.6%, 92.6%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	22	119.6/124 = 96.5% (75.1%, 99.6%)	119.6/124 = 96.5% (75.1%, 99.6%)	115.2/124 = 92.9% (75.0%, 98.3%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	13	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	18	72.2/101.5 = 71.1% (32.1%, 92.8%)	72.2/101.5 = 71.1% (32.1%, 92.8%)	72.2/101.5 = 71.1% (32.1%, 92.8%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	88	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1450.4/1450.4 = 100.0% (100.0%, 100.0%)	1357.1/1450.4 = 93.6% (77.2%, 98.4%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	22	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)	124/124 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	13	44.4/1292.7 = 3.4% (0.3%, 28.0%)	44.4/1292.7 = 3.4% (0.3%, 28.0%)	0/1292.7 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	18	91.8/101.5 = 90.4% (52.1%, 98.8%)	91.8/101.5 = 90.4% (52.1%, 98.8%)	74.6/101.5 = 73.5% (32.9%, 94.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	362	5915.2/6597 = 89.7% (84.2%, 93.4%)	5922.6/6597 = 89.8% (84.3%, 93.5%)	5515.3/6597 = 83.6% (77.6%, 88.3%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	733.3/773.8 = 94.8% (85.2%, 98.3%)	733.3/773.8 = 94.8% (85.2%, 98.3%)	671.1/773.8 = 86.7% (75.6%, 93.2%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	44.4/6586.8 = 0.7% (0.1%, 4.8%)	44.4/6586.8 = 0.7% (0.1%, 4.8%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	546.7/666.4 = 82.0% (70.0%, 90.0%)	550.2/666.4 = 82.6% (70.5%, 90.4%)	458.9/666.4 = 68.9% (56.4%, 79.1%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	362	6531.1/6597 = 99.0% (97.8%, 99.6%)	6531.1/6597 = 99.0% (97.8%, 99.6%)	6436.8/6597 = 97.6% (95.1%, 98.8%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	652.7/666.4 = 97.9% (86.3%, 99.7%)	652.7/666.4 = 97.9% (86.3%, 99.7%)	625.2/666.4 = 93.8% (82.4%, 98.0%)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	195	1743.5/2012.2 = 86.6% (78.6%, 92.0%)	1743.5/2012.2 = 86.6% (78.6%, 92.0%)	1549.3/2012.2 = 77.0% (67.8%, 84.2%)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	187/195.6 = 95.6% (72.5%, 99.4%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	220.4/265.1 = 83.2% (66.7%, 92.4%)	220.4/265.1 = 83.2% (66.7%, 92.4%)	154/265.1 = 58.1% (40.8%, 73.6%)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	195	1977.3/2012.2 = 98.3% (91.8%, 99.7%)	1977.3/2012.2 = 98.3% (91.8%, 99.7%)	1977.3/2012.2 = 98.3% (91.8%, 99.7%)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)	195.6/195.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	43.1/2311.6 = 1.9% (0.2%, 13.1%)	43.1/2311.6 = 1.9% (0.2%, 13.1%)	0/2311.6 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	243.2/265.1 = 91.7% (74.1%, 97.7%)	243.2/265.1 = 91.7% (74.1%, 97.7%)	241.6/265.1 = 91.1% (74.1%, 97.4%)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	67	653.8/673.6 = 97.1% (91.8%, 99.0%)	653.8/673.6 = 97.1% (91.8%, 99.0%)	630/673.6 = 93.5% (87.7%, 96.7%)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	24	78.8/81.1 = 97.1% (80.0%, 99.7%)	78.8/81.1 = 97.1% (80.0%, 99.7%)	76.5/81.1 = 94.3% (79.4%, 98.6%)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	12	28.8/609.1 = 4.7% (0.5%, 34.8%)	28.8/609.1 = 4.7% (0.5%, 34.8%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	13	45.9/48.4 = 94.9% (64.0%, 99.5%)	45.9/48.4 = 94.9% (64.0%, 99.5%)	31.3/48.4 = 64.6% (19.5%, 93.2%)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	67	669.7/673.6 = 99.4% (95.8%, 99.9%)	669.7/673.6 = 99.4% (95.8%, 99.9%)	665.7/673.6 = 98.8% (95.4%, 99.7%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)	81.1/81.1 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	12	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)	0/609.1 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	13	45.9/48.4 = 94.9% (64.0%, 99.5%)	45.9/48.4 = 94.9% (64.0%, 99.5%)	45.9/48.4 = 94.9% (64.0%, 99.5%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	139.5/151.4 = 92.1% (65.9%, 98.6%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	5.6/15.3 = 36.5%	5.6/15.3 = 36.5%	3.1/15.3 = 20.4%
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	13	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)	151.4/151.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)	31.1/31.1 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)	0/247.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%	15.3/15.3 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	94.3/98.2 = 96.0% (70.1%, 99.6%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	1	0/2.5 = 0.0%	0/2.5 = 0.0%	0/2.5 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	17	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)	98.2/98.2 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)	23/23 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	1	0/28.8 = 0.0%	0/28.8 = 0.0%	0/28.8 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	52	416.8/498.5 = 83.6% (62.3%, 94.0%)	416.8/498.5 = 83.6% (62.3%, 94.0%)	382/498.5 = 76.6% (54.9%, 89.8%)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	19	56.5/61.4 = 92.0% (71.7%, 98.1%)	56.5/61.4 = 92.0% (71.7%, 98.1%)	45.2/61.4 = 73.6% (30.6%, 94.6%)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	52	494.5/498.5 = 99.2% (94.3%, 99.9%)	494.5/498.5 = 99.2% (94.3%, 99.9%)	494.5/498.5 = 99.2% (94.3%, 99.9%)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	12	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)	56.4/56.4 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)	0/554 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	19	61.4/61.4 = 100.0% (100.0%, 100.0%)	61.4/61.4 = 100.0% (100.0%, 100.0%)	58.9/61.4 = 96.0% (72.4%, 99.5%)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	34	426.4/469.2 = 90.9% (68.6%, 97.8%)	426.4/469.2 = 90.9% (68.6%, 97.8%)	383.6/469.2 = 81.8% (59.3%, 93.2%)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	11.5/13.8 = 83.2% (18.4%, 99.1%)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	22.6/24.1 = 93.5% (32.5%, 99.8%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	34	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)	469.2/469.2 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)	13.8/13.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/232.6 = 0.0%	0/232.6 = 0.0%	0/232.6 = 0.0%
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	5	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)	24.1/24.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	87	1107.8/1413.2 = 78.4% (61.9%, 89.0%)	1154.4/1413.2 = 81.7% (65.2%, 91.4%)	1014/1413.2 = 71.8% (55.6%, 83.7%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	139.5/155 = 90.0% (45.7%, 99.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	14	76.3/1337.6 = 5.7% (0.6%, 38.4%)	76.3/1337.6 = 5.7% (0.6%, 38.4%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	24	149.2/165.4 = 90.2% (55.7%, 98.5%)	149.2/165.4 = 90.2% (55.7%, 98.5%)	103.1/165.4 = 62.3% (33.5%, 84.4%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	87	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1413.2/1413.2 = 100.0% (100.0%, 100.0%)	1400.5/1413.2 = 99.1% (93.6%, 99.9%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	20	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)	155/155 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	14	44.4/1337.6 = 3.3% (0.4%, 25.1%)	44.4/1337.6 = 3.3% (0.4%, 25.1%)	0/1337.6 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	24	148.3/165.4 = 89.6% (55.9%, 98.3%)	148.3/165.4 = 89.6% (55.9%, 98.3%)	148.3/165.4 = 89.6% (55.9%, 98.3%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	420	3833.3/4289 = 89.4% (84.6%, 92.8%)	3833.3/4289 = 89.4% (84.6%, 92.8%)	3490.9/4289 = 81.4% (75.8%, 86.0%)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	458/462 = 99.1% (96.5%, 99.8%)	458/462 = 99.1% (96.5%, 99.8%)	444.7/462 = 96.3% (89.1%, 98.8%)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	73	28.8/4319 = 0.7% (0.1%, 4.8%)	28.8/4319 = 0.7% (0.1%, 4.8%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	111	374.8/439 = 85.4% (74.2%, 92.2%)	374.8/439 = 85.4% (74.2%, 92.2%)	276.8/439 = 63.1% (50.1%, 74.4%)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	420	4219.3/4289 = 98.4% (95.2%, 99.5%)	4219.3/4289 = 98.4% (95.2%, 99.5%)	4215.3/4289 = 98.3% (95.2%, 99.4%)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)	462/462 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	73	43.1/4319 = 1.0% (0.1%, 7.0%)	43.1/4319 = 1.0% (0.1%, 7.0%)	0/4319 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	111	414.6/439 = 94.4% (83.7%, 98.3%)	414.6/439 = 94.4% (83.7%, 98.3%)	410.6/439 = 93.5% (83.4%, 97.7%)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	362	5915.2/6597 = 89.7% (84.2%, 93.4%)	5922.6/6597 = 89.8% (84.3%, 93.5%)	5515.3/6597 = 83.6% (77.6%, 88.3%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	733.3/773.8 = 94.8% (85.2%, 98.3%)	733.3/773.8 = 94.8% (85.2%, 98.3%)	671.1/773.8 = 86.7% (75.6%, 93.2%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	44.4/6586.8 = 0.7% (0.1%, 4.8%)	44.4/6586.8 = 0.7% (0.1%, 4.8%)	0/6586.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	546.7/666.4 = 82.0% (70.0%, 90.0%)	550.2/666.4 = 82.6% (70.5%, 90.4%)	458.9/666.4 = 68.9% (56.4%, 79.1%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	362	6531.1/6597 = 99.0% (97.8%, 99.6%)	6531.1/6597 = 99.0% (97.8%, 99.6%)	6436.8/6597 = 97.6% (95.1%, 98.8%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)	773.8/773.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)	0/6586.8 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	652.7/666.4 = 97.9% (86.3%, 99.7%)	652.7/666.4 = 97.9% (86.3%, 99.7%)	625.2/666.4 = 93.8% (82.4%, 98.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	192	2958/3386 = 87.4% (81.4%, 91.6%)	2958/3386 = 87.4% (81.4%, 91.6%)	2671.1/3386 = 78.9% (71.8%, 84.6%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	69	372.7/375 = 99.4% (95.6%, 99.9%)	372.7/375 = 99.4% (95.6%, 99.9%)	359.4/375 = 95.8% (86.7%, 98.8%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	299.9/361 = 83.1% (69.5%, 91.4%)	299.9/361 = 83.1% (69.5%, 91.4%)	209.7/361 = 58.1% (42.8%, 72.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	192	3324.2/3386 = 98.2% (93.9%, 99.5%)	3324.2/3386 = 98.2% (93.9%, 99.5%)	3324.2/3386 = 98.2% (93.9%, 99.5%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	69	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	43.1/3281 = 1.3% (0.2%, 9.4%)	43.1/3281 = 1.3% (0.2%, 9.4%)	0/3281 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	336.6/361 = 93.2% (80.2%, 97.9%)	336.6/361 = 93.2% (80.2%, 97.9%)	334.1/361 = 92.6% (80.0%, 97.5%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	175	4601.9/5217.3 = 88.2% (81.3%, 92.8%)	4601.9/5217.3 = 88.2% (81.3%, 92.8%)	4253.6/5217.3 = 81.5% (73.9%, 87.3%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	59	567/602.4 = 94.1% (81.1%, 98.4%)	567/602.4 = 94.1% (81.1%, 98.4%)	507.5/602.4 = 84.2% (69.9%, 92.5%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	407.9/517.6 = 78.8% (63.4%, 88.9%)	411.3/517.6 = 79.5% (64.0%, 89.4%)	332.4/517.6 = 64.2% (48.6%, 77.4%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	175	5166.2/5217.3 = 99.0% (97.4%, 99.6%)	5166.2/5217.3 = 99.0% (97.4%, 99.6%)	5094/5217.3 = 97.6% (94.3%, 99.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	59	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)	602.4/602.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)	0/4988.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	503.9/517.6 = 97.3% (82.5%, 99.7%)	503.9/517.6 = 97.3% (82.5%, 99.7%)	476.4/517.6 = 92.0% (77.5%, 97.5%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	228	875.3/903 = 96.9% (93.7%, 98.5%)	875.3/903 = 96.9% (93.7%, 98.5%)	819.8/903 = 90.8% (86.2%, 93.9%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	51	85.3/87 = 98.0% (86.6%, 99.7%)	85.3/87 = 98.0% (86.6%, 99.7%)	85.3/87 = 98.0% (86.6%, 99.7%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	28.8/1038 = 2.8% (0.4%, 18.7%)	28.8/1038 = 2.8% (0.4%, 18.7%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	50	74.9/78 = 96.0% (84.7%, 99.0%)	74.9/78 = 96.0% (84.7%, 99.0%)	67.1/78 = 86.0% (72.9%, 93.4%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	228	895.1/903 = 99.1% (96.5%, 99.8%)	895.1/903 = 99.1% (96.5%, 99.8%)	891.1/903 = 98.7% (96.0%, 99.6%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	51	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)	87/87 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)	0/1038 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	50	78/78 = 100.0% (100.0%, 100.0%)	78/78 = 100.0% (100.0%, 100.0%)	76.4/78 = 98.0% (86.3%, 99.7%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	187	1313.3/1379.7 = 95.2% (91.0%, 97.5%)	1320.7/1379.7 = 95.7% (91.6%, 97.9%)	1261.6/1379.7 = 91.4% (86.4%, 94.7%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	66	166.2/171.4 = 97.0% (88.3%, 99.3%)	166.2/171.4 = 97.0% (88.3%, 99.3%)	163.6/171.4 = 95.5% (86.5%, 98.6%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	44.4/1598.6 = 2.8% (0.4%, 18.7%)	44.4/1598.6 = 2.8% (0.4%, 18.7%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	138.8/148.8 = 93.3% (83.1%, 97.5%)	138.8/148.8 = 93.3% (83.1%, 97.5%)	126.5/148.8 = 85.0% (73.2%, 92.2%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	187	1364.9/1379.7 = 98.9% (95.8%, 99.7%)	1364.9/1379.7 = 98.9% (95.8%, 99.7%)	1342.8/1379.7 = 97.3% (93.7%, 98.9%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	66	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)	0/1598.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)	148.8/148.8 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
All participants						
	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	914	10 (10, 10)
	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	10 (10, 10)
	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	10 (10, 10)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	914	5 (5, 5)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	914	5 (5, 5)
	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	274	10 (10, 10)
	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	10 (10, 10)
	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	10 (10, 10)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	274	5 (5, 5)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	274	5 (5, 5)
	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)
	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 11)
	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	270	10 (10, 10)
	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	270	10 (10, 10)
	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	270	10 (10, 10)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	270	5 (5, 5)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	270	5 (5, 5)
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	914	23543 (19945, 27790)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	22926 (19863, 26460)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	40963 (36741, 45671)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	914	106 (91, 125)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	914	189 (161, 222)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	274	43010 (33140, 55819)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	36133 (28182, 46328)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	79981 (65041, 98352)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	274	186 (142, 243)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	274	420 (314, 560)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 10)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	270	12518 (9458, 16567)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	270	12861 (10150, 16296)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	270	18191 (15159, 21829)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	270	51 (40, 66)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	270	129 (98, 169)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	914	325136 (267241, 395574)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	966160 (823437, 1133621)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	2087965 (1831068, 2380904)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	914	1497 (1228, 1825)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	914	2223 (1809, 2733)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	274	980579 (697583, 1378379)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	2298869 (1785648, 2959596)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	5346334 (4339333, 6587023)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	274	5680 (3863, 8351)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	274	7837 (5545, 11076)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 10)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	270	130008 (92643, 182444)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	270	382614 (299829, 488256)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	270	676872 (531354, 862241)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	270	566 (409, 783)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	270	1324 (937, 1870)

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age						
Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	432	10 (10, 10)
Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	10 (10, 10)
Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	10 (10, 10)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	432	5 (5, 5)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	432	5 (5, 5)
Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	146	10 (10, 10)
Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	10 (10, 10)
Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	10 (10, 10)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	146	5 (5, 5)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	146	5 (5, 5)
Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 11)
Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 11)
Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	147	10 (10, 10)
Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	147	10 (10, 10)
Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	147	10 (10, 10)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	147	5 (5, 5)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	147	5 (5, 5)
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	432	18416 (15002, 22607)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	17393 (14565, 20770)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	31397 (27475, 35879)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	432	85 (69, 103)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	432	157 (129, 192)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	146	32567 (23744, 44670)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	24939 (18393, 33814)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	59400 (46119, 76506)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	146	144 (104, 198)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	146	339 (238, 482)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	147	9820 (7012, 13753)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	147	9737 (7318, 12957)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	147	13380 (10752, 16650)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	147	40 (29, 54)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	147	106 (76, 147)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	432	253319 (198848, 322710)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	737116 (604473, 898866)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	1643373 (1397160, 1932976)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	432	1136 (890, 1449)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	432	1750 (1355, 2260)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	146	739998 (487226, 1123907)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	1708031 (1250384, 2333179)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	4266733 (3292306, 5529560)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	146	4061 (2527, 6527)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	146	6238 (4090, 9513)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	147	93772 (62211, 141344)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	147	270061 (201183, 362521)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	147	484596 (361146, 650244)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	147	387 (262, 572)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	147	1009 (665, 1531)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	482	10 (10, 10)
Age \geq 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	10 (10, 10)
Age \geq 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	10 (10, 10)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	482	5 (5, 5)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	482	5 (5, 5)
Age \geq 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	128	10 (10, 10)
Age \geq 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	10 (10, 10)
Age \geq 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	10 (10, 10)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	128	5 (5, 5)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	128	5 (5, 5)
Age \geq 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	83	5 (5, 5)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	83	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)
Age \geq 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)
Age \geq 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)
Age \geq 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)
Age \geq 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)
Age \geq 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	482	59687 (50609, 70395)
Age \geq 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	65260 (56734, 75068)
Age \geq 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	112166 (98902, 127209)
Age \geq 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	482	254 (214, 300)
Age \geq 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	482	381 (321, 451)
Age \geq 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	128	130450 (94702, 179694)
Age \geq 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	158619 (123545, 203649)
Age \geq 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	262073 (211994, 323982)
Age \geq 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	128	522 (373, 731)
Age \geq 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	128	988 (733, 1331)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	83	5 (5, 5)
Age \geq 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	83	5 (5, 5)
Age \geq 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	35028 (24879, 49317)
Age \geq 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	41836 (32047, 54614)
Age \geq 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	66891 (53117, 84238)
Age \geq 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	156 (112, 216)
Age \geq 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	123	301 (219, 413)
Age \geq 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	482	836805 (684275, 1023335)
Age \geq 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	2692372 (2329146, 3112243)
Age \geq 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	5171042 (4536102, 5894857)
Age \geq 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	482	4259 (3414, 5312)
Age \geq 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	482	5506 (4535, 6685)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	128	3014476 (2173987, 4179907)
Age \geq 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	7520373 (6146909, 9200723)
Age \geq 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	13148461 (11661345, 14825221)
Age \geq 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	128	21658 (15437, 30385)
Age \geq 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	128	19480 (13318, 28494)
Age \geq 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	83	10 (10, 10)
Age \geq 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	83	5 (5, 5)
Age \geq 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	83	5 (5, 5)
Age \geq 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	519433 (364323, 740581)
Age \geq 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	1675605 (1276999, 2198632)
Age \geq 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	2790960 (2209589, 3525298)
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	2827 (1887, 4233)
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	123	4185 (2859, 6127)

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Risk for Severe Covid-19						
At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	469	10 (10, 10)
At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	10 (10, 10)
At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	10 (10, 10)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	469	5 (5, 5)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	469	5 (5, 5)
At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)
At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)
At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)
At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 11)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)
At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)
At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	469	23746 (19934, 28287)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	26276 (22610, 30535)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	45842 (40067, 52448)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	469	103 (87, 122)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	469	215 (180, 258)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	55180 (40419, 75332)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	55528 (43641, 70653)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	103862 (82479, 130788)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	220 (161, 302)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	125	443 (318, 617)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	16553 (12215, 22429)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	16713 (12642, 22096)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	26705 (21285, 33505)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	69 (52, 93)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	123	180 (133, 243)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	469	335374 (270080, 416453)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	1142597 (961925, 1357205)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	2144439 (1840509, 2498559)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	469	1796 (1424, 2264)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	469	2766 (2265, 3377)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	1327591 (937265, 1880469)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	2930270 (2216035, 3874704)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	6396516 (5214355, 7846688)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	6128 (4355, 8625)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	125	11182 (7684, 16271)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 10)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	197242 (138403, 281094)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	663561 (492320, 894363)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	1012116 (794913, 1288669)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	931 (651, 1331)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	123	2086 (1418, 3067)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	445	10 (10, 10)
Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	10 (10, 10)
Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	10 (10, 10)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5 (5, 5)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5 (5, 5)
Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	149	10 (10, 10)
Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	10 (10, 10)
Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	10 (10, 10)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	149	5 (5, 5)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	149	5 (5, 5)
Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 11)
Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 11)
Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	147	10 (10, 11)
Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	147	10 (10, 10)
Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	147	10 (10, 10)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	147	5 (5, 5)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	147	5 (5, 5)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	445	23464 (18827, 29244)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	21736 (17965, 26298)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	39200 (34023, 45165)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	445	108 (87, 133)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	445	180 (145, 223)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	149	39449 (28242, 55103)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	31130 (22510, 43050)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	73051 (55946, 95386)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	149	175 (124, 247)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	149	412 (284, 597)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	147	11438 (8001, 16352)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	147	11818 (8756, 15950)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	147	16070 (12770, 20222)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	147	47 (34, 64)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	147	116 (82, 164)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445	321219 (247884, 416250)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	904842 (732112, 1118324)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	2066294 (1739231, 2454861)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	445	1394 (1075, 1808)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	445	2041 (1549, 2690)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	149	882754 (567083, 1374143)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	2113273 (1525010, 2928453)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	5023873 (3827375, 6594416)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	149	5532 (3337, 9171)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	149	6928 (4429, 10838)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	147	113637 (73666, 175296)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	147	320294 (235413, 435781)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	147	594413 (435730, 810886)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	147	482 (318, 728)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	147	1143 (737, 1774)

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Risk for Severe Covid-19						
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	214	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	214	5 (5, 5)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	214	5 (5, 5)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	73	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	10 (10, 10)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5 (5, 5)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5 (5, 5)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 11)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	214	15066 (11800, 19236)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	16530 (13368, 20441)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	31028 (25725, 37423)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	214	68 (54, 85)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	214	159 (123, 204)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	35719 (23749, 53721)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	30603 (22501, 41623)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	62641 (46271, 84801)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	142 (95, 213)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73	291 (187, 453)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 6)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	11526 (8014, 16577)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10221 (7219, 14470)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	16112 (12299, 21107)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	48 (34, 67)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	75	127 (87, 186)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	214	227691 (168852, 307033)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	761200 (595277, 973370)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	1498825 (1211392, 1854460)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	214	1203 (876, 1652)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	214	2067 (1571, 2720)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	848831 (532838, 1352218)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	1815884 (1228679, 2683724)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	4547755 (3405518, 6073108)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	2953 (1859, 4690)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	73	7954 (4852, 13039)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 11)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	115913 (72906, 184288)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	417627 (286526, 608715)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	575539 (423609, 781958)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	502 (325, 776)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	75	1382 (851, 2245)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	218	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5 (5, 5)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5 (5, 5)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	73	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	10 (10, 10)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5 (5, 5)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5 (5, 5)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 11)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 11)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 11)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	19467 (15117, 25069)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	17639 (14174, 21953)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	31500 (26782, 37050)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	90 (70, 115)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	218	157 (122, 200)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	31746 (21553, 46760)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	23567 (16129, 34434)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	58534 (42846, 79967)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	144 (97, 214)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73	353 (229, 545)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72	9421 (6230, 14246)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	72	9616 (6788, 13622)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	72	12751 (9770, 16642)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	72	38 (26, 55)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	72	101 (68, 150)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	260904 (193707, 351412)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	730590 (572430, 932450)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	1685764 (1382036, 2056240)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	1118 (830, 1506)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	218	1671 (1216, 2295)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	712451 (424544, 1195605)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	1679359 (1144789, 2463552)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	4192147 (3040678, 5779665)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	4435 (2453, 8017)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	73	5833 (3464, 9821)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	72	88760 (53701, 146707)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	72	241209 (168681, 344922)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	72	463469 (322830, 665378)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	72	362 (224, 583)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	72	930 (559, 1549)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	255	10 (10, 10)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	10 (10, 10)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	10 (10, 10)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	255	5 (5, 5)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	255	5 (5, 5)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 6)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	10 (10, 11)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	48	5 (5, 5)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	48	5 (5, 5)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	255	48363 (38230, 61183)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	54232 (44615, 65922)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	84391 (70325, 101269)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	255	199 (157, 252)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	255	348 (276, 438)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	134756 (86047, 211040)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	188670 (129392, 275106)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	293282 (210942, 407763)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	541 (337, 870)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	52	1052 (680, 1627)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 5)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	48	36017 (20724, 62595)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48	48060 (30237, 76388)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	48	79058 (52125, 119908)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48	155 (89, 270)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	48	378 (233, 613)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	255	614449 (455495, 828875)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	2156196 (1736284, 2677662)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	3754377 (3053564, 4616033)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	255	3359 (2423, 4656)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	255	4361 (3299, 5763)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	3325369 (2089439, 5292368)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	7826271 (5853680, 10463591)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	12884976 (10641883, 15600868)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	27431 (17819, 42227)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	52	22502 (13237, 38254)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 6)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	48	617829 (374065, 1020446)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	48	1793880 (1112795, 2891824)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	48	3402410 (2325361, 4978321)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	48	3501 (1863, 6577)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	48	5048 (2709, 9408)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	227	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	227	5 (5, 5)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	227	5 (5, 5)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	76	10 (10, 11)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5 (5, 5)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	227	75305 (60091, 94371)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	80069 (65707, 97571)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	153593 (130667, 180543)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	227	332 (263, 418)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	227	421 (328, 540)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	127407 (81244, 199800)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	139826 (99996, 195520)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	241494 (182978, 318724)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	508 (317, 815)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	76	944 (626, 1422)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	34367 (22390, 52751)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	38048 (27669, 52321)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	59664 (45819, 77691)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	156 (105, 232)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	75	257 (170, 390)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	227	1177109 (909148, 1524048)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	3441017 (2860842, 4138850)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	7365218 (6408010, 8465410)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	227	5534 (4137, 7404)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	227	7125 (5468, 9285)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	2806906 (1779671, 4427066)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	7305563 (5522547, 9664247)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	13343347 (11421210, 15588971)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	18240 (11134, 29880)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	76	17541 (10280, 29932)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 6)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	461295 (282331, 753702)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	1599200 (1156266, 2211811)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	2437171 (1815977, 3270859)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	2442 (1442, 4134)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	75	3681 (2278, 5949)

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Sex						
Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	395	10 (10, 10)
Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	10 (10, 10)
Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	10 (10, 10)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	395	5 (5, 5)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	395	5 (5, 5)
Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)
Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)
Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)
Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	76	10 (10, 11)
Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	11 (9, 12)
Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	10 (10, 10)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	76	5 (5, 5)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	76	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)
Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)
Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	395	27118 (20803, 35351)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	25738 (20110, 32941)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	40290 (34397, 47193)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	395	121 (93, 157)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	395	207 (158, 272)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	52664 (36905, 75154)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	43301 (30763, 60949)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	83762 (65541, 107048)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	223 (158, 315)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	121	449 (303, 666)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	10 (10, 10)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	10 (10, 10)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	10 (10, 10)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	5 (5, 5)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	76	5 (5, 5)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	115	11707 (7655, 17903)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	115	12838 (8743, 18852)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	115	16359 (12044, 22219)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115	43 (29, 63)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	115	100 (68, 146)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	395	358185 (259645, 494122)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	1032572 (803692, 1326633)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	2448348 (1992531, 3008439)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	395	1983 (1427, 2754)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	395	2322 (1694, 3181)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	1379076 (895389, 2124049)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	2628794 (1842173, 3751308)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	5518909 (4222583, 7213204)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	5567 (3235, 9581)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	121	9590 (6259, 14696)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	10 (10, 10)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	10 (10, 10)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	10 (10, 10)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	5 (5, 5)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	76	5 (5, 5)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115	120405 (68919, 210356)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	115	361345 (243436, 536364)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	115	578439 (406742, 822616)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	115	606 (358, 1023)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	115	930 (554, 1559)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	519	10 (10, 10)
Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	10 (10, 10)
Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	10 (10, 10)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	519	5 (5, 5)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	519	5 (5, 5)
Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	153	10 (10, 10)
Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	10 (10, 10)
Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	10 (10, 10)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	153	5 (5, 5)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	153	5 (5, 5)
Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)
Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)
Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	87	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	155	10 (10, 11)
Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	155	10 (10, 10)
Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	155	10 (10, 10)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	155	5 (5, 5)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	155	5 (5, 5)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	519	21438 (17319, 26535)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	21234 (17837, 25278)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	41415 (35725, 48012)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	519	98 (80, 120)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	519	178 (145, 218)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	153	37697 (26222, 54193)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	32117 (22658, 45526)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	77611 (57216, 105276)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	153	165 (113, 242)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	153	401 (268, 602)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	87	5 (5, 5)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	155	13066 (8983, 19004)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	155	12876 (9489, 17472)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	155	19468 (15496, 24459)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	155	58 (42, 81)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	155	152 (105, 219)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	519	304934 (237911, 390840)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	924524 (750510, 1138886)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	1878895 (1586011, 2225864)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	519	1243 (972, 1588)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	519	2160 (1643, 2840)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	153	785331 (484933, 1271815)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	2106655 (1490680, 2977161)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	5236885 (3880756, 7066912)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	153	5754 (3356, 9868)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	153	6872 (4174, 11314)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	87	5 (5, 5)
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	155	136546 (89268, 208864)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	155	396863 (289955, 543189)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	155	748414 (540245, 1036794)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	155	541 (355, 825)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	155	1659 (1064, 2588)

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, sex						
Age < 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	269	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	269	5 (5, 5)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	269	5 (5, 5)
Age < 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	79	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	10 (10, 10)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	79	5 (5, 5)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	79	5 (5, 5)
Age < 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	52	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	83	10 (10, 11)
Age < 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	83	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	83	10 (10, 10)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	83	5 (5, 6)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	83	5 (5, 5)
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	269	17005 (13156, 21980)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	16543 (13418, 20396)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	32705 (27399, 39039)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	269	79 (62, 101)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	269	150 (118, 191)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	79	27788 (17970, 42970)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	21789 (14248, 33321)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	56962 (39317, 82526)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	79	124 (78, 197)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	79	319 (195, 522)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	52	5 (5, 5)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	83	10603 (6760, 16631)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	83	10100 (6984, 14608)
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	83	14961 (11369, 19689)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	83	46 (31, 69)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	83	133 (86, 207)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	269	240348 (178375, 323851)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	725439 (563976, 933126)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	1494002 (1218429, 1831901)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	269	946 (706, 1267)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	269	1691 (1216, 2352)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	79	582852 (324144, 1048040)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	1557246 (1019727, 2378101)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	4234642 (2930914, 6118296)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	79	4195 (2173, 8100)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	79	5422 (2964, 9918)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	52	5 (5, 5)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	83	100999 (60463, 168711)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	83	293632 (201048, 428852)
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	83	571578 (384900, 848795)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	83	387 (233, 641)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	83	1375 (804, 2349)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)
Age < 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	67	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10 (10, 10)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	67	5 (5, 5)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	67	5 (5, 5)
Age < 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	28	11 (9, 12)
Age < 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	28	11 (9, 13)
Age < 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	28	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	28	5 (5, 5)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	28	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	64	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	10 (10, 10)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	64	5 (5, 5)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	64	5 (5, 5)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	163	20977 (14896, 29540)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	18877 (13705, 26001)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	29372 (24030, 35901)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	163	94 (67, 132)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	163	169 (118, 240)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	67	41875 (27088, 64734)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	30884 (20281, 47031)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	63477 (47023, 85688)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	67	180 (119, 274)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	67	372 (229, 604)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	28	10 (10, 10)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	28	10 (10, 10)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	28	10 (10, 10)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	28	5 (5, 5)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	28	5 (5, 5)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	8697 (5222, 14483)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	9188 (5784, 14598)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	11210 (7775, 16161)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	31 (20, 50)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	64	73 (47, 115)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	163	276033 (182277, 418013)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	756600 (546757, 1046981)
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	1920202 (1472176, 2504576)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	163	1532 (1004, 2337)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	163	1850 (1231, 2781)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	67	1079995 (633450, 1841326)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	1977267 (1268954, 3080952)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	4318054 (3077671, 6058343)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	67	3857 (1960, 7590)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	67	7789 (4625, 13117)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	28	10 (10, 10)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	28	10 (10, 11)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	28	10 (10, 10)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	28	5 (5, 5)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	28	5 (5, 5)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	83366 (42296, 164315)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	236528 (146661, 381460)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	373064 (243212, 572245)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	387 (206, 728)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	64	618 (331, 1154)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	232	10 (10, 10)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	10 (10, 10)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	10 (10, 10)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	232	5 (5, 5)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	232	5 (5, 5)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	54	10 (10, 11)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	10 (10, 10)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	10 (10, 10)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5 (5, 6)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5 (5, 5)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	48	5 (5, 5)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	48	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	51	10 (10, 10)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	10 (10, 10)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	10 (10, 10)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	51	5 (5, 6)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	51	5 (5, 5)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	232	59503 (46453, 76219)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	66467 (53933, 81913)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	105989 (87935, 127749)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	232	259 (203, 330)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	232	390 (306, 496)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	121492 (77083, 191487)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	148457 (98119, 224620)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	230231 (167261, 316907)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	482 (286, 812)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	54	895 (560, 1432)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	48	5 (5, 5)
Age \geq 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	48	5 (5, 5)
Age \geq 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	51	39245 (22100, 69691)
Age \geq 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	51	50082 (30542, 82125)
Age \geq 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	51	76189 (49115, 118188)
Age \geq 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51	147 (82, 263)
Age \geq 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	51	350 (196, 626)
Age \geq 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	232	794988 (585435, 1079548)
Age \geq 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	2674328 (2152728, 3322311)
Age \geq 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	5149990 (4231902, 6267253)
Age \geq 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	232	4362 (3133, 6074)
Age \geq 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	232	4649 (3501, 6173)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	3362752 (2054881, 5503045)
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	7426127 (5296972, 10411111)
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	13502491 (11607977, 15706205)
Age \geq 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	21221 (12633, 35647)
Age \geq 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	54	20477 (11619, 36087)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	48	10 (10, 10)
Age \geq 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	48	5 (5, 5)
Age \geq 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	48	5 (5, 5)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	51	537607 (291471, 991596)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51	2027539 (1259961, 3262731)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	51	3447429 (2322804, 5116559)
Age \geq 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	51	3730 (1880, 7401)
Age \geq 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	51	4892 (2560, 9348)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	250	10 (10, 10)
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	10 (10, 10)
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	10 (10, 10)
Age \geq 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	250	5 (5, 5)
Age \geq 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	250	5 (5, 5)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	74	10 (10, 10)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	10 (10, 10)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	10 (10, 10)
Age \geq 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	74	5 (5, 6)
Age \geq 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	74	5 (5, 5)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Age \geq 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)
Age \geq 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 10)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	250	59851 (47954, 74699)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	64209 (53151, 77567)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	117943 (99447, 139878)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	250	249 (197, 315)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	250	373 (294, 474)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	74	137448 (87797, 215179)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	166523 (121761, 227741)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	288235 (216852, 383115)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	74	553 (354, 864)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	74	1062 (720, 1566)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72	32440 (21159, 49736)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	72	37051 (27449, 50013)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	72	61265 (47638, 78789)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	72	162 (110, 238)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	72	271 (188, 392)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	250	875715 (670811, 1143209)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	2708471 (2228982, 3291105)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	5189777 (4355492, 6183867)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	250	4169 (3097, 5612)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	250	6397 (4907, 8340)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	74	2781850 (1795669, 4309643)
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	7590360 (5921961, 9728799)
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	12894340 (10799304, 15395807)
Age \geq 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	74	21984 (13986, 34558)
Age \geq 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	74	18779 (11189, 31518)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Age \geq 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)
Age \geq 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 6)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	72	507512 (329028, 782814)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	72	1473236 (1067157, 2033836)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	72	2420004 (1820068, 3217693)
Age \geq 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	72	2344 (1427, 3849)
Age \geq 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	72	3767 (2352, 6032)

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino ethnicity						
Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	136	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	136	5 (5, 5)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	136	5 (5, 6)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	35	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	10 (10, 10)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	35	5 (5, 5)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	35	5 (5, 5)
Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	20	5 (5, 5)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	20	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	38	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	38	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	38	10 (10, 10)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	38	6 (5, 7)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	38	5 (5, 5)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	136	22074 (14121, 34506)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	22266 (15847, 31284)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	41773 (31562, 55289)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	136	101 (67, 152)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	136	190 (126, 284)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	35	66150 (37538, 116570)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	57339 (30559, 107588)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	90332 (50343, 162084)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	35	254 (155, 417)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	35	498 (236, 1049)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	20	5 (5, 5)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	20	6 (4, 8)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	38	26345 (9909, 70041)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	38	34815 (16110, 75239)
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	38	26708 (12585, 56680)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	38	118 (42, 327)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	38	351 (151, 818)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	136	332872 (193115, 573771)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	1087406 (737091, 1604213)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	2082654 (1564176, 2772993)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	136	1727 (1013, 2946)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	136	2444 (1373, 4350)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	35	1420449 (558648, 3611715)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	2735111 (1368395, 5466868)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	7578287 (5040721, 11393296)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	35	7727 (2908, 20532)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	35	10208 (4492, 23195)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	20	10 (10, 10)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	20	5 (5, 5)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	20	5 (5, 5)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	38	452690 (158709, 1291220)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	38	747435 (391924, 1425424)
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	38	1403460 (609038, 3234119)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	38	1522 (466, 4976)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	38	3063 (1057, 8877)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	690	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	690	5 (5, 5)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	690	5 (5, 5)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	217	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	10 (10, 10)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	217	5 (5, 5)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	217	5 (5, 5)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	130	10 (10, 11)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	130	5 (5, 5)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	130	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	214	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	214	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	214	10 (10, 10)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	214	5 (5, 5)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	214	5 (5, 5)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	690	23655 (19521, 28664)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	23020 (19425, 27280)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	39694 (35055, 44946)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	690	104 (86, 125)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	690	191 (158, 230)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	217	41747 (30714, 56743)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	35344 (26390, 47337)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	83383 (65546, 106075)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	217	183 (133, 251)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	217	411 (294, 575)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	130	5 (5, 5)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	130	5 (5, 5)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	214	12063 (8992, 16185)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	214	11608 (9046, 14896)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	214	18056 (14910, 21865)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	214	48 (37, 63)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	214	123 (92, 165)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	690	334364 (266627, 419309)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	987977 (822264, 1187086)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	2063432 (1775937, 2397468)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	690	1500 (1191, 1888)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	690	2270 (1788, 2883)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	217	968852 (654113, 1435033)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	2315554 (1731123, 3097290)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	5301268 (4150604, 6770929)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	217	5224 (3348, 8151)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	217	7937 (5300, 11886)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	130	10 (10, 10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	130	5 (5, 5)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	130	5 (5, 5)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	214	129424 (89788, 186557)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	214	381696 (293138, 497006)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	214	648311 (505732, 831086)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	214	555 (395, 782)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	214	1324 (921, 1904)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	88	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	88	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	88	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	22	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	22	6 (4, 7)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	22	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	13	12 (8, 18)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	18	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	18	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	18	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	18	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	18	5 (5, 5)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	88	24172 (15240, 38338)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	22876 (15904, 32905)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	50488 (35885, 71034)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	88	133 (84, 213)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	88	174 (106, 287)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	22	34292 (18107, 64943)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	25827 (18334, 36382)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	46903 (33825, 65038)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	22	154 (91, 259)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	22	420 (198, 891)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	18	7067 (1907, 26192)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	18	10750 (3611, 32001)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	18	11909 (5649, 25107)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	18	37 (15, 93)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	18	58 (19, 177)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	88	259797 (148513, 454466)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	735710 (462524, 1170251)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	2279592 (1446853, 3591615)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	88	1291 (765, 2178)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	88	1748 (990, 3088)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	22	710026 (245263, 2055490)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	1751283 (872333, 3515850)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	3840709 (2197166, 6713669)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	22	8669 (2979, 25223)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	22	5104 (2140, 12175)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	18	26411 (10028, 69563)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	18	162620 (55659, 475135)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	18	417076 (107739, 1614570)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	18	188 (46, 766)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	18	437 (69, 2773)

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Race						
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	362	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	362	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	362	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 11)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	362	26952 (20883, 34784)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	23438 (18669, 29425)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	40376 (34349, 47460)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	362	115 (90, 147)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	362	188 (146, 241)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	33909 (24023, 47863)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	30985 (21434, 44793)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	72481 (53061, 99008)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	148 (104, 211)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	125	348 (226, 535)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	12594 (8382, 18924)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10931 (7560, 15804)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	18868 (14808, 24043)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	52 (37, 74)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	121	107 (76, 150)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	362	328428 (241933, 445846)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	1035293 (809568, 1323956)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	2145772 (1770774, 2600184)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	362	1376 (1010, 1874)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	362	2011 (1465, 2761)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	855574 (517613, 1414198)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	1943813 (1349835, 2799166)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	4608987 (3338577, 6362819)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	4550 (2471, 8378)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	125	7994 (4646, 13757)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	105260 (65764, 168478)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	393045 (287516, 537306)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	674526 (485396, 937351)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	575 (371, 892)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	121	1478 (953, 2292)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	195	10 (10, 10)
Black or African American	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	10 (10, 11)
Black or African American	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	10 (10, 10)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	195	5 (5, 5)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	195	5 (5, 5)
Black or African American	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)
Black or African American	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Black or African American	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 5)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)
Black or African American	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)
Black or African American	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)
Black or African American	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 6)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	195	16417 (11437, 23568)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	18966 (14305, 25146)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	33478 (26923, 41629)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	195	80 (57, 111)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	195	168 (116, 244)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	70405 (39637, 125057)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	49806 (32279, 76849)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	92510 (63827, 134083)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	240 (126, 455)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	52	595 (282, 1255)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	9803 (5446, 17644)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	13142 (8909, 19387)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	17281 (11001, 27148)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	44 (24, 81)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	60	170 (88, 328)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	195	270892 (186938, 392550)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	700976 (482795, 1017755)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	1698222 (1265203, 2279444)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	195	1634 (1060, 2520)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	195	2461 (1568, 3861)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	1211651 (545292, 2692316)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	3863173 (2496394, 5978266)
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	5233980 (3292870, 8319352)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	9353 (5430, 16111)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	52	10207 (5426, 19200)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	162243 (80633, 326450)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	304404 (168043, 551417)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	604842 (358324, 1020956)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	572 (270, 1213)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	60	1276 (599, 2723)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
Asian	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
Asian	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)
Asian	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	24	10 (10, 11)
Asian	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)
Asian	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	24	5 (5, 5)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	24	6 (5, 7)
Asian	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)
Asian	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Asian	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	13	10 (10, 10)
Asian	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	13	10 (10, 10)
Asian	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	13	10 (10, 10)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	13	5 (5, 5)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	13	5 (5, 5)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	67	30141 (17403, 52204)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	33349 (22259, 49964)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	63758 (45931, 88504)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	67	144 (92, 225)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	67	330 (204, 534)
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	24	33316 (16935, 65545)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	24553 (12536, 48091)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	49522 (26709, 91821)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	24	174 (94, 325)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	24	368 (184, 735)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 6)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	13	17273 (6186, 48234)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	13	27396 (5431, 138186)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	13	12500 (4740, 32962)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	13	65 (17, 245)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	13	146 (18, 1215)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	67	759619 (426880, 1351718)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	1685637 (1167594, 2433528)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	2633046 (1864450, 3718486)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	67	2850 (1578, 5149)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	67	3805 (1835, 7889)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	24	639026 (148027, 2758648)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	2094481 (742718, 5906481)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	4848443 (2478358, 9485072)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24	6020 (2360, 15360)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	24	8404 (2608, 27081)
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	13	275834 (26204, 2903499)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	13	750472 (176753, 3186420)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	13	859200 (168867, 4371633)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	13	482 (269, 862)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	13	1167 (203, 6693)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	6	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5 (5, 5)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	6	7 (4, 14)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 7)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	10 (10, 10)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	4	5 (5, 5)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	4	5 (5, 5)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	13	45133 (16515, 123343)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	42283 (20288, 88120)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	30785 (13439, 70516)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	13	186 (63, 554)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	13	309 (55, 1753)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	42543 (10105, 179112)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	22761 (8134, 63689)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	85898 (68138, 108288)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	244 (182, 327)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	6	1338 (620, 2888)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 5)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	3080 (1115, 8510)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	7559 (3837, 14892)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	5348 (1735, 16488)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	13 (4, 46)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	4	79 (32, 190)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	13	982833 (235813, 4096296)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	836025 (283249, 2467576)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	4760602 (2359191, 9606399)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	13	3381 (548, 20856)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	13	4097 (1137, 14766)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	2398314 (427206, 13464021)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	2320038 (501453, 10733961)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	7507181 (3379449, 16676615)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	8919 (1502, 52953)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6	9789 (1020, 93964)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 5)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	36102 (4722, 276037)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	272152 (65917, 1123631)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	677711 (214540, 2140827)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	126 (26, 608)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	4	520 (61, 4436)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	17	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	11 (9, 14)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	17	6 (4, 8)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	1	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	17	114600 (47108, 278791)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	114776 (53301, 247155)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	116196 (67714, 199391)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	17	381 (198, 736)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	17	982 (339, 2849)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	55095 (9965, 304612)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	44998 (2885, 701952)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	107953 (71167, 163752)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	227 (17, 2989)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	5	489 (239, 1000)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	1	734 (734, 734)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	1	6237 (6237, 6237)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	1	10844 (10844, 10844)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	17	2236794 (700142, 7146051)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	5533419 (2490433, 12294540)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	7662810 (3323463, 17667914)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	17	10464 (2274, 48150)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	17	4635 (2089, 10284)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	513962 (93920, 2812583)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	1828480 (947016, 3530396)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	5139344 (595014, 44390337)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	2545 (185, 35084)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5	1804 (213, 15248)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	1	10 (10, 10)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	1	5 (5, 5)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1	969 (969, 969)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	1	4780 (4780, 4780)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	1	61376 (61376, 61376)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1	44 (44, 44)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1	144 (144, 144)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)
Multiracial	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)
Multiracial	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	52	5 (5, 5)
Multiracial	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	10 (10, 10)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	12	5 (5, 5)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	12	5 (5, 5)
Multiracial	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	8	5 (5, 5)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	8	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	19	10 (10, 10)
Multiracial	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	19	10 (10, 10)
Multiracial	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	19	10 (10, 10)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	19	5 (5, 5)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	19	5 (5, 5)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	52	20542 (10447, 40388)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	21505 (13701, 33755)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	45067 (27165, 74765)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	52	71 (38, 130)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	52	135 (82, 222)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	12	70589 (26321, 189314)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	55196 (16260, 187371)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	155885 (67996, 357377)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	12	398 (197, 804)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	12	277 (153, 502)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	5 (5, 5)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	8	5 (5, 5)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	19	15871 (7677, 32809)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	19	24792 (13458, 45670)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	19	25261 (11298, 56479)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	19	51 (28, 93)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	19	190 (60, 600)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	52	214922 (107912, 428046)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	1262157 (710446, 2242309)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	2195866 (1476648, 3265387)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	52	1524 (697, 3334)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	52	1963 (778, 4953)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	12	1276135 (551639, 2952150)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	3777504 (1786314, 7988255)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	8118223 (3167974, 20803689)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	12	2411 (687, 8455)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	12	10135 (6049, 16979)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	10 (10, 10)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	5 (5, 5)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	8	5 (5, 5)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	19	235861 (101669, 547174)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	19	693982 (285837, 1684912)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	19	791515 (327732, 1911609)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	19	1034 (211, 5057)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	19	2744 (676, 11140)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	34	10 (10, 10)
Other	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	10 (10, 10)
Other	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	10 (10, 10)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	34	5 (5, 5)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	34	6 (5, 7)
Other	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	7	10 (10, 10)
Other	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	10 (10, 10)
Other	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	10 (10, 10)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5 (5, 5)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5 (5, 5)
Other	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	6 (4, 8)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)
Other	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)
Other	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	34	21653 (9122, 51401)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	22295 (11570, 42963)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	38007 (21259, 67950)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	34	118 (54, 259)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	34	254 (100, 650)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	7	18596 (5457, 63367)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	18039 (7489, 43449)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	75844 (32129, 179037)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	7	63 (18, 221)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	7	283 (86, 936)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	5	44670 (548, 3638655)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	5	49870 (993, 2505753)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	5	40496 (1871, 876366)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	5	221 (12, 4185)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	5	295 (27, 3229)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	34	460615 (152205, 1393948)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	959325 (467189, 1969877)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	2238776 (1221484, 4103302)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	34	1974 (715, 5452)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	34	3391 (1017, 11315)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7	506707 (112863, 2274911)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	4612046 (1663462, 12787169)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	5745695 (3340937, 9881364)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7	2543 (573, 11275)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	7	4503 (1467, 13817)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5 (5, 5)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	5	635834 (21972, 18400096)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	5	390164 (12362, 12313729)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5	1950467 (62864, 60516607)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	5	6112 (27, 1395272)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	5	1609 (34, 75283)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	87	5 (5, 5)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	20	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	10 (10, 10)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	20	6 (5, 7)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	20	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	24	11 (9, 14)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	24	6 (5, 7)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	24	5 (5, 6)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	87	19313 (11899, 31347)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	19972 (12070, 33047)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	41499 (27382, 62895)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	87	85 (51, 144)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	87	167 (114, 245)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	20	67460 (18205, 249984)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	57668 (23639, 140684)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	112437 (52711, 239834)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	20	348 (94, 1295)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	20	581 (199, 1695)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	14	5 (5, 6)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	24	15732 (6215, 39822)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	24	11890 (6465, 21867)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	24	17779 (10512, 30069)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	24	46 (19, 111)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	24	168 (59, 476)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	87	313760 (169470, 580901)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	958206 (602856, 1523015)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	1898203 (1201387, 2999181)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	87	1331 (758, 2339)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	87	2345 (1156, 4755)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	20	1890562 (655546, 5452282)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	3239260 (1199389, 8748461)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	9280577 (5784309, 14890128)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	20	11045 (3104, 39295)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	20	5210 (1481, 18320)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	24	212439 (58037, 777613)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	24	401782 (153583, 1051084)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24	645039 (295340, 1408800)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	24	485 (159, 1481)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	24	1124 (299, 4219)

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Underrepresented minority status						
Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	420	10 (10, 10)
Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	10 (10, 10)
Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	10 (10, 10)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	420	5 (5, 5)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	420	5 (5, 5)
Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	120	10 (10, 10)
Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	10 (10, 10)
Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	10 (10, 10)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5 (5, 5)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5 (5, 6)
Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	73	5 (5, 5)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	73	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	111	10 (10, 10)
Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	111	10 (10, 10)
Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	111	10 (10, 10)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	111	5 (5, 6)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	111	5 (5, 5)
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	420	21539 (16824, 27575)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	23355 (19242, 28347)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	40216 (34320, 47124)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	420	99 (79, 124)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	420	208 (163, 266)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	59825 (42571, 84073)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	44605 (32113, 61955)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	90964 (70627, 117156)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	238 (171, 332)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	120	545 (371, 802)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	73	5 (5, 5)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	73	5 (5, 6)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	111	12076 (7763, 18784)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	111	17596 (12331, 25109)
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	111	18884 (13334, 26743)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	111	54 (34, 84)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	111	178 (110, 288)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	420	358864 (270757, 475643)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	977894 (775549, 1233031)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	2083276 (1732503, 2505069)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	420	1903 (1416, 2557)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	420	2744 (2021, 3725)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	1149410 (702292, 1881190)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	3146770 (2273084, 4356267)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	5991417 (4527248, 7929117)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	7086 (4582, 10956)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	120	8885 (5903, 13374)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	73	10 (10, 10)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	73	5 (5, 5)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	73	5 (5, 5)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	111	193321 (112530, 332117)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	111	397884 (256621, 616908)
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	111	734879 (489927, 1102301)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	111	684 (382, 1222)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	111	1409 (809, 2454)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	362	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	362	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	362	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 11)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	362	26952 (20883, 34784)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	23438 (18669, 29425)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	40376 (34349, 47460)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	362	115 (90, 147)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	362	188 (146, 241)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	33909 (24023, 47863)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	30985 (21434, 44793)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	72481 (53061, 99008)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	148 (104, 211)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	125	348 (226, 535)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	12594 (8382, 18924)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10931 (7560, 15804)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	18868 (14808, 24043)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	52 (37, 74)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	121	107 (76, 150)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	362	328428 (241933, 445846)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	1035293 (809568, 1323956)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	2145772 (1770774, 2600184)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	362	1376 (1010, 1874)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	362	2011 (1465, 2761)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	855574 (517613, 1414198)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	1943813 (1349835, 2799166)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	4608987 (3338577, 6362819)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	4550 (2471, 8378)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	125	7994 (4646, 13757)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 5)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	105260 (65764, 168478)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	393045 (287516, 537306)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	674526 (485396, 937351)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	575 (371, 892)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	121	1478 (953, 2292)

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Underrepresented minority status						
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	192	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	192	5 (5, 5)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	192	5 (5, 5)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	69	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	10 (10, 10)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	69	5 (5, 5)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	69	5 (5, 6)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	61	5 (5, 6)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	192	16236 (11950, 22060)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	17593 (13852, 22344)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	30531 (25113, 37119)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	192	76 (58, 101)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	192	174 (128, 236)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	69	50828 (33992, 76001)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	34937 (23612, 51692)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	70998 (52424, 96153)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	69	209 (141, 310)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	69	484 (305, 768)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 6)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	9484 (5617, 16014)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	13618 (8923, 20783)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	13717 (9065, 20756)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	42 (25, 72)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	61	150 (84, 267)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	192	292558 (206172, 415140)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	741900 (555661, 990562)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	1629402 (1297120, 2046806)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	192	1435 (996, 2067)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	192	2230 (1526, 3260)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	69	930919 (513604, 1687309)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	2542683 (1712040, 3776334)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	5081700 (3610831, 7151727)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	69	5550 (3299, 9337)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	69	7380 (4562, 11940)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	145989 (76394, 278984)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	277278 (163947, 468952)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	543679 (333997, 884998)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	466 (233, 933)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	61	1073 (554, 2078)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	175	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	175	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	175	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 11)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 6)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	61	5 (5, 5)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	175	22546 (16449, 30904)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	18239 (13758, 24181)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	31442 (25791, 38330)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	175	98 (72, 132)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	175	163 (120, 222)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	59	22816 (14927, 34875)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	19045 (11981, 30275)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	50450 (34089, 74664)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	59	100 (65, 155)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	59	255 (148, 438)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	9218 (5562, 15276)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	7844 (4943, 12447)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	13337 (9897, 17972)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	38 (25, 58)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	61	78 (51, 118)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	175	264562 (181376, 385898)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	821667 (605817, 1114423)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	1724310 (1360533, 2185355)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	175	1085 (742, 1587)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	175	1624 (1097, 2405)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	59	596002 (316557, 1122130)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	1330657 (839177, 2109982)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	3419951 (2265916, 5161739)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	59	2838 (1308, 6159)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	59	6125 (3095, 12121)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 5)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	69600 (38639, 125369)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	264698 (179593, 390131)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	451492 (299075, 681584)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	376 (219, 646)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	61	1102 (639, 1903)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	228	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	228	5 (5, 5)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	228	5 (5, 5)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	51	10 (10, 11)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	51	5 (5, 6)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	51	5 (5, 5)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	50	10 (10, 11)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	50	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	50	10 (10, 10)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	50	5 (5, 5)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	50	5 (5, 6)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	228	62158 (49075, 78729)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	67566 (54928, 83111)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	113000 (94968, 134457)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	228	263 (208, 334)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	228	409 (322, 520)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	51	120781 (72698, 200668)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	127850 (82403, 198362)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	264698 (193965, 361225)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	51	414 (254, 674)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	51	911 (557, 1491)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	50	36935 (21250, 64196)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	50	57615 (37847, 87707)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	50	82913 (55530, 123801)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	50	167 (101, 276)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	50	390 (234, 650)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	228	771969 (594098, 1003095)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	2754587 (2268630, 3344640)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	5234940 (4335352, 6321193)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	228	5478 (4015, 7473)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	228	5966 (4475, 7954)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	51	2851970 (1691139, 4809619)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	7886529 (5982602, 10396367)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	12184499 (9858697, 15058989)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	51	20307 (11438, 36054)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	51	19769 (10376, 37665)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	50	709142 (413162, 1217155)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	50	2116643 (1388474, 3226693)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	50	2964324 (2089369, 4205680)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	50	4026 (2199, 7373)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	50	4985 (2691, 9234)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	187	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	187	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	187	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	66	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5 (5, 6)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	187	52931 (40926, 68456)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	60501 (48781, 75037)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	103956 (85919, 125780)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	187	214 (164, 280)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	187	317 (243, 412)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66	136437 (87480, 212792)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	171330 (122104, 240402)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	258922 (193660, 346179)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	66	575 (355, 932)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	66	1037 (709, 1518)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	37306 (22911, 60744)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	34684 (23682, 50795)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	63090 (45886, 86746)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	160 (99, 257)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	60	323 (207, 502)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	187	744013 (543887, 1017778)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	2480906 (1963293, 3134986)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	4905828 (4009921, 6001900)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	187	3376 (2393, 4763)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	187	4511 (3339, 6096)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	66	3047576 (1943331, 4779276)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	7361735 (5495760, 9861264)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	13150407 (11178796, 15469753)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	66	23885 (15539, 36713)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	66	20383 (12350, 33642)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 6)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	443960 (270210, 729435)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	1555275 (1070146, 2260326)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	2726537 (1931325, 3849174)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	2516 (1427, 4435)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	60	4096 (2471, 6792)

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
All participants								
	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	914	10 (10, 10)	23543 (19945, 27790)	2348.16 (1989.36, 2771.67)
	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	10 (10, 10)	22926 (19863, 26460)	2279.09 (1975.09, 2629.88)
	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	10 (10, 10)	40963 (36741, 45671)	4091.68 (3670.04, 4561.76)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	914	5 (5, 5)	106 (91, 125)	21.01 (17.90, 24.67)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	914	5 (5, 5)	189 (161, 222)	37.28 (31.71, 43.83)
	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	274	10 (10, 10)	43010 (33140, 55819)	4284.83 (3302.19, 5559.89)
	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	10 (10, 10)	36133 (28182, 46328)	3613.33 (2818.21, 4632.79)
	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	10 (10, 10)	79981 (65041, 98352)	7998.08 (6504.13, 9835.19)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	274	5 (5, 5)	186 (142, 243)	36.50 (27.92, 47.71)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	274	5 (5, 5)	420 (314, 560)	82.61 (61.87, 110.32)
	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)	10 (10, 10)	0.98 (0.95, 1.02)
	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 11)	10 (10, 10)	0.98 (0.95, 1.02)
	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	270	10 (10, 10)	12518 (9458, 16567)	1232.97 (937.69, 1621.23)
	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	270	10 (10, 10)	12861 (10150, 16296)	1284.22 (1013.60, 1627.09)
	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	270	10 (10, 10)	18191 (15159, 21829)	1819.07 (1515.87, 2182.92)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	270	5 (5, 5)	51 (40, 66)	9.99 (7.85, 12.73)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	270	5 (5, 5)	129 (98, 169)	25.46 (19.48, 33.27)
	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	914	10 (10, 10)	325136 (267241, 395574)	32428.78 (26656.24, 39451.39)
	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	914	10 (10, 10)	966160 (823437, 1133621)	96047.59 (81866.19, 112685.58)
	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	914	10 (10, 10)	2087965 (1831068, 2380904)	208560.44 (182899.78, 237821.27)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	914	5 (5, 5)	1497 (1228, 1825)	295.67 (242.59, 360.37)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	914	5 (5, 5)	2223 (1809, 2733)	438.66 (357.19, 538.72)
	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	274	10 (10, 10)	980579 (697583, 1378379)	97689.42 (69501.88, 137308.83)
	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	274	10 (10, 10)	2298869 (1785648, 2959596)	229886.89 (178564.83, 295959.65)
	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	274	10 (10, 10)	5346334 (4339333, 6587023)	534633.43 (433933.34, 658702.34)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	274	5 (5, 5)	5680 (3863, 8351)	1114.53 (761.21, 1631.83)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	274	5 (5, 5)	7837 (5545, 11076)	1542.78 (1091.92, 2179.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)	10 (10, 10)	0.98 (0.95, 1.02)
	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 11)	10 (10, 10)	0.99 (0.95, 1.02)
	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.02)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.03)
	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	270	10 (10, 10)	130008 (92643, 182444)	12805.53 (9188.90, 17845.62)
	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	270	10 (10, 10)	382614 (299829, 488256)	38205.28 (29939.10, 48753.76)
	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	270	10 (10, 10)	676872 (531354, 862241)	67687.19 (53135.41, 86224.15)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	270	5 (5, 5)	566 (409, 783)	109.82 (79.77, 151.19)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	270	5 (5, 5)	1324 (937, 1870)	261.17 (185.46, 367.79)

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age								
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	432	10 (10, 10)	18416 (15002, 22607)	1838.80 (1497.94, 2257.21)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	10 (10, 10)	17393 (14565, 20770)	1728.59 (1447.96, 2063.60)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	10 (10, 10)	31397 (27475, 35879)	3139.72 (2747.52, 3587.91)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	432	5 (5, 5)	85 (69, 103)	16.72 (13.72, 20.38)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	432	5 (5, 5)	157 (129, 192)	31.07 (25.45, 37.94)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	146	10 (10, 10)	32567 (23744, 44670)	3251.72 (2370.72, 4460.12)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	10 (10, 10)	24939 (18393, 33814)	2493.88 (1839.31, 3381.39)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	10 (10, 10)	59400 (46119, 76506)	5940.04 (4611.93, 7650.60)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	146	5 (5, 5)	144 (104, 198)	28.34 (20.48, 39.21)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	146	5 (5, 5)	339 (238, 482)	66.39 (46.61, 94.58)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 11)	10 (10, 10)	0.98 (0.94, 1.02)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 11)	10 (10, 10)	0.98 (0.93, 1.02)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.03)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)	5 (5, 5)	0.99 (0.93, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	147	10 (10, 10)	9820 (7012, 13753)	966.54 (695.88, 1342.48)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	147	10 (10, 10)	9737 (7318, 12957)	973.73 (731.75, 1295.73)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	147	10 (10, 10)	13380 (10752, 16650)	1337.99 (1075.18, 1665.05)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	147	5 (5, 5)	40 (29, 54)	7.70 (5.77, 10.28)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	147	5 (5, 5)	106 (76, 147)	20.88 (15.13, 28.82)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	432	10 (10, 10)	253319 (198848, 322710)	25293.56 (19856.49, 32219.39)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	432	10 (10, 10)	737116 (604473, 898866)	73258.07 (60080.95, 89325.22)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	432	10 (10, 10)	1643373 (1397160, 1932976)	164337.35 (139715.98, 193297.60)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	432	5 (5, 5)	1136 (890, 1449)	224.61 (176.12, 286.46)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	432	5 (5, 5)	1750 (1355, 2260)	346.17 (268.34, 446.58)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	146	10 (10, 10)	739998 (487226, 1123907)	73885.65 (48648.51, 112214.94)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	10 (10, 10)	1708031 (1250384, 2333179)	170803.11 (125038.42, 233317.89)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	10 (10, 10)	4266733 (3292306, 5529560)	426673.25 (329230.63, 552956.04)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	146	5 (5, 5)	4061 (2527, 6527)	801.35 (501.10, 1281.50)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	146	5 (5, 5)	6238 (4090, 9513)	1223.09 (802.31, 1864.58)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	80	10 (10, 11)	10 (10, 10)	0.98 (0.94, 1.02)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	10 (10, 11)	10 (10, 10)	0.98 (0.93, 1.03)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	80	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.01)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	80	5 (5, 5)	5 (5, 5)	0.98 (0.93, 1.03)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	147	10 (10, 10)	93772 (62211, 141344)	9229.59 (6177.01, 13790.71)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	147	10 (10, 10)	270061 (201183, 362521)	27006.13 (20118.30, 36252.12)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	147	10 (10, 10)	484596 (361146, 650244)	48459.60 (36114.65, 65024.40)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	147	5 (5, 5)	387 (262, 572)	75.13 (51.19, 110.26)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	147	5 (5, 5)	1009 (665, 1531)	199.32 (131.81, 301.41)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	482	10 (10, 10)	59687 (50609, 70395)	5928.46 (5026.44, 6992.35)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	10 (10, 10)	65260 (56734, 75068)	6494.31 (5646.18, 7469.84)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	10 (10, 10)	112166 (98902, 127209)	11156.00 (9843.59, 12643.39)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	482	5 (5, 5)	254 (214, 300)	49.89 (42.15, 59.05)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	482	5 (5, 5)	381 (321, 451)	74.35 (62.85, 87.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	128	10 (10, 10)	130450 (94702, 179694)	12881.38 (9387.70, 17675.25)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	10 (10, 10)	158619 (123545, 203649)	15861.86 (12354.53, 20364.88)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	10 (10, 10)	262073 (211994, 323982)	26207.29 (21199.35, 32398.25)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	128	5 (5, 5)	522 (373, 731)	100.15 (72.09, 139.12)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	128	5 (5, 5)	988 (733, 1331)	197.60 (146.66, 266.24)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	83	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	83	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	83	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	83	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.04)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	83	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.03)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)	35028 (24879, 49317)	3460.86 (2457.33, 4874.22)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)	41836 (32047, 54614)	4151.56 (3184.55, 5412.22)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)	66891 (53117, 84238)	6689.12 (5311.68, 8423.77)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)	156 (112, 216)	30.24 (21.85, 41.85)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)	301 (219, 413)	59.03 (43.06, 80.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	482	10 (10, 10)	836805 (684275, 1023335)	83115.94 (67970.66, 101635.90)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	482	10 (10, 10)	2692372 (2329146, 3112243)	267928.32 (231855.79, 309613.08)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	482	10 (10, 10)	5171042 (4536102, 5894857)	514311.17 (451159.38, 586302.75)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	482	5 (5, 5)	4259 (3414, 5312)	837.43 (671.41, 1044.49)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	482	5 (5, 5)	5506 (4535, 6685)	1075.58 (887.15, 1304.01)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	128	10 (10, 10)	3014476 (2173987, 4179907)	297666.07 (215032.46, 412054.47)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	128	10 (10, 10)	7520373 (6146909, 9200723)	752037.26 (614690.86, 920072.32)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	128	10 (10, 10)	13148461 (11661345, 14825221)	1314846.07 (1166134.50, 1482522.12)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	128	5 (5, 5)	21658 (15437, 30385)	4155.93 (2979.90, 5796.08)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	128	5 (5, 5)	19480 (13318, 28494)	3896.02 (2663.58, 5698.73)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	83	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	83	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	83	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	83	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.05)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	83	5 (5, 5)	5 (5, 5)	1.01 (0.97, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)	519433 (364323, 740581)	51321.85 (36024.56, 73114.90)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)	1675605 (1276999, 2198632)	166277.45 (126741.57, 218146.20)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)	2790960 (2209589, 3525298)	279096.04 (220958.92, 352529.78)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)	2827 (1887, 4233)	549.05 (368.08, 818.99)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)	4185 (2859, 6127)	821.36 (562.39, 1199.58)

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Risk for Severe Covid-19								
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	469	10 (10, 10)	23746 (19934, 28287)	2359.08 (1981.02, 2809.29)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	10 (10, 10)	26276 (22610, 30535)	2615.50 (2250.98, 3039.05)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	10 (10, 10)	45842 (40067, 52448)	4565.75 (3992.37, 5221.47)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	469	5 (5, 5)	103 (87, 122)	20.04 (16.98, 23.65)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	469	5 (5, 5)	215 (180, 258)	42.59 (35.64, 50.91)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)	55180 (40419, 75332)	5491.58 (4022.46, 7497.26)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)	55528 (43641, 70653)	5552.80 (4364.10, 7065.28)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)	103862 (82479, 130788)	10386.18 (8247.90, 13078.81)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)	220 (161, 302)	43.07 (31.58, 58.75)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)	443 (318, 617)	87.77 (62.95, 122.37)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 11)	10 (10, 10)	0.98 (0.94, 1.02)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)	5 (5, 5)	1.02 (0.96, 1.08)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)	16553 (12215, 22429)	1648.35 (1215.87, 2234.65)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)	16713 (12642, 22096)	1661.32 (1257.58, 2194.67)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)	26705 (21285, 33505)	2670.50 (2128.48, 3350.54)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)	69 (52, 93)	13.57 (10.16, 18.12)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)	180 (133, 243)	35.50 (26.16, 48.18)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	469	10 (10, 10)	335374 (270080, 416453)	33318.69 (26852.88, 41341.37)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	469	10 (10, 10)	1142597 (961925, 1357205)	113734.61 (95775.71, 135060.99)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	469	10 (10, 10)	2144439 (1840509, 2498559)	213582.55 (183324.98, 248834.09)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	469	5 (5, 5)	1796 (1424, 2264)	349.12 (277.06, 439.92)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	469	5 (5, 5)	2766 (2265, 3377)	546.96 (448.44, 667.12)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)	1327591 (937265, 1880469)	132124.36 (93301.15, 187102.17)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)	2930270 (2216035, 3874704)	293027.00 (221603.54, 387470.44)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)	6396516 (5214355, 7846688)	639651.59 (521435.48, 784668.81)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)	6128 (4355, 8625)	1197.37 (852.46, 1681.83)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)	11182 (7684, 16271)	2214.72 (1523.03, 3220.55)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	84	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.04)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	84	10 (10, 11)	10 (10, 10)	0.98 (0.94, 1.02)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	84	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.03)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	84	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	10 (10, 10)	197242 (138403, 281094)	19641.88 (13780.65, 27996.01)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	10 (10, 10)	663561 (492320, 894363)	65958.42 (48940.12, 88894.61)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	10 (10, 10)	1012116 (794913, 1288669)	101211.63 (79491.29, 128866.87)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5 (5, 5)	931 (651, 1331)	182.03 (127.42, 260.06)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5 (5, 5)	2086 (1418, 3067)	412.34 (280.42, 606.33)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	445	10 (10, 10)	23464 (18827, 29244)	2343.90 (1880.63, 2921.30)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	10 (10, 10)	21736 (17965, 26298)	2159.67 (1785.56, 2612.16)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	10 (10, 10)	39200 (34023, 45165)	3920.03 (3402.34, 4516.49)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5 (5, 5)	108 (87, 133)	21.41 (17.29, 26.50)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5 (5, 5)	180 (145, 223)	35.39 (28.57, 43.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	149	10 (10, 10)	39449 (28242, 55103)	3931.45 (2815.34, 5490.03)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	10 (10, 10)	31130 (22510, 43050)	3113.00 (2251.05, 4305.00)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	10 (10, 10)	73051 (55946, 95386)	7305.09 (5594.58, 9538.58)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	149	5 (5, 5)	175 (124, 247)	34.46 (24.42, 48.63)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	149	5 (5, 5)	412 (284, 597)	80.90 (55.76, 117.37)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 11)	10 (10, 10)	0.98 (0.93, 1.02)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 11)	10 (10, 10)	0.97 (0.92, 1.03)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)	5 (5, 5)	0.99 (0.92, 1.06)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	147	10 (10, 11)	11438 (8001, 16352)	1122.63 (792.35, 1590.58)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	147	10 (10, 10)	11818 (8756, 15950)	1181.77 (875.58, 1595.05)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	147	10 (10, 10)	16070 (12770, 20222)	1606.98 (1277.02, 2022.19)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	147	5 (5, 5)	47 (34, 64)	9.06 (6.67, 12.30)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	147	5 (5, 5)	116 (82, 164)	22.87 (16.28, 32.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	445	10 (10, 10)	321219 (247884, 416250)	32087.38 (24761.78, 41580.21)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	10 (10, 10)	904842 (732112, 1118324)	89906.29 (72750.39, 111107.87)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	10 (10, 10)	2066294 (1739231, 2454861)	206629.43 (173923.14, 245486.15)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5 (5, 5)	1394 (1075, 1808)	277.07 (213.65, 359.32)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5 (5, 5)	2041 (1549, 2690)	402.41 (305.66, 529.78)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	149	10 (10, 10)	882754 (567083, 1374143)	87975.05 (56520.81, 136933.81)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	10 (10, 10)	2113273 (1525010, 2928453)	211327.27 (152501.04, 292845.31)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	10 (10, 10)	5023873 (3827375, 6594416)	502387.34 (382737.50, 659441.62)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	149	5 (5, 5)	5532 (3337, 9171)	1087.15 (659.48, 1792.15)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	149	5 (5, 5)	6928 (4429, 10838)	1360.94 (870.25, 2128.30)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	10 (10, 11)	10 (10, 10)	0.98 (0.93, 1.02)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	10 (10, 11)	10 (10, 10)	0.97 (0.92, 1.03)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.02)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5 (5, 5)	5 (5, 5)	0.97 (0.92, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	147	10 (10, 11) (73666, 175296)	113637 (7299.59, 17041.87)	11153.41
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	147	10 (10, 10) (235413, 435781)	320294 (23541.29, 43578.07)	32029.42
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	147	10 (10, 10) (435730, 810886)	594413 (43572.97, 81088.58)	59441.32
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	147	5 (5, 5) (318, 728)	482 (62.10, 140.13)	93.28
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	147	5 (5, 5) (737, 1774)	1143 (145.81, 348.33)	225.36

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Risk for Severe Covid-19								
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	214	10 (10, 10)	15066 (11800, 19236)	1496.11 (1172.51, 1909.02)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	10 (10, 10)	16530 (13368, 20441)	1647.12 (1332.23, 2036.44)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	10 (10, 10)	31028 (25725, 37423)	3102.75 (2572.47, 3742.34)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	214	5 (5, 5)	68 (54, 85)	13.04 (10.42, 16.32)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	214	5 (5, 5)	159 (123, 204)	31.54 (24.49, 40.62)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	10 (10, 10)	35719 (23749, 53721)	3546.51 (2357.97, 5334.12)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	10 (10, 10)	30603 (22501, 41623)	3060.34 (2250.14, 4162.27)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	10 (10, 10)	62641 (46271, 84801)	6264.08 (4627.13, 8480.14)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5 (5, 5)	142 (95, 213)	28.47 (19.00, 42.66)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5 (5, 5)	291 (187, 453)	57.32 (36.68, 89.56)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)	5 (5, 6)	1.01 (0.92, 1.11)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	11526 (8014, 16577)	1152.57 (801.38, 1657.66)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	10221 (7219, 14470)	1022.09 (721.94, 1447.04)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	16112 (12299, 21107)	1611.16 (1229.86, 2110.68)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	48 (34, 67)	9.40 (6.70, 13.17)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)	127 (87, 186)	25.12 (17.07, 36.96)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	214	10 (10, 10)	227691 (168852, 307033)	22610.51 (16792.97, 30443.42)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	10 (10, 10)	761200 (595277, 973370)	75848.48 (59325.91, 96972.66)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	10 (10, 10)	1498825 (1211392, 1854460)	149882.51 (121139.16, 185445.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	214	5 (5, 5)	1203 (876, 1652)	231.86 (169.01, 318.08)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	214	5 (5, 5)	2067 (1571, 2720)	411.15 (312.79, 540.45)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	10 (10, 10)	848831 (532838, 1352218)	84280.25 (52926.74, 134207.39)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	10 (10, 10)	1815884 (1228679, 2683724)	181588.39 (122867.87, 268372.40)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	10 (10, 10)	4547755 (3405518, 6073108)	454775.50 (340551.75, 607310.79)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5 (5, 5)	2953 (1859, 4690)	590.64 (371.88, 938.10)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5 (5, 5)	7954 (4852, 13039)	1567.92 (957.49, 2567.49)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 10)	10 (10, 11)	1.02 (0.98, 1.07)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)	5 (5, 5)	0.99 (0.93, 1.05)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 5)	5 (5, 5)	1.01 (0.96, 1.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	115913 (72906, 184288)	11591.25 (7290.61, 18428.80)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	417627 (286526, 608715)	41762.73 (28652.58, 60871.51)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	575539 (423609, 781958)	57553.86 (42360.90, 78195.85)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	502 (325, 776)	98.87 (64.02, 152.71)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)	1382 (851, 2245)	273.33 (168.28, 443.96)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	10 (10, 10)	19467 (15117, 25069)	1946.75 (1511.74, 2506.93)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	10 (10, 10)	17639 (14174, 21953)	1751.83 (1408.13, 2179.42)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	10 (10, 10)	31500 (26782, 37050)	3150.02 (2678.20, 3704.97)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5 (5, 5)	90 (70, 115)	17.91 (14.03, 22.88)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5 (5, 5)	157 (122, 200)	30.94 (24.21, 39.54)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	10 (10, 10)	31746 (21553, 46760)	3174.64 (2155.33, 4675.99)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	10 (10, 10)	23567 (16129, 34434)	2356.67 (1612.92, 3443.37)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	10 (10, 10)	58534 (42846, 79967)	5853.44 (4284.64, 7996.66)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5 (5, 5)	144 (97, 214)	28.30 (18.99, 42.19)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5 (5, 5)	353 (229, 545)	69.15 (44.78, 106.78)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 11)	10 (10, 10)	0.97 (0.92, 1.03)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 6)	5 (5, 5)	0.99 (0.91, 1.08)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 11)	9421 (6230, 14246)	923.44 (617.25, 1381.52)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)	9616 (6788, 13622)	961.58 (678.78, 1362.18)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)	12751 (9770, 16642)	1275.09 (976.97, 1664.19)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)	38 (26, 55)	7.31 (5.13, 10.41)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)	101 (68, 150)	19.90 (13.43, 29.49)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	10 (10, 10)	260904 (193707, 351412)	26090.40 (19370.69, 35141.19)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	10 (10, 10)	730590 (572430, 932450)	72557.28 (56856.08, 92594.47)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	10 (10, 10)	1685764 (1382036, 2056240)	168576.35 (138203.64, 205624.01)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5 (5, 5)	1118 (830, 1506)	222.65 (165.28, 299.92)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5 (5, 5)	1671 (1216, 2295)	330.08 (240.60, 452.85)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	10 (10, 10)	712451 (424544, 1195605)	71245.12 (42454.38, 119560.51)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	10 (10, 10)	1679359 (1144789, 2463552)	167935.92 (114478.90, 246355.20)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	10 (10, 10)	4192147 (3040678, 5779665)	419214.74 (304067.80, 577966.50)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5 (5, 5)	4435 (2453, 8017)	871.87 (485.49, 1565.77)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5 (5, 5)	5833 (3464, 9821)	1141.93 (678.45, 1922.04)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	10 (10, 11)	10 (10, 10)	0.97 (0.92, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5 (5, 6)	5 (5, 5)	0.97 (0.90, 1.03)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 11)	88760 (53701, 146707)	8700.37 (5323.82, 14218.42)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)	241209 (168681, 344922)	24120.91 (16868.12, 34492.19)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)	463469 (322830, 665378)	46346.93 (32282.95, 66537.83)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)	362 (224, 583)	69.97 (43.74, 111.92)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)	930 (559, 1549)	183.66 (110.80, 304.42)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	255	10 (10, 10)	48363 (38230, 61183)	4808.12 (3800.84, 6082.35)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	10 (10, 10)	54232 (44615, 65922)	5389.56 (4435.12, 6549.39)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	10 (10, 10)	84391 (70325, 101269)	8352.45 (6975.06, 10001.82)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	255	5 (5, 5)	199 (157, 252)	39.22 (30.90, 49.78)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	255	5 (5, 5)	348 (276, 438)	68.12 (54.16, 85.68)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)	134756 (86047, 211040)	13475.64 (8604.68, 21103.95)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)	188670 (129392, 275106)	18867.03 (12939.21, 27510.55)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)	293282 (210942, 407763)	29328.19 (21094.20, 40776.26)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 6)	541 (337, 870)	100.78 (63.88, 159.01)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)	1052 (680, 1627)	210.47 (136.09, 325.50)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)	5 (5, 5)	1.03 (0.99, 1.08)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	48	10 (10, 10)	36017 (20724, 62595)	3554.56 (2039.96, 6193.68)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	10 (10, 11)	48060 (30237, 76388)	4715.92 (2980.60, 7461.57)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	10 (10, 10)	79058 (52125, 119908)	7905.78 (5212.45, 11990.78)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	48	5 (5, 5)	155 (89, 270)	29.89 (17.24, 51.82)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	48	5 (5, 5)	378 (233, 613)	74.62 (45.91, 121.29)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	255	10 (10, 10)	614449 (455495, 828875)	61086.86 (45285.39, 82401.95)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	255	10 (10, 10)	2156196 (1736284, 2677662)	214282.06 (172705.04, 265868.34)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	255	10 (10, 10)	3754377 (3053564, 4616033)	371583.87 (302329.22, 456702.71)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	255	5 (5, 5)	3359 (2423, 4656)	662.04 (477.45, 917.99)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	255	5 (5, 5)	4361 (3299, 5763)	854.58 (648.16, 1126.74)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)	3325369 (2089439, 5292368)	332536.90 (208943.88, 529236.81)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)	7826271 (5853680, 10463591)	782627.11 (585368.05, 1046359.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)	12884976 (10641883, 15600868)	1288497.62 (1064188.30, 1560086.81)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 6)	27431 (17819, 42227)	5108.47 (3366.93, 7750.83)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)	22502 (13237, 38254)	4500.48 (2647.36, 7650.76)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	44	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	44	5 (5, 5)	5 (5, 6)	1.04 (0.97, 1.11)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	48	10 (10, 10)	617829 (374065, 1020446)	60974.99 (36881.21, 100808.77)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	10 (10, 11)	1793880 (1112795, 2891824)	176025.95 (109237.32, 283649.72)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	10 (10, 10)	3402410 (2325361, 4978321)	340240.98 (232536.09, 497832.07)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	48	5 (5, 5)	3501 (1863, 6577)	675.29 (361.89, 1260.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	48	5 (5, 5)	5048 (2709, 9408)	997.20 (534.99, 1858.76)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	227	10 (10, 10)	75305 (60091, 94371)	7472.04 (5960.28, 9367.23)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	10 (10, 10)	80069 (65707, 97571)	7979.90 (6548.33, 9724.45)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	10 (10, 10)	153593 (130667, 180543)	15359.34 (13066.69, 18054.25)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	227	5 (5, 5)	332 (263, 418)	65.09 (51.60, 82.12)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	227	5 (5, 5)	421 (328, 540)	81.90 (63.99, 104.83)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	10 (10, 11)	127407 (81244, 199800)	12465.97 (8016.45, 19385.18)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)	139826 (99996, 195520)	13982.56 (9999.60, 19552.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)	241494 (182978, 318724)	24149.39 (18297.76, 31872.38)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5 (5, 5)	508 (317, 815)	99.68 (62.60, 158.74)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)	944 (626, 1422)	188.75 (125.29, 284.35)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	34367 (22390, 52751)	3398.18 (2213.28, 5217.45)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	38048 (27669, 52321)	3804.83 (2766.90, 5232.12)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	59664 (45819, 77691)	5966.37 (4581.94, 7769.08)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	156 (105, 232)	30.49 (20.53, 45.27)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)	257 (170, 390)	50.29 (33.38, 75.76)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	227	10 (10, 10)	1177109 (909148, 1524048)	116797.25 (90218.92, 151205.51)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	227	10 (10, 10)	3441017 (2860842, 4138850)	342939.68 (285103.95, 412507.88)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	227	10 (10, 10)	7365218 (6408010, 8465410)	736521.80 (640801.04, 846541.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	227	5 (5, 5)	5534 (4137, 7404)	1085.68 (812.27, 1451.14)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	227	5 (5, 5)	7125 (5468, 9285)	1386.74 (1065.57, 1804.72)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	10 (10, 11)	2806906 (1779671, 4427066)	274637.99 (174793.56, 431514.90)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	10 (10, 10)	7305563 (5522547, 9664247)	730556.35 (552254.70, 966424.70)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	10 (10, 10)	13343347 (11421210, 15588971)	1334334.72 (1142121.04, 1558897.08)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5 (5, 5)	18240 (11134, 29880)	3577.07 (2192.53, 5835.90)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5 (5, 5)	17541 (10280, 29932)	3508.28 (2056.01, 5986.35)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)	5 (5, 6)	1.05 (0.98, 1.11)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	10 (10, 10)	461295 (282331, 753702)	45612.82 (27970.09, 74384.08)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	10 (10, 10)	1599200 (1156266, 2211811)	159920.02 (115626.58, 221181.10)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	10 (10, 10)	2437171 (1815977, 3270859)	243717.12 (181597.68, 327085.88)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5 (5, 5)	2442 (1442, 4134)	476.56 (282.81, 803.04)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5 (5, 5)	3681 (2278, 5949)	719.25 (447.61, 1155.75)

Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Sex								
Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	395	10 (10, 10)	27118 (20803, 35351)	2707.97 (2077.28, 3530.15)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	10 (10, 10)	25738 (20110, 32941)	2547.65 (1992.51, 3257.47)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	10 (10, 10)	40290 (34397, 47193)	4021.73 (3433.73, 4710.40)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	395	5 (5, 5)	121 (93, 157)	23.94 (18.44, 31.08)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	395	5 (5, 5)	207 (158, 272)	41.19 (31.36, 54.12)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	52664 (36905, 75154)	5247.05 (3679.29, 7482.84)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	43301 (30763, 60949)	4330.07 (3076.26, 6094.90)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	83762 (65541, 107048)	8376.20 (6554.14, 10704.79)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	223 (158, 315)	44.26 (31.35, 62.49)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	449 (303, 666)	88.19 (59.60, 130.49)
Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	10 (10, 11)	10 (10, 10)	0.96 (0.88, 1.04)
Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	11 (9, 12)	10 (10, 10)	0.95 (0.85, 1.05)
Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	11707 (7655, 17903)	1170.65 (765.46, 1790.34)
Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	12838 (8743, 18852)	1283.80 (874.26, 1885.18)
Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	16359 (12044, 22219)	1635.88 (1204.42, 2221.91)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	43 (29, 63)	8.45 (5.76, 12.39)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	100 (68, 146)	19.80 (13.54, 28.93)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	395	10 (10, 10)	358185 (259645, 494122)	35767.67 (25927.56, 49342.34)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	395	10 (10, 10)	1032572 (803692, 1326633)	102207.86 (79582.66, 131265.36)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	395	10 (10, 10)	2448348 (1992531, 3008439)	244392.84 (198889.12, 300307.33)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	395	5 (5, 5)	1983 (1427, 2754)	392.99 (282.86, 546.00)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	395	5 (5, 5)	2322 (1694, 3181)	461.27 (336.67, 631.96)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	1379076 (895389, 2124049)	137399.94 (89225.93, 211583.59)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	2628794 (1842173, 3751308)	262879.40 (184217.30, 375130.79)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	5518909 (4222583, 7213204)	551890.89 (422258.33, 721320.40)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	5567 (3235, 9581)	1105.10 (642.29, 1901.37)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	9590 (6259, 14696)	1881.91 (1235.71, 2866.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	10 (10, 11)	10 (10, 10)	0.96 (0.88, 1.04)
Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	11 (9, 12)	10 (10, 10)	0.96 (0.86, 1.07)
Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.00)
Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	115	10 (10, 10)	120405 (68919, 210356)	12040.55 (6891.87, 21035.63)
Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	115	10 (10, 10)	361345 (243436, 536364)	36134.52 (24343.59, 53636.45)
Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	115	10 (10, 10)	578439 (406742, 822616)	57843.93 (40674.16, 82261.55)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	115	5 (5, 5)	606 (358, 1023)	120.00 (71.07, 202.60)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	115	5 (5, 5)	930 (554, 1559)	184.20 (109.85, 308.87)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	519	10 (10, 10)	21438 (17319, 26535)	2136.48 (1726.18, 2644.32)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	10 (10, 10)	21234 (17837, 25278)	2116.93 (1778.05, 2520.39)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	10 (10, 10)	41415 (35725, 48012)	4138.70 (3570.16, 4797.78)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	519	5 (5, 5)	98 (80, 120)	19.27 (15.73, 23.62)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	519	5 (5, 5)	178 (145, 218)	34.90 (28.55, 42.66)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	153	10 (10, 10)	37697 (26222, 54193)	3755.35 (2612.56, 5398.02)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	10 (10, 10)	32117 (22658, 45526)	3211.74 (2265.79, 4552.63)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	10 (10, 10)	77611 (57216, 105276)	7761.12 (5721.63, 10527.59)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	153	5 (5, 5)	165 (113, 242)	32.19 (21.92, 47.27)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	153	5 (5, 5)	401 (268, 602)	79.18 (52.69, 118.97)
Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.01)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	87	5 (5, 6)	5 (5, 5)	0.99 (0.92, 1.07)
Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	155	10 (10, 11)	13066 (8983, 19004)	1274.54 (888.11, 1829.10)
Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	155	10 (10, 10)	12876 (9489, 17472)	1284.49 (946.73, 1742.74)
Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	155	10 (10, 10)	19468 (15496, 24459)	1946.81 (1549.59, 2445.85)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	155	5 (5, 5)	58 (42, 81)	11.13 (8.13, 15.24)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	155	5 (5, 5)	152 (105, 219)	29.90 (20.91, 42.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	519	10 (10, 10)	304934 (237911, 390840)	30389.88 (23713.90, 38945.28)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	519	10 (10, 10)	924524 (750510, 1138886)	92171.55 (74822.64, 113543.10)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	519	10 (10, 10)	1878895 (1586011, 2225864)	187761.05 (158494.70, 222431.47)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	519	5 (5, 5)	1243 (972, 1588)	244.86 (191.72, 312.74)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	519	5 (5, 5)	2160 (1643, 2840)	424.30 (323.30, 556.85)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	153	10 (10, 10)	785331 (484933, 1271815)	78234.14 (48312.07, 126688.43)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	153	10 (10, 10)	2106655 (1490680, 2977161)	210665.51 (149068.03, 297716.12)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	153	10 (10, 10)	5236885 (3880756, 7066912)	523688.47 (388075.59, 706691.20)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	153	5 (5, 5)	5754 (3356, 9868)	1120.71 (659.00, 1905.91)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	153	5 (5, 5)	6872 (4174, 11314)	1355.55 (821.91, 2235.68)
Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	87	5 (5, 6)	5 (5, 5)	0.98 (0.92, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	155	10 (10, 11) 10 (10, 10) 10 (10, 10)	136546 (89268, 208864) 396863 (289955, 543189) 748414 (540245, 1036794)	13319.90 (8844.86, 20059.09) 39591.01 (28926.67, 54186.94) 74841.37 (54024.52, 103679.41)
Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	155	5 (5, 5)	541 (355, 825)	103.77 (68.77, 156.56)
Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	155	5 (5, 5)	1659 (1064, 2588)	326.50 (210.44, 506.55)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	155	541 (355, 825)	103.77 (68.77, 156.56)	
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	155	1659 (1064, 2588)	326.50 (210.44, 506.55)	

Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, sex								
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	269	10 (10, 10)	17005 (13156, 21980)	1696.36 (1312.50, 2192.48)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	10 (10, 10)	16543 (13418, 20396)	1649.23 (1337.49, 2033.63)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	10 (10, 10)	32705 (27399, 39039)	3270.52 (2739.91, 3903.89)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	269	5 (5, 5)	79 (62, 101)	15.62 (12.24, 19.92)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	269	5 (5, 5)	150 (118, 191)	29.60 (23.28, 37.64)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	79	10 (10, 10)	27788 (17970, 42970)	2771.79 (1792.45, 4286.21)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	10 (10, 10)	21789 (14248, 33321)	2178.91 (1424.83, 3332.11)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	10 (10, 10)	56962 (39317, 82526)	5696.22 (3931.72, 8252.62)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	79	5 (5, 5)	124 (78, 197)	24.32 (15.30, 38.67)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	79	5 (5, 5)	319 (195, 522)	62.74 (38.25, 102.90)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	52	5 (5, 6)	5 (5, 5)	0.99 (0.90, 1.08)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	83	10 (10, 11)	10603 (6760, 16631)	1033.17 (669.94, 1593.35)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	83	10 (10, 10)	10100 (6984, 14608)	1010.05 (698.40, 1460.75)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	83	10 (10, 10)	14961 (11369, 19689)	1496.11 (1136.86, 1968.90)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	83	5 (5, 6)	46 (31, 69)	8.74 (6.00, 12.74)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	83	5 (5, 5)	133 (86, 207)	26.17 (16.99, 40.31)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	269	10 (10, 10)	240348 (178375, 323851)	23976.19 (17797.28, 32300.31)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	269	10 (10, 10)	725439 (563976, 933126)	72323.27 (56225.78, 93029.48)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	269	10 (10, 10)	1494002 (1218429, 1831901)	149400.21 (121842.92, 183190.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	269	5 (5, 5)	946 (706, 1267)	186.45 (139.19, 249.76)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	269	5 (5, 5)	1691 (1216, 2352)	332.97 (239.88, 462.17)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	79	10 (10, 10)	582852 (324144, 1048040)	58138.58 (32334.21, 104536.20)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	10 (10, 10)	1557246 (1019727, 2378101)	155724.56 (101972.70, 237810.10)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	10 (10, 10)	4234642 (2930914, 6118296)	423464.24 (293091.36, 611829.57)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	79	5 (5, 5)	4195 (2173, 8100)	820.85 (429.44, 1568.99)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	79	5 (5, 5)	5422 (2964, 9918)	1066.04 (581.49, 1954.38)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.02)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	52	5 (5, 6)	5 (5, 5)	0.97 (0.90, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	83	10 (10, 11) (60463, 168711)	100999 (201048, 428852)	9841.83 (6007.63, 16123.08)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	83	10 (10, 10) (384900, 848795)	293632 (20104.77, 42885.16)	29363.18 (57157.76, 38489.96, 84879.54)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	83	10 (10, 10) (233, 641)	571578 (804, 2349)	73.68 (45.02, 120.60)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	83	5 (5, 6) (14896, 29540)	387 (13705, 26001)	270.38 (1866.53, 2097.68)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	83	5 (5, 5) (24030, 35901)	1375 (2402.98, 3590.15)	(159.26, 459.03)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	163	10 (10, 10) (118, 240)	20977 (41875, 4187.48)	(1489.60, 2953.97)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 10) (20281, 47031)	18877 (30884, 63477)	(1356.91, 2567.57)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10) (47023, 85688)	29372 (4702.33, 8568.81)	(2937.19, 33.64)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	163	5 (5, 5) (5, 5)	94 (67, 132) (119, 274)	(18.70, 36.09)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	163	5 (5, 5) (27088, 64734)	169 (118, 240)	(23.62, 47.90)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	67	10 (10, 10) (20281, 47031)	41875 (30884, 63477)	(4187.48, 3088.44)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	10 (10, 10) (47023, 85688)	30884 (4702.33, 8568.81)	(2028.11, 4703.13)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10 (10, 10) (119, 274)	63477 (180, 2349)	6347.70 (36.09)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	67	5 (5, 5)	180 (23.79, 54.76)	(4702.33, 8568.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	67	5 (5, 5)	372 (229, 604)	72.62 (44.83, 117.63)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	28	11 (9, 12)	10 (10, 10)	0.93 (0.81, 1.07)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	28	11 (9, 13)	10 (10, 10)	0.92 (0.78, 1.08)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	28	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	28	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.10)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	28	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	10 (10, 10)	8697 (5222, 14483)	869.66 (522.19, 1448.34)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	10 (10, 10)	9188 (5784, 14598)	918.85 (578.36, 1459.77)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	10 (10, 10)	11210 (7775, 16161)	1120.96 (777.52, 1616.12)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5 (5, 5)	31 (20, 50)	6.29 (3.99, 9.92)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5 (5, 5)	73 (47, 115)	14.60 (9.30, 22.92)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	163	10 (10, 10)	276033 (182277, 418013)	27603.26 (18227.67, 41801.29)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	163	10 (10, 10)	756600 (546757, 1046981)	74811.32 (54086.35, 103477.74)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	163	10 (10, 10)	1920202 (1472176, 2504576)	192020.23 (147217.61, 250457.60)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	163	5 (5, 5)	1532 (1004, 2337)	304.47 (199.53, 464.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	163	5 (5, 5)	1850 (1231, 2781)	368.88 (245.44, 554.40)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	67	10 (10, 10)	1079995 (633450, 1841326)	107999.49 (63345.04, 184132.65)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	67	10 (10, 10)	1977267 (1268954, 3080952)	197726.73 (126895.40, 308095.19)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	67	10 (10, 10)	4318054 (3077671, 6058343)	431805.36 (307767.09, 605834.32)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	67	5 (5, 5)	3857 (1960, 7590)	771.41 (392.00, 1518.05)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	67	5 (5, 5)	7789 (4625, 13117)	1520.50 (910.33, 2539.66)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	28	11 (9, 12)	10 (10, 10)	0.93 (0.81, 1.07)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	28	11 (9, 13)	10 (10, 11)	0.94 (0.79, 1.11)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	28	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	28	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	28	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	10 (10, 10)	83366 (42296, 164315)	8336.56 (4229.57, 16431.52)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	10 (10, 10)	236528 (146661, 381460)	23652.81 (14666.14, 38146.03)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	10 (10, 10)	373064 (243212, 572245)	37306.38 (24321.16, 57224.48)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5 (5, 5)	387 (206, 728)	77.48 (41.21, 145.66)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5 (5, 5)	618 (331, 1154)	122.95 (65.86, 229.52)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	232	10 (10, 10)	59503 (46453, 76219)	5916.13 (4616.71, 7581.30)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	10 (10, 10)	66467 (53933, 81913)	6600.68 (5356.98, 8133.11)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	10 (10, 10)	105989 (87935, 127749)	10521.42 (8738.17, 12668.58)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	232	5 (5, 5)	259 (203, 330)	50.93 (39.90, 65.01)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	232	5 (5, 5)	390 (306, 496)	76.59 (60.31, 97.27)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	10 (10, 11)	121492 (77083, 191487)	11942.84 (7662.16, 18615.06)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	10 (10, 10)	148457 (98119, 224620)	14845.72 (9811.94, 22461.95)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	10 (10, 10)	230231 (167261, 316907)	23023.06 (16726.06, 31690.75)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5 (5, 6)	482 (286, 812)	93.10 (56.09, 154.53)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5 (5, 5)	895 (560, 1432)	179.10 (111.99, 286.42)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	48	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	48	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	48	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	48	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	48	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	51	10 (10, 10)	39245 (22100, 69691)	3924.48 (2209.96, 6969.15)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	10 (10, 10)	50082 (30542, 82125)	5008.22 (3054.16, 8212.50)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	10 (10, 10)	76189 (49115, 118188)	7618.89 (4911.45, 11818.80)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	51	5 (5, 6)	147 (82, 263)	28.06 (15.81, 49.79)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	51	5 (5, 5)	350 (196, 626)	68.37 (38.37, 121.82)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	232	10 (10, 10)	794988 (585435, 1079548)	79042.03 (58202.65, 107342.91)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	232	10 (10, 10)	2674328 (2152728, 3322311)	265580.56 (213995.04, 329601.25)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	232	10 (10, 10)	5149990 (4231902, 6267253)	511235.06 (419941.28, 622375.80)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	232	5 (5, 5)	4362 (3133, 6074)	858.16 (615.90, 1195.72)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	232	5 (5, 5)	4649 (3501, 6173)	914.10 (689.08, 1212.60)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	10 (10, 11)	3362752 (2054881, 5503045)	330562.39 (202713.86, 539043.05)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	10 (10, 10)	7426127 (5296972, 10411111)	742612.73 (529697.25, 104111.05)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	10 (10, 10)	13502491 (11607977, 15706205)	1350249.15 (1160797.74, 1570620.53)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5 (5, 6)	21221 (12633, 35647)	4098.51 (2451.98, 6850.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5 (5, 5)	20477 (11619, 36087)	4095.32 (2323.81, 7217.31)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	48	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	48	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	48	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	48	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.06)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	48	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	51	10 (10, 10)	537607 (291471, 991596)	53760.68 (29147.06, 99159.60)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	10 (10, 10)	2027539 (1259961, 3262731)	202753.90 (125996.11, 326273.11)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	10 (10, 10)	3447429 (2322804, 5116559)	344742.86 (232280.42, 511655.88)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	51	5 (5, 6)	3730 (1880, 7401)	712.08 (364.28, 1391.96)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	51	5 (5, 5)	4892 (2560, 9348)	954.53 (501.47, 1816.94)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	250	10 (10, 10)	59851 (47954, 74699)	5939.41 (4759.85, 7411.27)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	10 (10, 10)	64209 (53151, 77567)	6401.45 (5299.06, 7733.16)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	10 (10, 10)	117943 (99447, 139878)	11750.53 (9917.62, 13922.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	250	5 (5, 5)	249 (197, 315)	48.99 (38.78, 61.89)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	250	5 (5, 5)	373 (294, 474)	72.42 (57.16, 91.75)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	74	10 (10, 10)	137448 (87797, 215179)	13617.44 (8720.37, 21264.54)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	10 (10, 10)	166523 (121761, 227741)	16652.29 (12176.06, 22774.10)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	10 (10, 10)	288235 (216852, 383115)	28823.47 (21685.20, 38311.49)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	74	5 (5, 6)	553 (354, 864)	105.66 (68.26, 163.53)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	74	5 (5, 5)	1062 (720, 1566)	212.40 (144.04, 313.21)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 10)	32440 (21159, 49736)	3179.25 (2072.58, 4876.82)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)	37051 (27449, 50013)	3657.70 (2719.73, 4919.14)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)	61265 (47638, 78789)	6126.46 (4763.78, 7878.92)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)	162 (110, 238)	31.81 (21.63, 46.78)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)	271 (188, 392)	53.46 (37.23, 76.76)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	250	10 (10, 10)	875715 (670811, 1143209)	86902.97 (66586.59, 113418.14)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	10 (10, 10)	2708471 (2228982, 3291105)	270027.12 (222227.95, 328107.44)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	10 (10, 10)	5189777 (4355492, 6183867)	517053.81 (434090.43, 615873.16)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	250	5 (5, 5)	4169 (3097, 5612)	819.46 (609.36, 1102.00)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	250	5 (5, 5)	6397 (4907, 8340)	1242.43 (955.63, 1615.30)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	74	10 (10, 10)	2781850 (1795669, 4309643)	275607.01 (178109.07, 426475.89)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	74	10 (10, 10)	7590360 (5921961, 9728799)	759036.03 (592196.09, 972879.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	74	10 (10, 10)	12894340 (10799304, 15395807)	1289433.98 (1079930.42, 1539580.67)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	74	5 (5, 6)	21984 (13986, 34558)	4198.62 (2698.65, 6532.30)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	74	5 (5, 5)	18779 (11189, 31518)	3755.84 (2237.83, 6303.56)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5 (5, 5)	5 (5, 6)	1.04 (0.96, 1.13)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	72	10 (10, 10)	507512 (329028, 782814)	49738.19 (32306.17, 76576.34)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	72	10 (10, 10)	1473236 (1067157, 2033836)	145438.84 (105433.61, 200623.47)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	72	10 (10, 10)	2420004 (1820068, 3217693)	242000.40 (182006.75, 321769.35)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	72	5 (5, 5)	2344 (1427, 3849)	460.66 (280.22, 757.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	72	5 (5, 5)	3767 (2352, 6032)	742.12 (464.89, 1184.66)
Female								

MOCK

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino ethnicity								
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	136	10 (10, 10)	22074 (14121, 34506)	2207.38 (1412.06, 3450.64)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	10 (10, 10)	22266 (15847, 31284)	2226.58 (1584.75, 3128.36)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	10 (10, 10)	41773 (31562, 55289)	4177.34 (3156.18, 5528.90)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	136	5 (5, 5)	101 (67, 152)	20.07 (13.32, 30.26)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	136	5 (5, 6)	190 (126, 284)	35.82 (24.42, 52.53)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	35	10 (10, 10)	66150 (37538, 116570)	6614.98 (3753.79, 11657.02)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	10 (10, 10)	57339 (30559, 107588)	5733.92 (3055.89, 10758.85)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	10 (10, 10)	90332 (50343, 162084)	9033.16 (5034.32, 16208.37)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	35	5 (5, 5)	254 (155, 417)	50.85 (31.04, 83.31)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	35	5 (5, 5)	498 (236, 1049)	97.19 (45.87, 205.93)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	20	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	20	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	20	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	20	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	20	5 (5, 5)	6 (4, 8)	1.21 (0.87, 1.67)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	38	10 (10, 10)	26345 (9909, 70041)	2607.33 (980.41, 6934.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	38	10 (10, 10)	34815 (16110, 75239)	3481.54 (1611.02, 7523.86)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	38	10 (10, 10)	26708 (12585, 56680)	2670.83 (1258.52, 5668.01)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	38	6 (5, 7)	118 (42, 327)	21.01 (8.52, 51.83)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	38	5 (5, 5)	351 (151, 818)	70.21 (30.13, 163.62)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	136	10 (10, 10)	332872 (193115, 573771)	33287.22 (19311.52, 57377.11)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	136	10 (10, 10)	1087406 (737091, 1604213)	108740.60 (73709.14, 160421.34)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	136	10 (10, 10)	2082654 (1564176, 2772993)	208265.41 (156417.59, 277299.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	136	5 (5, 5)	1727 (1013, 2946)	344.71 (202.11, 587.93)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	136	5 (5, 6)	2444 (1373, 4350)	461.92 (266.06, 801.97)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	35	10 (10, 10)	1420449 (558648, 3611715)	142044.90 (55864.75, 361171.46)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	35	10 (10, 10)	2735111 (1368395, 5466868)	273511.13 (136839.49, 546686.78)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	35	10 (10, 10)	7578287 (5040721, 11393296)	757828.67 (504072.13, 1139329.58)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	35	5 (5, 5)	7727 (2908, 20532)	1545.45 (581.63, 4106.42)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	35	5 (5, 5)	10208 (4492, 23195)	1991.90 (877.85, 4519.79)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	20	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	20	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	20	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	20	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	20	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	38	10 (10, 10)	452690 (158709, 1291220)	44802.56 (15709.89, 127771.11)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	38	10 (10, 10)	747435 (391924, 1425424)	74743.46 (39192.45, 142542.38)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	38	10 (10, 10)	1403460 (609038, 3234119)	140346.03 (60903.77, 323411.95)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	38	6 (5, 7)	1522 (466, 4976)	271.27 (88.81, 828.62)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	38	5 (5, 5)	3063 (1057, 8877)	612.54 (211.34, 1775.33)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	690	10 (10, 10)	23655 (19521, 28664)	2361.23 (1948.59, 2861.26)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10 (10, 10)	23020 (19425, 27280)	2286.61 (1930.10, 2708.97)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10 (10, 10)	39694 (35055, 44946)	3963.68 (3500.65, 4487.96)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	690	5 (5, 5)	104 (86, 125)	20.56 (17.07, 24.76)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	690	5 (5, 5)	191 (158, 230)	37.96 (31.48, 45.77)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	217	10 (10, 10)	41747 (30714, 56743)	4155.34 (3057.89, 5646.66)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	10 (10, 10)	35344 (26390, 47337)	3534.42 (2639.00, 4733.66)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	10 (10, 10)	83383 (65546, 106075)	8338.33 (6554.59, 10607.48)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	217	5 (5, 5)	183 (133, 251)	36.13 (26.25, 49.73)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	217	5 (5, 5)	411 (294, 575)	80.81 (57.70, 113.17)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	130	10 (10, 11)	10 (10, 10)	0.98 (0.94, 1.02)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	130	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	130	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	130	5 (5, 5)	5 (5, 5)	1.01 (0.98, 1.03)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	130	5 (5, 5)	5 (5, 5)	0.97 (0.93, 1.02)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	214	10 (10, 10)	12063 (8992, 16185)	1185.92 (892.08, 1576.54)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	214	10 (10, 10)	11608 (9046, 14896)	1158.76 (903.07, 1486.86)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	214	10 (10, 10)	18056 (14910, 21865)	1805.57 (1490.99, 2186.53)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	214	5 (5, 5)	48 (37, 63)	9.40 (7.28, 12.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	214	5 (5, 5)	123 (92, 165)	24.28 (18.23, 32.35)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	690	10 (10, 10)	334364 (266627, 419309)	33376.43 (26615.01, 41855.57)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10 (10, 10)	987977 (822264, 1187086)	98137.11 (81690.28, 117895.20)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10 (10, 10)	2063432 (1775937, 2397468)	206047.30 (177339.03, 239402.97)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	690	5 (5, 5)	1500 (1191, 1888)	296.84 (235.74, 373.77)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	690	5 (5, 5)	2270 (1788, 2883)	451.12 (355.29, 572.80)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	217	10 (10, 10)	968852 (654113, 1435033)	96436.92 (65115.44, 142824.48)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	217	10 (10, 10)	2315554 (1731123, 3097290)	231555.38 (173112.28, 309728.99)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	217	10 (10, 10)	5301268 (4150604, 6770929)	530126.82 (415060.39, 677092.90)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	217	5 (5, 5)	5224 (3348, 8151)	1034.14 (662.98, 1613.08)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	217	5 (5, 5)	7937 (5300, 11886)	1561.42 (1043.13, 2337.23)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	130	10 (10, 11)	10 (10, 10)	0.98 (0.94, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	130	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.02)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	130	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	130	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.02)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	130	5 (5, 5)	5 (5, 5)	0.98 (0.93, 1.03)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	214	10 (10, 10)	129424 (89788, 186557)	12723.27 (8908.87, 18170.84)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	214	10 (10, 10)	381696 (293138, 497006)	38101.89 (29262.14, 49612.02)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	214	10 (10, 10)	648311 (505732, 831086)	64831.06 (50573.21, 83108.56)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	214	5 (5, 5)	555 (395, 782)	108.64 (77.40, 152.49)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	214	5 (5, 5)	1324 (921, 1904)	261.10 (182.28, 374.00)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	88	10 (10, 10)	24172 (15240, 38338)	2390.80 (1508.53, 3789.06)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	10 (10, 10)	22876 (15904, 32905)	2274.83 (1582.12, 3270.83)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	10 (10, 10)	50488 (35885, 71034)	5048.79 (3588.47, 7103.37)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	88	5 (5, 5)	133 (84, 213)	25.71 (16.13, 40.96)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	88	5 (5, 5)	174 (106, 287)	34.02 (20.65, 56.04)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	22	10 (10, 10)	34292 (18107, 64943)	3429.17 (1810.69, 6494.31)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	10 (10, 10)	25827 (18334, 36382)	2582.70 (1833.44, 3638.16)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	10 (10, 10)	46903 (33825, 65038)	4690.32 (3382.48, 6503.83)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	22	6 (4, 7)	154 (91, 259)	27.15 (16.58, 44.47)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	22	5 (5, 5)	420 (198, 891)	83.98 (39.57, 178.24)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	13	12 (8, 18)	10 (10, 10)	0.82 (0.56, 1.21)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	18	10 (10, 10)	7067 (1907, 26192)	706.66 (190.66, 2619.21)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	18	10 (10, 10)	10750 (3611, 32001)	1075.02 (361.13, 3200.07)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	18	10 (10, 10)	11909 (5649, 25107)	1190.89 (564.87, 2510.66)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	18	5 (5, 5)	37 (15, 93)	7.39 (2.93, 18.63)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	18	5 (5, 5)	58 (19, 177)	11.28 (3.70, 34.45)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	88	10 (10, 10)	259797 (148513, 454466)	25696.00 (14717.82, 44862.93)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	88	10 (10, 10)	735710 (462524, 1170251)	73159.15 (46013.55, 116319.24)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	88	10 (10, 10)	2279592 (1446853, 3591615)	227959.19 (144685.30, 359161.52)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	88	5 (5, 5)	1291 (765, 2178)	248.75 (147.56, 419.33)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	88	5 (5, 5)	1748 (990, 3088)	341.31 (194.13, 600.06)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	22	10 (10, 10)	710026 (245263, 2055490)	71002.57 (24526.34, 205549.00)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	10 (10, 10)	1751283 (872333, 3515850)	175128.31 (87233.31, 351585.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	10 (10, 10)	3840709 (2197166, 6713669)	384070.92 (219716.64, 671366.86)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	22	6 (4, 7)	8669 (2979, 25223)	1531.30 (641.99, 3652.47)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	22	5 (5, 5)	5104 (2140, 12175)	1020.81 (427.96, 2434.92)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	13	12 (8, 18)	10 (10, 10)	0.82 (0.56, 1.21)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.08)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	18	10 (10, 10)	26411 (10028, 69563)	2641.13 (1002.77, 6956.29)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	18	10 (10, 10)	162620 (55659, 475135)	16262.02 (5565.86, 47513.49)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	18	10 (10, 10)	417076 (107739, 1614570)	41707.62 (10773.92, 161457.03)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	18	5 (5, 5)	188 (46, 766)	37.59 (9.22, 153.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	18	5 (5, 5)	437 (69, 2773)	85.21 (13.47, 538.99)

MOCK

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Race								
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	362	10 (10, 10)	26952 (20883, 34784)	2692.55 (2086.26, 3475.03)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	10 (10, 10)	23438 (18669, 29425)	2343.79 (1866.88, 2942.53)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	10 (10, 10)	40376 (34349, 47460)	4031.72 (3430.05, 4738.93)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	362	5 (5, 5)	115 (90, 147)	22.83 (17.82, 29.23)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	362	5 (5, 5)	188 (146, 241)	37.41 (29.16, 48.00)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)	33909 (24023, 47863)	3381.77 (2396.63, 4771.84)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)	30985 (21434, 44793)	3098.50 (2143.36, 4479.29)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)	72481 (53061, 99008)	7248.12 (5306.15, 9900.82)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)	148 (104, 211)	29.21 (20.49, 41.65)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)	348 (226, 535)	69.53 (45.18, 106.99)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.02)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	5 (5, 5)	0.96 (0.89, 1.04)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	12594 (8382, 18924)	1256.17 (836.02, 1887.47)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	10931 (7560, 15804)	1089.81 (753.88, 1575.44)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	18868 (14808, 24043)	1886.83 (1480.76, 2404.27)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	52 (37, 74)	10.37 (7.32, 14.70)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	107 (76, 150)	21.32 (15.15, 29.99)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	362	10 (10, 10)	328428 (241933, 445846)	32810.77 (24169.70, 44541.16)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	10 (10, 10)	1035293 (809568, 1323956)	103529.30 (80956.76, 132395.58)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	10 (10, 10)	2145772 (1770774, 2600184)	214266.04 (176817.71, 259645.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	362	5 (5, 5)	1376 (1010, 1874)	273.04 (200.41, 371.99)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	362	5 (5, 5)	2011 (1465, 2761)	400.97 (292.11, 550.40)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)	855574 (517613, 1414198)	85327.48 (51627.40, 141025.47)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)	1943813 (1349835, 2799166)	194381.34 (134983.46, 279916.55)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)	4608987 (3338577, 6362819)	460898.73 (333857.72, 636281.94)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)	4550 (2471, 8378)	899.93 (488.90, 1656.55)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)	7994 (4646, 13757)	1598.88 (929.14, 2751.39)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.03)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	5 (5, 5)	0.98 (0.90, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	105260 (65764, 168478)	10498.69 (6559.92, 16802.41)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	393045 (287516, 537306)	39187.22 (28666.35, 53569.39)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	674526 (485396, 937351)	67452.65 (48539.56, 93735.08)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	575 (371, 892)	114.01 (73.52, 176.80)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	1478 (953, 2292)	295.55 (190.57, 458.35)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	195	10 (10, 10)	16417 (11437, 23568)	1634.81 (1138.84, 2346.77)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	10 (10, 11)	18966 (14305, 25146)	1843.84 (1399.25, 2429.70)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	10 (10, 10)	33478 (26923, 41629)	3347.79 (2692.25, 4162.95)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	195	5 (5, 5)	80 (57, 111)	15.88 (11.38, 22.16)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	195	5 (5, 5)	168 (116, 244)	33.41 (23.02, 48.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)	70405 (39637, 125057)	6985.30 (3937.62, 12391.85)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)	49806 (32279, 76849)	4980.58 (3227.90, 7684.92)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)	92510 (63827, 134083)	9251.02 (6382.72, 13408.29)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 5)	240 (126, 455)	47.20 (24.97, 89.23)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)	595 (282, 1255)	116.76 (55.14, 247.22)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)	5 (5, 5)	0.97 (0.92, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)	9803 (5446, 17644)	975.15 (541.69, 1755.46)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)	13142 (8909, 19387)	1314.25 (890.92, 1938.73)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)	17281 (11001, 27148)	1728.13 (1100.06, 2714.79)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 6)	44 (24, 81)	8.34 (4.87, 14.28)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)	170 (88, 328)	33.37 (17.33, 64.24)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	195	10 (10, 10)	270892 (186938, 392550)	26974.76 (18614.75, 39089.32)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	10 (10, 11)	700976 (482795, 1017755)	68147.28 (47075.98, 98650.13)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	10 (10, 10)	1698222 (1265203, 2279444)	169822.23 (126520.28, 227944.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	195	5 (5, 5)	1634 (1060, 2520)	325.53 (211.14, 501.88)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	195	5 (5, 5)	2461 (1568, 3861)	488.47 (311.61, 765.72)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	10 (10, 10)	1211651 (545292, 2692316)	120214.66 (54113.01, 267062.68)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	10 (10, 10)	3863173 (2496394, 5978266)	386317.31 (249639.38, 597826.60)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	10 (10, 10)	5233980 (3292870, 8319352)	523397.96 (329286.96, 831935.23)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5 (5, 5)	9353 (5430, 16111)	1839.68 (1070.22, 3162.36)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5 (5, 5)	10207 (5426, 19200)	2004.31 (1066.53, 3766.66)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5 (5, 5)	5 (5, 5)	0.99 (0.92, 1.06)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)	162243 (80633, 326450)	16139.73 (8020.79, 32476.93)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)	304404 (168043, 551417)	30440.40 (16804.30, 55141.74)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)	604842 (358324, 1020956)	60484.17 (35832.44, 102095.63)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 6)	572 (270, 1213)	107.39 (52.57, 219.36)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)	1276 (599, 2723)	250.63 (117.65, 533.90)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	30141 (17403, 52204)	2996.97 (1730.61, 5189.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	33349 (22259, 49964)	3334.89 (2225.89, 4996.41)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	63758 (45931, 88504)	6375.81 (4593.12, 8850.40)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	144 (92, 225)	28.35 (18.13, 44.32)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	330 (204, 534)	62.08 (38.25, 100.73)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	24	10 (10, 11)	33316 (16935, 65545)	3259.82 (1663.18, 6389.20)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)	24553 (12536, 48091)	2455.34 (1253.59, 4809.13)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)	49522 (26709, 91821)	4952.19 (2670.86, 9182.14)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	24	5 (5, 5)	174 (94, 325)	34.87 (18.71, 64.97)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	24	6 (5, 7)	368 (184, 735)	66.35 (30.44, 144.62)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)	5 (5, 6)	1.03 (0.97, 1.11)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	13	10 (10, 10)	17273 (6186, 48234)	1727.30 (618.56, 4823.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	13	10 (10, 10)	27396 (5431, 138186)	2739.55 (543.12, 13818.59)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	13	10 (10, 10)	12500 (4740, 32962)	1250.02 (474.04, 3296.21)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	13	5 (5, 5)	65 (17, 245)	12.91 (3.40, 49.02)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	13	5 (5, 5)	146 (18, 1215)	29.22 (3.51, 243.00)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	67	10 (10, 10)	759619 (426880, 1351718)	75529.70 (42469.21, 134326.40)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	1685637 (1167594, 2433528)	168563.68 (116759.36, 243352.76)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	2633046 (1864450, 3718486)	263304.56 (186444.95, 371848.60)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	2850 (1578, 5149)	562.24 (311.66, 1014.28)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	3805 (1835, 7889)	715.18 (348.74, 1466.64)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	24	10 (10, 11)	639026 (148027, 2758648)	62525.33 (14515.66, 269324.12)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)	2094481 (742718, 5906481)	209448.13 (74271.83, 590648.10)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)	4848443 (2478358, 9485072)	484844.34 (247835.80, 948507.20)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	24	5 (5, 5)	6020 (2360, 15360)	1204.08 (471.94, 3072.01)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	24	6 (5, 7)	8404 (2608, 27081)	1516.02 (420.28, 5468.58)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	12	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	13	10 (10, 10)	275834 (26204, 2903499)	27583.39 (2620.44, 290349.91)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	13	10 (10, 10)	750472 (176753, 3186420)	75047.23 (17675.28, 318642.03)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	13	10 (10, 10)	859200 (168867, 4371633)	85919.98 (16886.69, 437163.32)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	13	5 (5, 5)	482 (269, 862)	96.37 (53.86, 172.43)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	13	5 (5, 5)	1167 (203, 6693)	233.34 (40.67, 1338.57)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)	45133 (16515, 123343)	4513.35 (1651.52, 12334.31)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	10 (10, 10)	42283 (20288, 88120)	4228.26 (2028.84, 8812.00)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)	30785 (13439, 70516)	3078.46 (1343.94, 7051.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)	186 (63, 554)	37.27 (12.54, 110.76)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)	309 (55, 1753)	61.82 (10.90, 350.55)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	10 (10, 10)	42543 (10105, 179112)	4254.32 (1010.50, 17911.17)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)	22761 (8134, 63689)	2276.11 (813.43, 6368.93)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)	85898 (68138, 108288)	8589.81 (6813.79, 10828.76)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5 (5, 5)	244 (182, 327)	48.86 (36.48, 65.43)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	7 (4, 14)	1338 (620, 2888)	189.36 (70.73, 506.98)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 7)	5 (5, 5)	0.92 (0.76, 1.11)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	10 (10, 10)	3080 (1115, 8510)	307.99 (111.47, 851.02)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	10 (10, 10)	7559 (3837, 14892)	755.89 (383.69, 1489.16)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	10 (10, 10)	5348 (1735, 16488)	534.82 (173.48, 1648.79)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5 (5, 5)	13 (4, 46)	2.68 (0.78, 9.17)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5 (5, 5)	79 (32, 190)	15.71 (6.48, 38.08)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	13	10 (10, 10)	982833 (235813, 4096296)	98283.35 (23581.35, 409629.55)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml) Anti Spike IgG (IU/ml)	13	10 (10, 10)	836025 (283249, 2467576)	83602.47 (28324.85, 246757.62)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	10 (10, 10)	4760602 (2359191, 9606399)	476060.17 (235919.09, 960639.89)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	13	5 (5, 5)	3381 (548, 20856)	676.29 (109.65, 4171.15)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	13	5 (5, 5)	4097 (1137, 14766)	819.48 (227.39, 2953.28)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	10 (10, 10)	2398314 (427206, 13464021)	239831.36 (42720.58, 1346402.09)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	10 (10, 10)	2320038 (501453, 10733961)	232003.84 (50145.31, 1073396.08)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	10 (10, 10)	7507181 (3379449, 16676615)	750718.10 (337944.88, 1667661.53)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5 (5, 5)	8919 (1502, 52953)	1783.72 (300.42, 10590.56)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	7 (4, 14)	9789 (1020, 93964)	1385.06 (263.35, 7284.52)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5 (5, 7)	5 (5, 5)	0.92 (0.76, 1.11)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	10 (10, 10)	36102 (4722, 276037)	3610.19 (472.16, 27603.67)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	10 (10, 10)	272152 (65917, 1123631)	27215.15 (6591.71, 112363.10)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	10 (10, 10)	677711 (214540, 2140827)	67771.11 (21453.97, 214082.67)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5 (5, 5)	126 (26, 608)	25.11 (5.18, 121.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5 (5, 5)	520 (61, 4436)	104.04 (12.20, 887.23)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	17	10 (10, 10)	114600 (47108, 278791)	11460.05 (4710.80, 27879.06)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	11 (9, 14)	114776 (53301, 247155)	10095.55 (4569.91, 22302.43)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	10 (10, 10)	116196 (67714, 199391)	11619.59 (6771.36, 19939.11)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	17	6 (4, 8)	381 (198, 736)	66.42 (37.70, 117.02)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5 (5, 5)	982 (339, 2849)	196.48 (67.76, 569.73)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)	55095 (9965, 304612)	5509.47 (996.49, 30461.20)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)	44998 (2885, 701952)	4499.84 (288.46, 70195.19)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)	107953 (71167, 163752)	10795.26 (7116.74, 16375.16)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)	227 (17, 2989)	45.50 (3.46, 597.82)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)	489 (239, 1000)	97.88 (47.90, 200.01)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	1	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	1	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	1	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	1	10 (10, 10)	734 (734, 734)	73.38 (73.38, 73.38)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	1	10 (10, 10)	6237 (6237, 6237)	623.73 (623.73, 623.73)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	1	10 (10, 10)	10844 (10844, 10844)	1084.43 (1084.43, 1084.43)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	1	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	1	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	17	10 (10, 10)	2236794 (700142, 7146051)	223679.40 (70014.16, 714605.11)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	11 (9, 14)	5533419 (2490433, 12294540)	486710.15 (203427.87, 1164475.48)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	10 (10, 10)	7662810 (3323463, 17667914)	766281.01 (332346.29, 1766791.43)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	17	6 (4, 8)	10464 (2274, 48150)	1821.72 (378.83, 8760.18)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5 (5, 5)	4635 (2089, 10284)	927.06 (417.84, 2056.86)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)	513962 (93920, 2812583)	51396.21 (9391.97, 281258.27)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)	1828480 (947016, 3530396)	182848.03 (94701.55, 353039.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml) Pseudovirus-nAb ID50	5	10 (10, 10)	5139344 (595014, 44390337)	513934.43 (59501.37, 4439033.72)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)	2545 (185, 35084)	509.01 (36.92, 7016.90)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	1	10 (10, 10)	1804 (213, 15248)	360.81 (42.69, 3049.51)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	1	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	1	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	1	10 (10, 10)	969 (969, 969)	96.94 (96.94, 96.94)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	1	10 (10, 10)	4780 (4780, 4780)	477.97 (477.97, 477.97)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	1	10 (10, 10)	61376 (61376, 61376)	6137.62 (6137.62, 6137.62)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	1	5 (5, 5)	44 (44, 44)	8.78 (8.78, 8.78)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	1	5 (5, 5)	144 (144, 144)	28.88 (28.88, 28.88)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)	20542 (10447, 40388)	2054.15 (1044.75, 4038.82)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)	21505 (13701, 33755)	2150.54 (1370.10, 3375.53)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)	45067 (27165, 74765)	4506.67 (2716.51, 7476.53)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)	71 (38, 130)	14.15 (7.67, 26.10)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	52	5 (5, 5)	135 (82, 222)	27.01 (16.44, 44.37)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	12	10 (10, 10)	70589 (26321, 189314)	7058.93 (2632.06, 18931.39)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	10 (10, 10)	55196 (16260, 187371)	5519.61 (1625.98, 18737.06)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	10 (10, 10)	155885 (67996, 357377)	15588.50 (6799.58, 35737.70)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	12	5 (5, 5)	398 (197, 804)	79.65 (39.46, 160.77)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	12	5 (5, 5)	277 (153, 502)	55.46 (30.62, 100.45)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	19	10 (10, 10)	15871 (7677, 32809)	1587.06 (767.70, 3280.89)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	19	10 (10, 10)	24792 (13458, 45670)	2479.22 (1345.85, 4567.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	19	10 (10, 10)	25261 (11298, 56479)	2526.08 (1129.81, 5647.92)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	19	5 (5, 5)	51 (28, 93)	10.28 (5.69, 18.57)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	19	5 (5, 5)	190 (60, 600)	38.04 (12.06, 119.98)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	52	10 (10, 10)	214922 (107912, 428046)	21492.16 (10791.19, 42804.62)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	52	10 (10, 10)	1262157 (710446, 2242309)	126215.68 (71044.61, 224230.92)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	52	10 (10, 10)	2195866 (1476648, 3265387)	219586.59 (147664.79, 326538.73)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	52	5 (5, 5)	1524 (697, 3334)	304.82 (139.36, 666.71)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	52	5 (5, 5)	1963 (778, 4953)	392.69 (155.66, 990.65)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	12	10 (10, 10)	1276135 (551639, 2952150)	127613.54 (55163.92, 295214.95)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	12	10 (10, 10)	3777504 (1786314, 7988255)	377750.36 (178631.43, 798825.46)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	12	10 (10, 10)	8118223 (3167974, 20803689)	811822.28 (316797.37, 2080368.91)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	12	5 (5, 5)	2411 (687, 8455)	482.14 (137.47, 1690.96)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	12	5 (5, 5)	10135 (6049, 16979)	2026.93 (1209.86, 3395.82)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	19	10 (10, 10)	235861 (101669, 547174)	23586.11 (10166.87, 54717.37)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	19	10 (10, 10)	693982 (285837, 1684912)	69398.16 (28583.71, 168491.21)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	19	10 (10, 10)	791515 (327732, 1911609)	79151.46 (32773.19, 191160.91)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	19	5 (5, 5)	1034 (211, 5057)	206.71 (42.25, 1011.44)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	19	5 (5, 5)	2744 (676, 11140)	548.80 (135.18, 2227.99)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	34	10 (10, 10)	21653 (9122, 51401)	2165.33 (912.17, 5140.10)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	10 (10, 10)	22295 (11570, 42963)	2229.51 (1156.96, 4296.34)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	10 (10, 10)	38007 (21259, 67950)	3800.73 (2125.91, 6794.99)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	34	5 (5, 5)	118 (54, 259)	23.46 (10.69, 51.49)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	34	6 (5, 7)	254 (100, 650)	45.07 (19.22, 105.68)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	7	10 (10, 10)	18596 (5457, 63367)	1859.60 (545.72, 6336.73)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	10 (10, 10)	18039 (7489, 43449)	1803.88 (748.91, 4344.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	10 (10, 10)	75844 (32129, 179037)	7584.42 (3212.93, 17903.73)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5 (5, 5)	63 (18, 221)	12.67 (3.62, 44.29)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5 (5, 5)	283 (86, 936)	56.63 (17.13, 187.20)
Other	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	6 (4, 8)	5 (5, 5)	0.87 (0.67, 1.14)
Other	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)	44670 (548, 3638655)	4466.95 (54.84, 363865.54)
Other	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)	49870 (993, 2505753)	4987.05 (99.25, 250575.29)
Other	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)	40496 (1871, 876366)	4049.58 (187.13, 87636.61)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)	221 (12, 4185)	44.21 (2.34, 836.92)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)	295 (27, 3229)	58.92 (5.37, 645.90)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	34	10 (10, 10)	460615 (152205, 1393948)	46061.47 (15220.51, 139394.78)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	34	10 (10, 10)	959325 (467189, 1969877)	95932.51 (46718.88, 196987.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	34	10 (10, 10)	2238776 (1221484, 4103302)	223877.62 (122148.43, 410330.20)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	34	5 (5, 5)	1974 (715, 5452)	392.38 (142.10, 1083.45)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	34	6 (5, 7)	3391 (1017, 11315)	600.81 (201.25, 1793.66)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	7	10 (10, 10)	506707 (112863, 2274911)	50670.72 (11286.25, 227491.09)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	10 (10, 10)	4612046 (1663462, 12787169)	461204.60 (166346.19, 1278716.85)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	10 (10, 10)	5745695 (3340937, 9881364)	574569.52 (334093.70, 988136.36)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5 (5, 5)	2543 (573, 11275)	508.53 (114.67, 2255.10)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5 (5, 5)	4503 (1467, 13817)	900.51 (293.45, 2763.40)
Other	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	6 (4, 8)	5 (5, 5)	0.87 (0.67, 1.14)
Other	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	5	10 (10, 10)	635834 (21972, 18400096)	63583.42 (2197.19, 1840009.60)
Other	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	5	10 (10, 10)	390164 (12362, 12313729)	39016.41 (1236.25, 1231372.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	5	10 (10, 10)	1950467 (62864, 60516607)	195046.73 (6286.41, 6051660.72)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	5	5 (5, 5)	6112 (27, 1395272)	1222.45 (5.36, 279054.32)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	5	5 (5, 5)	1609 (34, 75283)	321.73 (6.87, 15056.61)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)	19313 (11899, 31347)	1931.33 (1189.92, 3134.71)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)	19972 (12070, 33047)	1984.44 (1199.39, 3283.33)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)	41499 (27382, 62895)	4133.86 (2728.77, 6262.46)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)	85 (51, 144)	16.41 (9.71, 27.74)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	87	5 (5, 5)	167 (114, 245)	32.87 (22.41, 48.19)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	20	10 (10, 10)	67460 (18205, 249984)	6745.99 (1820.46, 24998.37)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	10 (10, 10)	57668 (23639, 140684)	5766.80 (2363.88, 14068.40)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	10 (10, 10)	112437 (52711, 239834)	11243.65 (5271.13, 23983.41)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	20	6 (5, 7)	348 (94, 1295)	63.04 (16.08, 247.10)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	20	5 (5, 5)	581 (199, 1695)	116.20 (39.84, 338.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)	5 (5, 6)	1.07 (0.93, 1.23)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	24	11 (9, 14)	15732 (6215, 39822)	1415.94 (642.37, 3121.07)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)	11890 (6465, 21867)	1188.99 (646.49, 2186.73)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)	17779 (10512, 30069)	1777.89 (1051.21, 3006.90)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	24	6 (5, 7)	46 (19, 111)	8.22 (3.79, 17.84)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	24	5 (5, 6)	168 (59, 476)	31.45 (11.89, 83.22)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	87	10 (10, 10)	313760 (169470, 580901)	31376.01 (16947.01, 58090.14)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	87	10 (10, 10)	958206 (602856, 1523015)	95207.62 (59917.16, 151283.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	87	10 (10, 10)	1898203 (1201387, 2999181)	189087.45 (119691.94, 298717.41)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	87	5 (5, 5)	1331 (758, 2339)	256.28 (146.58, 448.08)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	87	5 (5, 5)	2345 (1156, 4755)	461.94 (227.90, 936.32)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	20	10 (10, 10)	1890562 (655546, 5452282)	189056.18 (65554.64, 545228.19)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	20	10 (10, 10)	3239260 (1199389, 8748461)	323926.04 (119938.90, 874846.13)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	20	10 (10, 10)	9280577 (5784309, 14890128)	928057.68 (578430.93, 1489012.80)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	20	6 (5, 7)	11045 (3104, 39295)	2000.02 (606.29, 6597.67)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	20	5 (5, 5)	5210 (1481, 18320)	1041.90 (296.28, 3663.93)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	14	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	14	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	14	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	14	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	14	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	24	11 (9, 14)	212439 (58037, 777613)	19119.79 (5831.21, 62691.28)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	10 (10, 10)	401782 (153583, 1051084)	40178.22 (15358.33, 105108.37)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	10 (10, 10)	645039 (295340, 1408800)	64503.88 (29533.99, 140880.03)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	24	6 (5, 7)	485 (159, 1481)	87.38 (29.73, 256.78)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	24	5 (5, 6)	1124 (299, 4219)	209.99 (58.57, 752.84)

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Underrepresented minority status								
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	420	10 (10, 10)	21539 (16824, 27575)	2147.71 (1677.60, 2749.55)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	10 (10, 10)	23355 (19242, 28347)	2298.01 (1896.26, 2784.86)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	10 (10, 10)	40216 (34320, 47124)	4021.60 (3432.03, 4712.44)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	420	5 (5, 5)	99 (79, 124)	19.66 (15.68, 24.64)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	420	5 (5, 5)	208 (163, 266)	40.35 (31.69, 51.38)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	10 (10, 10)	59825 (42571, 84073)	5939.85 (4228.47, 8343.87)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	10 (10, 10)	44605 (32113, 61955)	4460.46 (3211.32, 6195.47)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	10 (10, 10)	90964 (70627, 117156)	9096.36 (7062.72, 11715.57)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5 (5, 5)	238 (171, 332)	47.22 (33.91, 65.75)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5 (5, 6)	545 (371, 802)	103.86 (70.31, 153.42)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	73	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	73	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	73	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	73	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.02)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	73	5 (5, 5)	5 (5, 6)	1.04 (0.95, 1.15)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	111	10 (10, 10)	12076 (7763, 18784)	1203.77 (773.81, 1872.63)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	111	10 (10, 10)	17596 (12331, 25109)	1759.61 (1233.11, 2510.90)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	111	10 (10, 10)	18884 (13334, 26743)	1888.39 (1333.43, 2674.32)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	111	5 (5, 6)	54 (34, 84)	10.35 (6.82, 15.71)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	111	5 (5, 5)	178 (110, 288)	35.18 (21.73, 56.94)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	420	10 (10, 10)	358864 (270757, 475643)	35783.11 (26998.45, 47426.08)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	10 (10, 10)	977894 (775549, 1233031)	96220.17 (76347.07, 121266.24)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	10 (10, 10)	2083276 (1732503, 2505069)	208327.61 (173250.30, 250506.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	420	5 (5, 5)	1903 (1416, 2557)	377.51 (280.96, 507.24)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	420	5 (5, 5)	2744 (2021, 3725)	531.46 (393.63, 717.56)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	10 (10, 10)	1149410 (702292, 1881190)	114120.94 (69745.73, 186729.57)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	10 (10, 10)	3146770 (2273084, 4356267)	314676.99 (227308.38, 435626.74)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	10 (10, 10)	5991417 (4527248, 7929117)	599141.71 (452724.79, 792911.71)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5 (5, 5)	7086 (4582, 10956)	1407.15 (910.55, 2174.59)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5 (5, 6)	8885 (5903, 13374)	1691.75 (1126.45, 2540.74)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	73	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	73	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	73	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	73	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.03)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	73	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	111	10 (10, 10)	193321 (112530, 332117)	19271.20 (11217.36, 33107.55)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	111	10 (10, 10)	397884 (256621, 616908)	39788.42 (25662.15, 61690.79)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	111	10 (10, 10)	734879 (489927, 1102301)	73487.92 (48992.72, 110230.12)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	111	5 (5, 6)	684 (382, 1222)	131.54 (74.79, 231.36)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	111	5 (5, 5)	1409 (809, 2454)	278.73 (160.13, 485.18)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	362	10 (10, 10)	26952 (20883, 34784)	2692.55 (2086.26, 3475.03)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	10 (10, 10)	23438 (18669, 29425)	2343.79 (1866.88, 2942.53)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	10 (10, 10)	40376 (34349, 47460)	4031.72 (3430.05, 4738.93)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	362	5 (5, 5)	115 (90, 147)	22.83 (17.82, 29.23)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	362	5 (5, 5)	188 (146, 241)	37.41 (29.16, 48.00)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)	33909 (24023, 47863)	3381.77 (2396.63, 4771.84)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)	30985 (21434, 44793)	3098.50 (2143.36, 4479.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)	72481 (53061, 99008)	7248.12 (5306.15, 9900.82)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)	148 (104, 211)	29.21 (20.49, 41.65)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)	348 (226, 535)	69.53 (45.18, 106.99)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.02)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	5 (5, 5)	0.96 (0.89, 1.04)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	12594 (8382, 18924)	1256.17 (836.02, 1887.47)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	10931 (7560, 15804)	1089.81 (753.88, 1575.44)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	18868 (14808, 24043)	1886.83 (1480.76, 2404.27)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	52 (37, 74)	10.37 (7.32, 14.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	107 (76, 150)	21.32 (15.15, 29.99)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	362	10 (10, 10)	328428 (241933, 445846)	32810.77 (24169.70, 44541.16)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	362	10 (10, 10)	1035293 (809568, 1323956)	103529.30 (80956.76, 132395.58)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	362	10 (10, 10)	2145772 (1770774, 2600184)	214266.04 (176817.71, 259645.59)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	362	5 (5, 5)	1376 (1010, 1874)	273.04 (200.41, 371.99)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	362	5 (5, 5)	2011 (1465, 2761)	400.97 (292.11, 550.40)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	10 (10, 10)	855574 (517613, 1414198)	85327.48 (51627.40, 141025.47)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	10 (10, 10)	1943813 (1349835, 2799166)	194381.34 (134983.46, 279916.55)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	10 (10, 10)	4608987 (3338577, 6362819)	460898.73 (333857.72, 636281.94)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5 (5, 5)	4550 (2471, 8378)	899.93 (488.90, 1656.55)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5 (5, 5)	7994 (4646, 13757)	1598.88 (929.14, 2751.39)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	10 (10, 11)	10 (10, 10)	0.97 (0.91, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.03)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5 (5, 6)	5 (5, 5)	0.98 (0.90, 1.06)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	10 (10, 10)	105260 (65764, 168478)	10498.69 (6559.92, 16802.41)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	10 (10, 10)	393045 (287516, 537306)	39187.22 (28666.35, 53569.39)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	10 (10, 10)	674526 (485396, 937351)	67452.65 (48539.56, 93735.08)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5 (5, 5)	575 (371, 892)	114.01 (73.52, 176.80)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5 (5, 5)	1478 (953, 2292)	295.55 (190.57, 458.35)

Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Underrepresented minority status								
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	192	10 (10, 10)	16236 (11950, 22060)	1623.60 (1194.98, 2205.96)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	10 (10, 10)	17593 (13852, 22344)	1725.89 (1361.64, 2187.59)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	10 (10, 10)	30531 (25113, 37119)	3053.10 (2511.25, 3711.87)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	192	5 (5, 5)	76 (58, 101)	15.18 (11.48, 20.07)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	192	5 (5, 5)	174 (128, 236)	33.64 (24.93, 45.38)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	69	10 (10, 10)	50828 (33992, 76001)	5058.85 (3383.17, 7564.49)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	10 (10, 10)	34937 (23612, 51692)	3493.66 (2361.25, 5169.16)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	10 (10, 10)	70998 (52424, 96153)	7099.81 (5242.39, 9615.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	69	5 (5, 5)	209 (141, 310)	41.82 (28.22, 61.98)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	69	5 (5, 6)	484 (305, 768)	91.16 (57.15, 145.40)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)	5 (5, 5)	0.98 (0.94, 1.02)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)	5 (5, 6)	1.05 (0.93, 1.19)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)	9484 (5617, 16014)	948.43 (561.72, 1601.39)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)	13618 (8923, 20783)	1361.81 (892.33, 2078.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)	13717 (9065, 20756)	1371.71 (906.53, 2075.61)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5 (5, 6)	42 (25, 72)	8.09 (4.93, 13.29)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)	150 (84, 267)	30.02 (16.87, 53.39)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	192	10 (10, 10)	292558 (206172, 415140)	29255.76 (20617.15, 41513.96)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	192	10 (10, 10)	741900 (555661, 990562)	72781.13 (54544.47, 97115.13)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	192	10 (10, 10)	1629402 (1297120, 2046806)	162940.23 (129711.97, 204680.56)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	192	5 (5, 5)	1435 (996, 2067)	285.33 (198.09, 411.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	192	5 (5, 5)	2230 (1526, 3260)	431.29 (297.10, 626.08)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	69	10 (10, 10)	930919 (513604, 1687309)	92654.09 (51125.98, 167914.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	69	10 (10, 10)	2542683 (1712040, 3776334)	254268.26 (171204.01, 377633.36)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	69	10 (10, 10)	5081700 (3610831, 7151727)	508170.01 (361083.05, 715172.74)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	69	5 (5, 5)	5550 (3299, 9337)	1109.99 (659.78, 1867.40)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	69	5 (5, 6)	7380 (4562, 11940)	1389.33 (861.24, 2241.22)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.04)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)	145989 (76394, 278984)	14598.87 (7639.41, 27898.36)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)	277278 (163947, 468952)	27727.83 (16394.70, 46895.20)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)	543679 (333997, 884998)	54367.88 (33399.71, 88499.76)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5 (5, 6)	466 (233, 933)	89.60 (45.67, 175.78)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)	1073 (554, 2078)	214.52 (110.72, 415.67)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	175	10 (10, 10)	22546 (16449, 30904)	2254.62 (1644.88, 3090.40)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	10 (10, 10)	18239 (13758, 24181)	1823.94 (1375.79, 2418.07)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	10 (10, 10)	31442 (25791, 38330)	3144.18 (2579.11, 3833.04)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	175	5 (5, 5)	98 (72, 132)	19.42 (14.32, 26.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	175	5 (5, 5)	163 (120, 222)	32.68 (24.04, 44.44)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)	22816 (14927, 34875)	2281.61 (1492.66, 3487.54)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)	19045 (11981, 30275)	1904.54 (1198.08, 3027.54)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)	50450 (34089, 74664)	5044.99 (3408.87, 7466.38)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)	100 (65, 155)	20.06 (12.98, 31.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)	255 (148, 438)	50.94 (29.59, 87.68)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 11)	10 (10, 10)	0.96 (0.88, 1.04)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	0.98 (0.95, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 6)	5 (5, 5)	0.95 (0.85, 1.05)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)	9218 (5562, 15276)	921.79 (556.25, 1527.56)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)	7844 (4943, 12447)	784.36 (494.26, 1244.74)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)	13337 (9897, 17972)	1333.71 (989.74, 1797.23)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5 (5, 5)	38 (25, 58)	7.54 (4.91, 11.57)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)	78 (51, 118)	15.51 (10.18, 23.62)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	175	10 (10, 10)	264562 (181376, 385898)	26456.16 (18137.64, 38589.80)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	175	10 (10, 10)	821667 (605817, 1114423)	82166.69 (60581.70, 111442.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	175	10 (10, 10)	1724310 (1360533, 2185355)	172431.05 (136053.26, 218535.49)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	175	5 (5, 5)	1085 (742, 1587)	215.99 (147.67, 315.94)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	175	5 (5, 5)	1624 (1097, 2405)	324.87 (219.40, 481.06)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	59	10 (10, 10)	596002 (316557, 1122130)	59600.20 (31655.74, 112212.97)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	59	10 (10, 10)	1330657 (839177, 2109982)	133065.71 (83917.71, 210998.18)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	59	10 (10, 10)	3419951 (2265916, 5161739)	341995.14 (226591.60, 516173.95)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	59	5 (5, 5)	2838 (1308, 6159)	567.69 (261.64, 1231.71)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	59	5 (5, 5)	6125 (3095, 12121)	1224.99 (619.02, 2424.13)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	10 (10, 11)	10 (10, 10)	0.96 (0.88, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.03)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	10 (10, 10)	10 (10, 10)	0.98 (0.95, 1.02)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5 (5, 6)	5 (5, 5)	0.96 (0.86, 1.07)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	10 (10, 10)	69600 (38639, 125369)	6959.96 (3863.88, 12536.92)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	10 (10, 10)	264698 (179593, 390131)	26469.79 (17959.33, 39013.14)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	10 (10, 10)	451492 (299075, 681584)	45149.17 (29907.49, 68158.43)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5 (5, 5)	376 (219, 646)	74.74 (43.50, 128.41)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5 (5, 5)	1102 (639, 1903)	220.47 (127.72, 380.58)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	228	10 (10, 10)	62158 (49075, 78729)	6131.29 (4841.75, 7764.28)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	10 (10, 10)	67566 (54928, 83111)	6723.29 (5465.75, 8270.15)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	10 (10, 10)	113000 (94968, 134457)	11300.05 (9496.80, 13445.69)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	228	5 (5, 5)	263 (208, 334)	51.85 (40.91, 65.71)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	228	5 (5, 5)	409 (322, 520)	79.83 (63.06, 101.06)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	51	10 (10, 11)	120781 (72698, 200668)	11866.15 (7200.38, 19555.30)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	10 (10, 10)	127850 (82403, 198362)	12784.98 (8240.28, 19836.18)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	10 (10, 10)	264698 (193965, 361225)	26469.82 (19396.51, 36122.55)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	51	5 (5, 6)	414 (254, 674)	79.73 (50.17, 126.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	51	5 (5, 5)	911 (557, 1491)	182.23 (111.38, 298.14)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.06)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	1.01 (0.94, 1.09)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	50	10 (10, 11)	36935 (21250, 64196)	3628.46 (2082.95, 6320.71)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	50	10 (10, 10)	57615 (37847, 87707)	5761.48 (3784.71, 8770.72)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	50	10 (10, 10)	82913 (55530, 123801)	8291.33 (5552.97, 12380.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	50	5 (5, 5)	167 (101, 276)	32.28 (19.55, 53.29)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	50	5 (5, 6)	390 (234, 650)	73.32 (44.82, 119.94)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	228	10 (10, 10)	771969 (594098, 1003095)	76147.19 (58640.43, 98880.49)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	228	10 (10, 10)	2754587 (2268630, 3344640)	274100.63 (225748.76, 332808.72)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	228	10 (10, 10)	5234940 (4335352, 6321193)	523493.98 (433535.17, 632119.29)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	228	5 (5, 5)	5478 (4015, 7473)	1078.45 (791.36, 1469.70)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	228	5 (5, 5)	5966 (4475, 7954)	1163.05 (875.98, 1544.19)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	51	10 (10, 11)	2851970 (1691139, 4809619)	280191.41 (166781.09, 470720.20)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	10 (10, 10)	7886529 (5982602, 10396367)	788652.86 (598260.24, 1039636.74)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	10 (10, 10)	12184499 (9858697, 15058989)	1218449.89 (985869.74, 1505898.89)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	51	5 (5, 6)	20307 (11438, 36054)	3912.01 (2231.34, 6858.57)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	51	5 (5, 5)	19769 (10376, 37665)	3953.73 (2075.11, 7533.05)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	0.98 (0.94, 1.02)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	50	10 (10, 11)	709142 (413162, 1217155)	69666.09 (40572.33, 119622.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	50	10 (10, 10)	2116643 (1388474, 3226693)	211664.33 (138847.41, 322669.26)
Age \geq 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	50	10 (10, 10)	2964324 (2089369, 4205680)	296432.41 (208936.91, 420567.97)
Age \geq 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	50	5 (5, 5)	4026 (2199, 7373)	777.87 (423.25, 1429.59)
Age \geq 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	50	5 (5, 6)	4985 (2691, 9234)	936.31 (513.96, 1705.72)
Age \geq 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	187	10 (10, 10)	52931 (40926, 68456)	5268.42 (4072.81, 6815.00)
Age \geq 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	10 (10, 10)	60501 (48781, 75037)	6050.09 (4878.07, 7503.69)
Age \geq 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	10 (10, 10)	103956 (85919, 125780)	10323.75 (8540.15, 12479.85)
Age \geq 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	187	5 (5, 5)	214 (164, 280)	42.04 (32.14, 54.99)
Age \geq 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	187	5 (5, 5)	317 (243, 412)	62.39 (47.99, 81.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml) Anti RBD IgG (IU/ml) Anti Spike IgG (IU/ml)	66	10 (10, 10)	136437 (87480, 212792)	13478.95 (8689.60, 20908.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	66	10 (10, 10)	171330 (122104, 240402)	17133.00 (12210.38, 24040.16)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5 (5, 6)	258922 (193660, 346179)	25892.24 (19365.96, 34617.87)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	36	10 (10, 10)	575 (355, 932)	109.39 (68.12, 175.65)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	36	10 (10, 10)	1037 (709, 1518)	207.43 (141.72, 303.60)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)	37306 (22911, 60744)	3687.38 (2264.32, 6004.81)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)	34684 (23682, 50795)	3422.26 (2343.82, 4996.92)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)	63090 (45886, 86746)	6309.04 (4588.59, 8674.56)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 5)	160 (99, 257)	31.48 (19.58, 50.61)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)	323 (207, 502)	64.50 (41.47, 100.34)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	187	10 (10, 10)	744013 (543887, 1017778)	74055.02 (54135.35, 101304.35)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	10 (10, 10)	2480906 (1963293, 3134986)	248090.62 (196329.26, 313498.63)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	10 (10, 10)	4905828 (4009921, 6001900)	487190.64 (398077.65, 596252.31)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	187	5 (5, 5)	3376 (2393, 4763)	662.37 (469.40, 934.65)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	187	5 (5, 5)	4511 (3339, 6096)	888.68 (657.99, 1200.26)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	66	10 (10, 10)	3047576 (1943331, 4779276)	301077.79 (192430.18, 471068.71)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	10 (10, 10)	7361735 (5495760, 9861264)	736173.49 (549575.99, 986126.43)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	10 (10, 10)	13150407 (11178796, 15469753)	1315040.71 (1117879.58, 1546975.29)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5 (5, 6)	23885 (15539, 36713)	4542.74 (2980.14, 6924.67)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5 (5, 5)	20383 (12350, 33642)	4076.69 (2470.01, 6728.46)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5 (5, 5)	5 (5, 6)	1.04 (0.96, 1.12)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	10 (10, 10)	443960 (270210, 729435)	43882.05 (26757.87, 71965.14)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	10 (10, 10)	1555275 (1070146, 2260326)	153460.09 (105621.81, 222965.32)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	10 (10, 10)	2726537 (1931325, 3849174)	272653.70 (193132.47, 384917.37)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5 (5, 5)	2516 (1427, 4435)	495.52 (282.39, 869.51)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5 (5, 5)	4096 (2471, 6792)	819.28 (494.12, 1358.43)

Table 7. The ratios of GMTs/GMCs between groups

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 vs Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.01)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.01)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.02)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.04)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.03)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.03 (0.98, 1.08)
Age \geq 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.00)
Age \geq 65 vs Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.94, 1.02)
Age \geq 65 vs Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.93, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 vs Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Age \geq 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
Age \geq 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.98 (0.93, 1.03)
Age \geq 65 vs Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.96, 1.03)
Age \geq 65 vs Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Age \geq 65 vs Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.95, 1.05)
Age \geq 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.98, 1.04)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59687 (50609, 70395)	18416 (15002, 22607)	3.24 (2.49, 4.22)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	65260 (56734, 75068)	17393 (14565, 20770)	3.75 (2.99, 4.70)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	112166 (98902, 127209)	31397 (27475, 35879)	3.57 (2.97, 4.29)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	254 (214, 300)	85 (69, 103)	3.00 (2.32, 3.89)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	381 (321, 451)	157 (129, 192)	2.42 (1.86, 3.15)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	130450 (94702, 179694)	32567 (23744, 44670)	4.01 (2.55, 6.28)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	158619 (123545, 203649)	24939 (18393, 33814)	6.36 (4.29, 9.43)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	262073 (211994, 323982)	59400 (46119, 76506)	4.41 (3.17, 6.14)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	522 (373, 731)	144 (104, 198)	3.63 (2.28, 5.80)
Age \geq 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	988 (733, 1331)	339 (238, 482)	2.92 (1.84, 4.63)
Age \geq 65 vs Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.98, 1.04)
Age \geq 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.03)
Age \geq 65 vs Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	35028 (24879, 49317)	9820 (7012, 13753)	3.57 (2.21, 5.77)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 vs Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	41836 (32047, 54614)	9737 (7318, 12957)	4.30 (2.91, 6.35)
Age \geq 65 vs Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	66891 (53117, 84238)	13380 (10752, 16650)	5.00 (3.64, 6.87)
Age \geq 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	156 (112, 216)	40 (29, 54)	3.93 (2.51, 6.13)
Age \geq 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	301 (219, 413)	106 (76, 147)	2.85 (1.80, 4.49)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	836805 (684275, 1023335)	253319 (198848, 322710)	3.30 (2.41, 4.53)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	2692372 (2329146, 3112243)	737116 (604473, 898866)	3.65 (2.86, 4.67)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	5171042 (4536102, 5894857)	1643373 (1397160, 1932976)	3.15 (2.55, 3.88)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	4259 (3414, 5312)	1136 (890, 1449)	3.75 (2.70, 5.21)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	5506 (4535, 6685)	1750 (1355, 2260)	3.15 (2.28, 4.34)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	3014476 (2173987, 4179907)	739998 (487226, 1123907)	4.07 (2.40, 6.92)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7520373 (6146909, 9200723)	1708031 (1250384, 2333179)	4.40 (3.04, 6.38)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	13148461 (11661345, 14825221)	4266733 (3292306, 5529560)	3.08 (2.32, 4.10)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	21658 (15437, 30385)	4061 (2527, 6527)	5.33 (2.98, 9.55)
Age \geq 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	19480 (13318, 28494)	6238 (4090, 9513)	3.12 (1.77, 5.51)
Age \geq 65 vs Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Age \geq 65 vs Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.05)
Age \geq 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.97, 1.05)
Age \geq 65 vs Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	519433 (364323, 740581)	93772 (62211, 141344)	5.54 (3.22, 9.53)
Age \geq 65 vs Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	1675605 (1276999, 2198632)	270061 (201183, 362521)	6.20 (4.16, 9.26)
Age \geq 65 vs Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	2790960 (2209589, 3525298)	484596 (361146, 650244)	5.76 (3.96, 8.38)
Age \geq 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	2827 (1887, 4233)	387 (262, 572)	7.30 (4.17, 12.81)
Age \geq 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	4185 (2859, 6127)	1009 (665, 1531)	4.15 (2.36, 7.30)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (1.00, 1.04)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.97, 1.05)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.93, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.97 (0.92, 1.03)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.02 (0.98, 1.06)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.98 (0.92, 1.04)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.99 (0.95, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.94, 1.04)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.03)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	23746 (19934, 28287)	23464 (18827, 29244)	1.01 (0.76, 1.34)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	26276 (22610, 30535)	21736 (17965, 26298)	1.21 (0.95, 1.55)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	45842 (40067, 52448)	39200 (34023, 45165)	1.17 (0.96, 1.43)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	103 (87, 122)	108 (87, 133)	0.96 (0.73, 1.26)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	215 (180, 258)	180 (145, 223)	1.20 (0.91, 1.59)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	55180 (40419, 75332)	39449 (28242, 55103)	1.40 (0.88, 2.23)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	55528 (43641, 70653)	31130 (22510, 43050)	1.78 (1.17, 2.72)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	103862 (82479, 130788)	73051 (55946, 95386)	1.42 (0.99, 2.05)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	220 (161, 302)	175 (124, 247)	1.26 (0.78, 2.02)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	443 (318, 617)	412 (284, 597)	1.08 (0.65, 1.78)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.04 (0.99, 1.09)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.94, 1.03)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	16553 (12215, 22429)	11438 (8001, 16352)	1.45 (0.90, 2.33)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	16713 (12642, 22096)	11818 (8756, 15950)	1.41 (0.93, 2.16)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	26705 (21285, 33505)	16070 (12770, 20222)	1.66 (1.18, 2.33)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	69 (52, 93)	47 (34, 64)	1.48 (0.96, 2.30)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	180 (133, 243)	116 (82, 164)	1.55 (0.97, 2.47)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	335374 (270080, 416453)	321219 (247884, 416250)	1.04 (0.74, 1.47)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	1142597 (961925, 1357205)	904842 (732112, 1118324)	1.26 (0.96, 1.66)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2144439 (1840509, 2498559)	2066294 (1739231, 2454861)	1.04 (0.82, 1.31)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1796 (1424, 2264)	1394 (1075, 1808)	1.29 (0.91, 1.83)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	2766 (2265, 3377)	2041 (1549, 2690)	1.35 (0.96, 1.91)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1327591 (937265, 1880469)	882754 (567083, 1374143)	1.50 (0.85, 2.66)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2930270 (2216035, 3874704)	2113273 (1525010, 2928453)	1.39 (0.89, 2.15)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6396516 (5214355, 7846688)	5023873 (3827375, 6594416)	1.27 (0.90, 1.80)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6128 (4355, 8625)	5532 (3337, 9171)	1.11 (0.59, 2.07)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	11182 (7684, 16271)	6928 (4429, 10838)	1.61 (0.90, 2.90)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.04)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.03 (0.99, 1.07)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	197242 (138403, 281094)	113637 (73666, 175296)	1.74 (0.98, 3.07)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	663561 (492320, 894363)	320294 (235413, 435781)	2.07 (1.33, 3.22)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	1012116 (794913, 1288669)	594413 (435730, 810886)	1.70 (1.13, 2.56)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	931 (651, 1331)	482 (318, 728)	1.93 (1.10, 3.39)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	2086 (1418, 3067)	1143 (737, 1774)	1.82 (1.01, 3.29)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.98, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.03 (1.00, 1.07)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.98 (0.95, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.97 (0.92, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.97 (0.91, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.03 (0.97, 1.10)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.03 (0.97, 1.08)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 6)	0.98 (0.91, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.94, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.98 (0.93, 1.04)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	15066 (11800, 19236)	19467 (15117, 25069)	0.77 (0.54, 1.10)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	16530 (13368, 20441)	17639 (14174, 21953)	0.94 (0.69, 1.27)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	31028 (25725, 37423)	31500 (26782, 37050)	0.98 (0.77, 1.26)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	68 (54, 85)	90 (70, 115)	0.75 (0.54, 1.05)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	159 (123, 204)	157 (122, 200)	1.01 (0.71, 1.44)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	35719 (23749, 53721)	31746 (21553, 46760)	1.13 (0.64, 1.97)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	30603 (22501, 41623)	23567 (16129, 34434)	1.30 (0.80, 2.12)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62641 (46271, 84801)	58534 (42846, 79967)	1.07 (0.69, 1.65)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	142 (95, 213)	144 (97, 214)	0.99 (0.56, 1.74)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	291 (187, 453)	353 (229, 545)	0.82 (0.44, 1.53)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 6)	5 (5, 5)	1.04 (0.96, 1.12)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.97 (0.93, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	11526 (8014, 16577)	9421 (6230, 14246)	1.22 (0.71, 2.12)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	10221 (7219, 14470)	9616 (6788, 13622)	1.06 (0.65, 1.74)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	16112 (12299, 21107)	12751 (9770, 16642)	1.26 (0.86, 1.85)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48 (34, 67)	38 (26, 55)	1.26 (0.77, 2.08)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	127 (87, 186)	101 (68, 150)	1.26 (0.72, 2.19)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	227691 (168852, 307033)	260904 (193707, 351412)	0.87 (0.57, 1.33)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	761200 (595277, 973370)	730590 (572430, 932450)	1.04 (0.74, 1.47)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	1498825 (1211392, 1854460)	1685764 (1382036, 2056240)	0.89 (0.66, 1.19)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1203 (876, 1652)	1118 (830, 1506)	1.08 (0.70, 1.66)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	2067 (1571, 2720)	1671 (1216, 2295)	1.24 (0.81, 1.88)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	848831 (532838, 1352218)	712451 (424544, 1195605)	1.19 (0.59, 2.39)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	1815884 (1228679, 2683724)	1679359 (1144789, 2463552)	1.08 (0.63, 1.87)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	4547755 (3405518, 6073108)	4192147 (3040678, 5779665)	1.08 (0.70, 1.67)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2953 (1859, 4690)	4435 (2453, 8017)	0.67 (0.31, 1.41)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	7954 (4852, 13039)	5833 (3464, 9821)	1.36 (0.66, 2.80)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.02 (0.98, 1.07)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.07)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	115913 (72906, 184288)	88760 (53701, 146707)	1.31 (0.66, 2.59)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	417627 (286526, 608715)	241209 (168681, 344922)	1.73 (1.03, 2.91)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	575539 (423609, 781958)	463469 (322830, 665378)	1.24 (0.77, 1.99)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	502 (325, 776)	362 (224, 583)	1.39 (0.73, 2.65)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1382 (851, 2245)	930 (559, 1549)	1.49 (0.73, 3.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.98, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (1.00, 1.03)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.03)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.95, 1.01)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 6)	5 (5, 5)	1.05 (0.96, 1.15)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.01)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.97, 1.04)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.02 (0.98, 1.06)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.95, 1.08)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.95, 1.03)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	48363 (38230, 61183)	75305 (60091, 94371)	0.64 (0.46, 0.89)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	54232 (44615, 65922)	80069 (65707, 97571)	0.68 (0.51, 0.89)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	84391 (70325, 101269)	153593 (130667, 180543)	0.55 (0.43, 0.70)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	199 (157, 252)	332 (263, 418)	0.60 (0.43, 0.84)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	348 (276, 438)	421 (328, 540)	0.83 (0.59, 1.16)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	134756 (86047, 211040)	127407 (81244, 199800)	1.06 (0.56, 1.99)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	188670 (129392, 275106)	139826 (99996, 195520)	1.35 (0.82, 2.23)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	293282 (210942, 407763)	241494 (182978, 318724)	1.21 (0.79, 1.86)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	541 (337, 870)	508 (317, 815)	1.06 (0.55, 2.08)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	1052 (680, 1627)	944 (626, 1422)	1.12 (0.62, 2.02)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.03 (0.99, 1.08)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.06)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	36017 (20724, 62595)	34367 (22390, 52751)	1.05 (0.52, 2.11)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48060 (30237, 76388)	38048 (27669, 52321)	1.26 (0.72, 2.22)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	79058 (52125, 119908)	59664 (45819, 77691)	1.33 (0.81, 2.17)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	155 (89, 270)	156 (105, 232)	0.99 (0.50, 1.96)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	378 (233, 613)	257 (170, 390)	1.47 (0.77, 2.79)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	614449 (455495, 828875)	1177109 (909148, 1524048)	0.52 (0.35, 0.77)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	2156196 (1736284, 2677662)	3441017 (2860842, 4138850)	0.63 (0.47, 0.83)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	3754377 (3053564, 4616033)	7365218 (6408010, 8465410)	0.51 (0.40, 0.65)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3359 (2423, 4656)	5534 (4137, 7404)	0.61 (0.39, 0.94)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	4361 (3299, 5763)	7125 (5468, 9285)	0.61 (0.42, 0.90)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	3325369 (2089439, 5292368)	2806906 (1779671, 4427066)	1.18 (0.62, 2.26)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7826271 (5853680, 10463591)	7305563 (5522547, 9664247)	1.07 (0.72, 1.60)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	12884976 (10641883, 15600868)	13343347 (11421210, 15588971)	0.97 (0.76, 1.23)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	27431 (17819, 42227)	18240 (11134, 29880)	1.50 (0.78, 2.88)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	22502 (13237, 38254)	17541 (10280, 29932)	1.28 (0.61, 2.71)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 6)	0.96 (0.90, 1.02)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.04 (0.97, 1.11)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	617829 (374065, 1020446)	461295 (282331, 753702)	1.34 (0.66, 2.70)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	1793880 (1112795, 2891824)	1599200 (1156266, 2211811)	1.12 (0.63, 1.99)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3402410 (2325361, 4978321)	2437171 (1815977, 3270859)	1.40 (0.87, 2.25)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3501 (1863, 6577)	2442 (1442, 4134)	1.43 (0.63, 3.27)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	5048 (2709, 9408)	3681 (2278, 5949)	1.37 (0.63, 3.00)
Male vs Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.02)
Male vs Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)
Male vs Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
Male vs Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.98 (0.94, 1.02)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.96, 1.05)
Male vs Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 11)	10 (10, 10)	1.05 (0.96, 1.14)
Male vs Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	11 (9, 12)	10 (10, 10)	1.05 (0.95, 1.17)
Male vs Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.97, 1.01)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 6)	0.97 (0.91, 1.03)
Male vs Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.94, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.97 (0.92, 1.02)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.96, 1.02)
Male vs Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	27118 (20803, 35351)	21438 (17319, 26535)	1.26 (0.90, 1.78)
Male vs Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	25738 (20110, 32941)	21234 (17837, 25278)	1.21 (0.89, 1.65)
Male vs Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	40290 (34397, 47193)	41415 (35725, 48012)	0.97 (0.78, 1.22)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	121 (93, 157)	98 (80, 120)	1.23 (0.89, 1.72)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	207 (158, 272)	178 (145, 218)	1.17 (0.83, 1.64)
Male vs Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52664 (36905, 75154)	37697 (26222, 54193)	1.40 (0.84, 2.33)
Male vs Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	43301 (30763, 60949)	32117 (22658, 45526)	1.35 (0.81, 2.24)
Male vs Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	83762 (65541, 107048)	77611 (57216, 105276)	1.08 (0.72, 1.62)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	223 (158, 315)	165 (113, 242)	1.35 (0.80, 2.27)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	449 (303, 666)	401 (268, 602)	1.12 (0.64, 1.97)
Male vs Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.98, 1.06)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.97 (0.93, 1.02)
Male vs Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	11707 (7655, 17903)	13066 (8983, 19004)	0.90 (0.51, 1.58)
Male vs Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	12838 (8743, 18852)	12876 (9489, 17472)	1.00 (0.60, 1.65)
Male vs Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	16359 (12044, 22219)	19468 (15496, 24459)	0.84 (0.56, 1.26)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	43 (29, 63)	58 (42, 81)	0.73 (0.44, 1.23)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	100 (68, 146)	152 (105, 219)	0.66 (0.38, 1.14)
Male vs Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	358185 (259645, 494122)	304934 (237911, 390840)	1.17 (0.78, 1.77)
Male vs Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	1032572 (803692, 1326633)	924524 (750510, 1138886)	1.12 (0.80, 1.56)
Male vs Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2448348 (1992531, 3008439)	1878895 (1586011, 2225864)	1.30 (0.99, 1.71)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1983 (1427, 2754)	1243 (972, 1588)	1.60 (1.05, 2.41)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	2322 (1694, 3181)	2160 (1643, 2840)	1.07 (0.70, 1.64)
Male vs Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1379076 (895389, 2124049)	785331 (484933, 1271815)	1.76 (0.92, 3.34)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2628794 (1842173, 3751308)	2106655 (1490680, 2977161)	1.25 (0.76, 2.06)
Male vs Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5518909 (4222583, 7213204)	5236885 (3880756, 7066912)	1.05 (0.70, 1.59)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5567 (3235, 9581)	5754 (3356, 9868)	0.97 (0.45, 2.07)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	9590 (6259, 14696)	6872 (4174, 11314)	1.40 (0.73, 2.67)
Male vs Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.01 (0.99, 1.03)
Male vs Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)
Male vs Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	120405 (68919, 210356)	136546 (89268, 208864)	0.88 (0.43, 1.79)
Male vs Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	361345 (243436, 536364)	396863 (289955, 543189)	0.91 (0.54, 1.55)
Male vs Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	578439 (406742, 822616)	748414 (540245, 1036794)	0.77 (0.47, 1.28)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	606 (358, 1023)	541 (355, 825)	1.12 (0.56, 2.23)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	930 (554, 1559)	1659 (1064, 2588)	0.56 (0.28, 1.12)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.05 (0.97, 1.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (0.96, 1.06)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.98 (0.94, 1.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.97 (0.93, 1.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.03)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	6 (5, 7)	5 (5, 5)	1.10 (0.90, 1.34)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22074 (14121, 34506)	23655 (19521, 28664)	0.93 (0.57, 1.52)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22266 (15847, 31284)	23020 (19425, 27280)	0.97 (0.66, 1.42)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	41773 (31562, 55289)	39694 (35055, 44946)	1.05 (0.77, 1.44)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	101 (67, 152)	104 (86, 125)	0.97 (0.62, 1.52)


(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	190 (126, 284)	191 (158, 230)	0.99 (0.63, 1.55)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66150 (37538, 116570)	41747 (30714, 56743)	1.58 (0.84, 2.98)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57339 (30559, 107588)	35344 (26390, 47337)	1.62 (0.82, 3.20)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90332 (50343, 162084)	83383 (65546, 106075)	1.08 (0.58, 2.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	254 (155, 417)	183 (133, 251)	1.39 (0.78, 2.48)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	498 (236, 1049)	411 (294, 575)	1.21 (0.55, 2.69)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.97, 1.04)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	6 (4, 8)	5 (5, 5)	1.21 (0.89, 1.64)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	26345 (9909, 70041)	12063 (8992, 16185)	2.18 (0.81, 5.85)

(continued)



(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2082654 (1564176, 2772993)	2063432 (1775937, 2397468)	1.01 (0.73, 1.40)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1727 (1013, 2946)	1500 (1191, 1888)	1.15 (0.64, 2.06)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	2444 (1373, 4350)	2270 (1788, 2883)	1.08 (0.58, 2.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1420449 (558648, 3611715)	968852 (654113, 1435033)	1.47 (0.54, 3.95)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2735111 (1368395, 5466868)	2315554 (1731123, 3097290)	1.18 (0.56, 2.47)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7578287 (5040721, 11393296)	5301268 (4150604, 6770929)	1.43 (0.90, 2.28)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7727 (2908, 20532)	5224 (3348, 8151)	1.48 (0.52, 4.24)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	10208 (4492, 23195)	7937 (5300, 11886)	1.29 (0.53, 3.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	0.99 (0.98, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.99 (0.97, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	452690 (158709, 1291220)	129424 (89788, 186557)	3.50 (1.19, 10.30)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	747435 (391924, 1425424)	381696 (293138, 497006)	1.96 (0.99, 3.89)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	1403460 (609038, 3234119)	648311 (505732, 831086)	2.16 (0.93, 5.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1522 (466, 4976)	555 (395, 782)	2.74 (0.84, 8.96)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	3063 (1057, 8877)	1324 (921, 1904)	2.31 (0.78, 6.86)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.01)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.02 (1.00, 1.04)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.03 (1.00, 1.06)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.98, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.05 (0.99, 1.11)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 11)	0.97 (0.91, 1.03)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.96, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.02 (0.99, 1.05)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 6)	0.97 (0.90, 1.05)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5 (5, 6)	5 (5, 5)	1.03 (0.97, 1.10)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	1.01 (1.00, 1.02)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21539 (16824, 27575)	26952 (20883, 34784)	0.80 (0.56, 1.14)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	23355 (19242, 28347)	23438 (18669, 29425)	1.00 (0.74, 1.34)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	40216 (34320, 47124)	40376 (34349, 47460)	1.00 (0.79, 1.25)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	99 (79, 124)	115 (90, 147)	0.86 (0.62, 1.20)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	208 (163, 266)	188 (146, 241)	1.11 (0.78, 1.57)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	59825 (42571, 84073)	33909 (24023, 47863)	1.76 (1.09, 2.86)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	44605 (32113, 61955)	30985 (21434, 44793)	1.44 (0.88, 2.36)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90964 (70627, 117156)	72481 (53061, 99008)	1.25 (0.84, 1.88)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	238 (171, 332)	148 (104, 211)	1.61 (0.99, 2.62)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	545 (371, 802)	348 (226, 535)	1.57 (0.88, 2.80)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.00 (0.99, 1.01)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 6)	5 (5, 5)	1.06 (0.96, 1.16)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	12076 (7763, 18784)	12594 (8382, 18924)	0.96 (0.53, 1.75)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	17596 (12331, 25109)	10931 (7560, 15804)	1.61 (0.96, 2.69)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	18884 (13334, 26743)	18868 (14808, 24043)	1.00 (0.65, 1.53)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	54 (34, 84)	52 (37, 74)	1.03 (0.58, 1.81)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	178 (110, 288)	107 (76, 150)	1.67 (0.92, 3.01)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	358864 (270757, 475643)	328428 (241933, 445846)	1.09 (0.72, 1.66)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	977894 (775549, 1233031)	1035293 (809568, 1323956)	0.94 (0.67, 1.32)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	2083276 (1732503, 2505069)	2145772 (1770774, 2600184)	0.97 (0.74, 1.27)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1903 (1416, 2557)	1376 (1010, 1874)	1.38 (0.90, 2.12)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	2744 (2021, 3725)	2011 (1465, 2761)	1.36 (0.88, 2.12)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1149410 (702292, 1881190)	855574 (517613, 1414198)	1.34 (0.66, 2.72)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	3146770 (2273084, 4356267)	1943813 (1349835, 2799166)	1.62 (0.99, 2.64)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5991417 (4527248, 7929117)	4608987 (3338577, 6362819)	1.30 (0.85, 1.99)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7086 (4582, 10956)	4550 (2471, 8378)	1.56 (0.74, 3.30)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	8885 (5903, 13374)	7994 (4646, 13757)	1.11 (0.56, 2.19)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10 (10, 10)	10 (10, 10)	0.99 (0.98, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10 (10, 10)	10 (10, 10)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5 (5, 5)	5 (5, 5)	1.01 (0.99, 1.03)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5 (5, 5)	5 (5, 5)	0.98 (0.96, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	193321 (112530, 332117)	105260 (65764, 168478)	1.84 (0.90, 3.76)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	397884 (256621, 616908)	393045 (287516, 537306)	1.01 (0.59, 1.73)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	734879 (489927, 1102301)	674526 (485396, 937351)	1.09 (0.65, 1.84)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	684 (382, 1222)	575 (371, 892)	1.19 (0.57, 2.46)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1409 (809, 2454)	1478 (953, 2292)	0.95 (0.47, 1.93)

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the vaccine arm and the placebo arm by All participants

Group	Visit	Baseline SARS-CoV-2	Marker	Comparison	Responder	% 2-Fold Rise	% 4-Fold Rise
Day 29	Negative		Anti N IgG (IU/ml)	Vaccine vs Placebo	100% (100%, 100%)	100% (100%, 100%)	99.8% (98.6%, 100%)
	Negative		Anti RBD IgG (IU/ml)	Vaccine vs Placebo	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
	Negative		Anti Spike IgG (IU/ml)	Vaccine vs Placebo	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
	Negative		Pseudovirus-nAb ID50	Vaccine vs Placebo	87.1% (82.7%, 90%)	87.5% (83.2%, 90.4%)	81.8% (77.9%, 85.1%)
	Negative		Pseudovirus-nAb ID80	Vaccine vs Placebo	93% (87.4%, 95.1%)	93% (87.4%, 95.1%)	87.3% (80.6%, 90.2%)
	Positive		Anti N IgG (IU/ml)	Vaccine vs Placebo	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
	Positive		Anti RBD IgG (IU/ml)	Vaccine vs Placebo	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
	Positive		Anti Spike IgG (IU/ml)	Vaccine vs Placebo	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
	Positive		Pseudovirus-nAb ID50	Vaccine vs Placebo	12.6% (5.3%, 20.1%)	12.3% (5.1%, 19.9%)	23.2% (13.3%, 32.3%)
	Positive		Pseudovirus-nAb ID80	Vaccine vs Placebo	5.5% (-0.1%, 11.6%)	5.4% (-0.4%, 11.5%)	9.9% (3.5%, 17%)
Day 57	Negative		Anti N IgG (IU/ml)	Vaccine vs Placebo	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
	Negative		Anti RBD IgG (IU/ml)	Vaccine vs Placebo	99.4% (96%, 99.9%)	99.4% (96%, 99.9%)	100% (100%, 100%)
	Negative		Anti Spike IgG (IU/ml)	Vaccine vs Placebo	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
	Negative		Pseudovirus-nAb ID50	Vaccine vs Placebo	98% (95.7%, 98.8%)	98% (95.7%, 98.8%)	97.4% (95.6%, 98.5%)
	Negative		Pseudovirus-nAb ID80	Vaccine vs Placebo	98.2% (94.7%, 99.1%)	98.2% (94.7%, 99.1%)	98.3% (96.4%, 99.2%)

(continued)

Group	Visit	Baseline SARS-CoV-2	Marker	Comparison	Responder	% 2-Fold Rise	% 4-Fold Rise
	Day 57	Positive	Anti N IgG (IU/ml)	Vaccine vs Placebo	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
	Day 57	Positive	Anti RBD IgG (IU/ml)	Vaccine vs Placebo	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
	Day 57	Positive	Anti Spike IgG (IU/ml)	Vaccine vs Placebo	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
	Day 57	Positive	Pseudovirus-nAb ID50	Vaccine vs Placebo	4.1% (1.7%, 9.4%)	4.1% (1.7%, 9.4%)	7.7% (4.1%, 14%)
	Day 57	Positive	Pseudovirus-nAb ID80	Vaccine vs Placebo	2% (0.6%, 6.8%)	2% (0.6%, 6.8%)	2.5% (0.9%, 6.8%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Negative							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	914 13295/13295 = 100.0% (100.0%, 100.0%)	23543 (19945, 27790)	163 0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	2354.30 (1994.51, 2778.99)		
Day 29	Anti RBD IgG (IU/ml)	914 13295/13295 = 100.0% (100.0%, 100.0%)	22926 (19863, 26460)	163 0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	2292.58 (1986.35, 2646.03)		
Day 29	Anti Spike IgG (IU/ml)	914 13295/13295 = 100.0% (100.0%, 100.0%)	40963 (36741, 45671)	163 0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	4096.31 (3674.06, 4567.08)		
Day 29	Pseudovirus-nAb ID50	914 11733.1/13295 = 88.3% (84.7%, 91.0%)	106 (91, 125)	163 149.5/13359 = 1.1% (0.3%, 3.8%)	5 (5, 5)	87.1% (82.7%, 90%)	21.04 (17.92, 24.71)		
Day 29	Pseudovirus-nAb ID80	914 12521.7/13295 = 94.2% (91.6%, 96.0%)	189 (161, 222)	163 160.7/13359 = 1.2% (0.2%, 6.1%)	5 (5, 5)	93% (87.4%, 95.1%)	37.14 (31.48, 43.81)		
Day 57	Anti N IgG (IU/ml)	914 13295/13295 = 100.0% (100.0%, 100.0%)	325136 (267241, 395574)	163 0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	32513.59 (26724.06, 39557.36)		
Day 57	Anti RBD IgG (IU/ml)	914 13295/13295 = 100.0% (100.0%, 100.0%)	966160 (823437, 1133621)	163 76.3/13359 = 0.6% (0.1%, 4.0%)	10 (10, 10)	99.4% (96%, 99.9%)	96216.76 (81986.55, 112916.89)		
Day 57	Anti Spike IgG (IU/ml)	914 13295/13295 = 100.0% (100.0%, 100.0%)	2087965 (1831068, 2380904)	163 0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	208796.50 (183106.81, 238090.43)		
Day 57	Pseudovirus-nAb ID50	914 13159.4/13295 = 99.0% (98.0%, 99.5%)	1497 (1228, 1825)	163 131.9/13359 = 1.0% (0.3%, 3.0%)	5 (5, 5)	98% (95.7%, 98.8%)	297.04 (243.64, 362.15)		
Day 57	Pseudovirus-nAb ID80	914 13174.8/13295 = 99.1% (97.1%, 99.7%)	2223 (1809, 2733)	163 120.7/13359 = 0.9% (0.2%, 3.8%)	5 (5, 5)	98.2% (94.7%, 99.1%)	440.71 (358.41, 541.91)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Positive							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	43010 (33140, 55819)	270	1357/1357 = 100.0% (100.0%, 100.0%)	12518 (9458, 16567)	0% (0%, 0%)	3.44 (2.34, 5.04)
Day 29	Anti RBD IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	36133 (28182, 46328)	270	1357/1357 = 100.0% (100.0%, 100.0%)	12861 (10150, 16296)	0% (0%, 0%)	2.81 (1.99, 3.96)
Day 29	Anti Spike IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	79981 (65041, 98352)	270	1357/1357 = 100.0% (100.0%, 100.0%)	18191 (15159, 21829)	0% (0%, 0%)	4.40 (3.34, 5.79)
Day 29	Pseudovirus-nAb ID50	274	1383.1/1432 = 96.6% (91.6%, 98.7%)	186 (142, 243)	270	1139.8/1357 = 84.0% (76.8%, 89.3%)	51 (40, 66)	12.6% (5.3%, 20.1%)	3.61 (2.50, 5.22)
Day 29	Pseudovirus-nAb ID80	274	1407.2/1432 = 98.3% (93.8%, 99.5%)	420 (314, 560)	270	1258.5/1357 = 92.7% (86.8%, 96.1%)	129 (98, 169)	5.5% (-0.1%, 11.6%)	3.25 (2.19, 4.83)
Day 57	Anti N IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	980579 (697583, 1378379)	270	1357/1357 = 100.0% (100.0%, 100.0%)	130008 (92643, 182444)	0% (0%, 0%)	7.54 (4.67, 12.19)
Day 57	Anti RBD IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	2298869 (1785648, 2959596)	270	1357/1357 = 100.0% (100.0%, 100.0%)	382614 (299829, 488256)	0% (0%, 0%)	6.01 (4.23, 8.54)
Day 57	Anti Spike IgG (IU/ml)	274	1432/1432 = 100.0% (100.0%, 100.0%)	5346334 (4339333, 6587023)	270	1357/1357 = 100.0% (100.0%, 100.0%)	676872 (531354, 862241)	0% (0%, 0%)	7.90 (5.74, 10.87)
Day 57	Pseudovirus-nAb ID50	274	1432/1432 = 100.0% (100.0%, 100.0%)	5680 (3863, 8351)	270	1301.8/1357 = 95.9% (90.6%, 98.3%)	566 (409, 783)	4.1% (1.7%, 9.4%)	10.04 (6.07, 16.62)
Day 57	Pseudovirus-nAb ID80	274	1432/1432 = 100.0% (100.0%, 100.0%)	7837 (5545, 11076)	270	1330.1/1357 = 98.0% (93.2%, 99.4%)	1324 (937, 1870)	2% (0.6%, 6.8%)	5.92 (3.63, 9.65)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

Visit	Marker	Vaccine Recipients							
		Baseline SARS-CoV-2 Positive				Baseline SARS-CoV-2 Negative			Comparison
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	274 1432/1432 = 100.0% (100.0%, 100.0%)	43010 (33140, 55819)	914 13295/13295 = 100.0% (100.0%, 100.0%)	23543 (19945, 27790)	0% (0%, 0%)	1.83 (1.34, 2.49)		
Day 29	Anti RBD IgG (IU/ml)	274 1432/1432 = 100.0% (100.0%, 100.0%)	36133 (28182, 46328)	914 13295/13295 = 100.0% (100.0%, 100.0%)	22926 (19863, 26460)	0% (0%, 0%)	1.58 (1.18, 2.10)		
Day 29	Anti Spike IgG (IU/ml)	274 1432/1432 = 100.0% (100.0%, 100.0%)	79981 (65041, 98352)	914 13295/13295 = 100.0% (100.0%, 100.0%)	40963 (36741, 45671)	0% (0%, 0%)	1.95 (1.55, 2.47)		
Day 29	Pseudovirus-nAb ID50	274 1383.1/1432 = 96.6% (91.6%, 98.7%)	186 (142, 243)	914 11733.1/13295 = 88.3% (84.7%, 91.0%)	106 (91, 125)	8.3% (2.6%, 12.4%)	1.75 (1.28, 2.39)		
Day 29	Pseudovirus-nAb ID80	274 1407.2/1432 = 98.3% (93.8%, 99.5%)	420 (314, 560)	914 12521.7/13295 = 94.2% (91.6%, 96.0%)	189 (161, 222)	4.1% (-0.8%, 7%)	2.22 (1.59, 3.09)		
Day 57	Anti N IgG (IU/ml)	274 1432/1432 = 100.0% (100.0%, 100.0%)	980579 (697583, 1378379)	914 13295/13295 = 100.0% (100.0%, 100.0%)	325136 (267241, 395574)	0% (0%, 0%)	3.02 (2.04, 4.47)		
Day 57	Anti RBD IgG (IU/ml)	274 1432/1432 = 100.0% (100.0%, 100.0%)	2298869 (1785648, 2959596)	914 13295/13295 = 100.0% (100.0%, 100.0%)	966160 (823437, 1133621)	0% (0%, 0%)	2.38 (1.76, 3.21)		
Day 57	Anti Spike IgG (IU/ml)	274 1432/1432 = 100.0% (100.0%, 100.0%)	5346334 (4339333, 6587023)	914 13295/13295 = 100.0% (100.0%, 100.0%)	2087965 (1831068, 2380904)	0% (0%, 0%)	2.56 (2.00, 3.28)		
Day 57	Pseudovirus-nAb ID50	274 1432/1432 = 100.0% (100.0%, 100.0%)	5680 (3863, 8351)	914 13159.4/13295 = 99.0% (98.0%, 99.5%)	1497 (1228, 1825)	1% (0.5%, 2%)	3.79 (2.46, 5.85)		
Day 57	Pseudovirus-nAb ID80	274 1432/1432 = 100.0% (100.0%, 100.0%)	7837 (5545, 11076)	914 13174.8/13295 = 99.1% (97.1%, 99.7%)	2223 (1809, 2733)	0.9% (0.3%, 2.9%)	3.53 (2.36, 5.27)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

Visit	Marker	Placebo Recipients							
		Baseline SARS-CoV-2 Positive				Baseline SARS-CoV-2 Negative			Comparison
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	12518 (9458, 16567)	163	0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	1251.77 (945.80, 1656.72)
Day 29	Anti RBD IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	12861 (10150, 16296)	163	0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	1286.10 (1015.03, 1629.57)
Day 29	Anti Spike IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	18191 (15159, 21829)	163	0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	1819.07 (1515.87, 2182.92)
Day 29	Pseudovirus-nAb ID50	270	1139.8/1357 = 84.0% (76.8%, 89.3%)	51 (40, 66)	163	149.5/13359 = 1.1% (0.3%, 3.8%)	5 (5, 5)	82.9% (75.2%, 88.2%)	10.18 (7.90, 13.11)
Day 29	Pseudovirus-nAb ID80	270	1258.5/1357 = 92.7% (86.8%, 96.1%)	129 (98, 169)	163	160.7/13359 = 1.2% (0.2%, 6.1%)	5 (5, 5)	91.5% (83.8%, 95.1%)	25.36 (19.29, 33.34)
Day 57	Anti N IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	130008 (92643, 182444)	163	0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	13000.84 (9264.31, 18244.40)
Day 57	Anti RBD IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	382614 (299829, 488256)	163	76.3/13359 = 0.6% (0.1%, 4.0%)	10 (10, 10)	99.4% (96%, 99.9%)	38103.25 (29854.93, 48630.43)
Day 57	Anti Spike IgG (IU/ml)	270	1357/1357 = 100.0% (100.0%, 100.0%)	676872 (531354, 862241)	163	0/13359 = 0.0% (0.0%, 0.0%)	10 (10, 10)	100% (100%, 100%)	67687.19 (53135.41, 86224.15)
Day 57	Pseudovirus-nAb ID50	270	1301.8/1357 = 95.9% (90.6%, 98.3%)	566 (409, 783)	163	131.9/13359 = 1.0% (0.3%, 3.0%)	5 (5, 5)	94.9% (89.3%, 97.4%)	112.24 (81.10, 155.32)
Day 57	Pseudovirus-nAb ID80	270	1330.1/1357 = 98.0% (93.2%, 99.4%)	1324 (937, 1870)	163	120.7/13359 = 0.9% (0.2%, 3.8%)	5 (5, 5)	97.1% (91.5%, 98.7%)	262.45 (185.80, 370.71)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Chapter 2

Graphical Description of Immunogenicity Data

2.1 Pairs plots of antibody markers for overall per-protocol cohort

2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm

D29 Fold-rise over D1 Ab markers: baseline negative, vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm

2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.9: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.10: Pair plots of D57 Ab markers: baseline negative vaccine arm

D29 Fold-rise over D1 Ab markers: baseline positive, vaccine arm




Figure 2.11: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm

D57 Fold-rise over D1 Ab markers: baseline positive, vaccine arm




Figure 2.12: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.13: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm

PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm

2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.17: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.18: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.19: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 Ab markers: by baseline status for the vaccine arm




Figure 2.22: RCDF plots for D57 Ab markers: by baseline status for the vaccine arm




Figure 2.23: RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D29 Ab markers: baseline negative vaccine arm




Figure 2.26: RCDF plots for D57 Ab markers: baseline negative vaccine arm




Figure 2.27: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.28: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm

2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

2.3.1 Baseline SARS-CoV-2 negative




Figure 2.29: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT443




Figure 2.30: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

2.3.2 Baseline SARS-CoV-2 positive




Figure 2.31: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT445




Figure 2.32: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

2.4 Box plots of antibody markers for overall per-protocol cohort

2.4.1 Baseline SARS-CoV-2 negative




Figure 2.33: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.34: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.35: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.36: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

2.4.2 Baseline SARS-CoV-2 positive




Figure 2.37: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.38: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.39: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.40: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.41: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.42: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.43: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.44: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.45: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.46: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.47: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.48: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort

2.5.1 Baseline SARS-CoV-2 negative




Figure 2.49: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

2.5.2 Baseline SARS-CoV-2 positive




Figure 2.50: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

2.6 RCDF plots of antibody markers by demographics for per-protocol cohort

2.6.1 Baseline SARS-CoV-2 negative




Figure 2.51: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT465




Figure 2.52: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.53: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT467




Figure 2.54: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.55: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT469




Figure 2.56: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.57: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.58: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.59: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT473




Figure 2.60: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.61: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT475




Figure 2.62: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.63: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT477




Figure 2.64: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.65: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT479




Figure 2.66: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.67: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT481




Figure 2.68: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.69: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT483




Figure 2.70: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.71: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.72: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.73: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.74: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.75: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.76: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.77: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.78: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.79: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.80: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.81: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.82: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.83: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.84: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.85: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.86: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6.2 Baseline SARS-CoV-2 positive




Figure 2.87: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.88: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.89: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.90: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.91: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.92: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.93: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.94: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.95: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.96: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.97: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.98: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.99: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT513




Figure 2.100: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.101: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.102: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.103: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.104: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.105: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.106: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.107: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.108: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.109: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.110: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.111: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.112: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.113: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.114: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.115: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.116: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.117: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.118: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.119: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.120: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.121: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.122: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7 Boxplots of antibody markers by demographics for per-protocol cohort

2.7.1 Baseline SARS-CoV-2 negative




Figure 2.123: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.124: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.125: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.126: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.127: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.128: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.129: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.130: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.131: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.132: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.133: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.134: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7.2 Baseline SARS-CoV-2 positive

MOCK

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.135: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.136: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.137: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.138: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.139: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.140: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT555




Figure 2.141: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.142: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT557




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.